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Abstract 
Traditional small molecule chemotherapeutics show limited effectiveness in the 
clinic as their poor pharmacokinetics lead to rapid clearance from circulation and their 
exposure to off-target tissues results in dose-limiting toxicity. The objective of this 
dissertation is to exploit a class of recombinant chimeric polypeptides (CPs) to actively 
target drugs to tumors as conjugation to macromolecular carriers has demonstrated 
improved efficacy by increasing plasma retention time, reducing uptake by healthy 
tissues, and enhancing tumor accumulation by exploiting the leaky vasculature and 
impaired lymphatic drainage characteristic of solid tumors. CPs consist of two principal 
components: (1) a thermally responsive elastin-like polypeptide (ELP) that displays a 
soluble-to-aggregate phase transition above a characteristic transition temperature (Tt); 
and (2) a cysteine-rich peptide fused to one end of the ELP to which small molecule 
therapeutics can be covalently attached (the conjugation domain). This work describes 
the development of CP drug-loaded nanoparticles that can be targeted to solid tumors 
by the external application of mild regional hyperthermia (39-43°C).  
Highly repetitive ELP polymers were assembled by Plasmid Reconstruction 
Recursive Directional Ligation (PRe-RDL), in which two halves of a parent plasmid, 
each containing a copy of an oligomer, were ligated together to dimerize the oligomer 
and reconstitute the functional plasmid. Chimeric polypeptides were constructed by 
  
v 
fusing the ELP sequence to a (CGG)8 conjugation domain, expressed in Escherichia coli, 
and loaded with small molecule hydrophobes through site specific attachment to the 
conjugation domain. Drug attachment induced the assembly of nanoparticles that 
retained the thermal responsiveness of the parent ELP in that they experienced a phase 
transition from soluble nanoparticles to an aggregated phase above their Tt. Importantly, 
the Tt of these nanoparticles was near-independent of the CP concentration and the 
structure of the conjugated molecule as long as it displayed an octanol-water 
distribution coefficient (LogD) > 1.5.  
A series of CP nanoparticles with varying ratios of alanine and valine in the 
guest residue position was used to develop a quantitative model that described the CP 
transition temperature in terms of three variables – sequence, chain length, and 
concentration - and the model was used to identify CPs of varying molecular weights 
that displayed transition temperatures between 39°C and 43°C. A murine dorsal skin 
fold window chamber model using a human tumor xenograft was used to validate that 
only the thermoresponsive CP nanoparticles (and not the controls) exhibited a micelle-
to-aggregate phase transition between 39-43°C in vivo. Furthermore, quantitative 
analysis of the biodistribution profile demonstrated that accumulation of these 
thermoresponsive CP nanoparticles was significantly enhanced by applying heat in a 
cyclical manner. It is hoped that this work will provide a helpful resource for the use of 
thermoresponsive CP nanoparticles in a variety of biomedical applications.  
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1. Introduction to Cancer and Drug Delivery 
1.1 Cancer as a Disease 
Since the war on cancer began in the early 1970’s, an estimated $300 billion has 
been spent on R&D to develop new therapeutics and treatments, increase the sensitivity 
and efficiency of detection and screening methods, and elucidate the genetic factors that 
cause cancer [1]. Despite this massive effort, the total incidence and mortality of those 
suffering from cancer clearly illustrate that cancer treatment and prevention remain 
critical issues for improving the quality of healthcare for an aging U.S. population. 
Cancer will kill over a half million Americans in 2013 – accounting for nearly 23% of all 
deaths – and an additional 1.7 million new patients will be diagnosed with the disease, 
resulting in an estimated cost to the U.S. economy of over $202 billion annually from 
direct healthcare costs and loss of productivity [2].  
Cancer is a collection of diseases typically caused by several genetic mutations 
that can arise from environmental factors, internal processes, and inherited defects [3]. 
Although all cancers can display vast phenotypic and genotypic differences – even 
between cells within the same tumor - all contain a series of hallmark characteristics 
essential to the survival and proliferation of these abnormal cells [4, 5]. These acquired 
characteristics, outlined in a theory put forth by Hanahan and Weinberg, include the 
following: (1) the ability to sustain proliferative signaling while (2) circumventing 
pathways that suppress growth; (3) the ability to divide an unlimited number of times 
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and (4) evade apoptotic pathways; (5) the ability to induce the formation and growth of 
neovasculature that can provide tumor cells with essential nutrients and oxygen in a 
process known as angiogenesis; and (6) the ability to invade neighboring tissues, 
extravasate into the blood stream, and form distant metastases [6]. An increasing body 
of evidence suggests that many cancers are also able to evade recognition by the 
immune system (in particular, B and T lymphocytes, macrophages and natural killer 
cells) as well as modify and reprogram their cellular metabolism to more effectively 
support their state of rapid proliferation, although it is still unknown whether these 
characteristics are universal to all cancers [6]. 
 
1.2 Treatment 
Despite the vast degree of heterogeneity between tumors, the standard of care is 
a combination of three primary strategies: surgery, radiation, and chemotherapy, as well 
as the emerging fields of molecularly targeted therapeutics and hormone therapies [7]. 
This section will focus on the first three strategies with an emphasis on chemotherapy.  
Surgical intervention remains the oldest and most common form of treatment; 
complete removal of the diseased tissue is a highly effective strategy when performed 
prior to local invasion and metastasis [7]. Surgery is also commonly used to remove 
nonmalignant tissue surrounding the tumor site to prevent recurrence, diagnose the 
malignant potential of a tumor through biopsy, determine the stage and type of a tumor 
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to facilitate diagnosis and assess treatment options, and debulk unresectable tumors to 
relieve pain or increase the effectiveness of radiotherapy or chemotherapy [7]. However, 
surgery is limited to providing control over the primary tumor; once a tumor has 
metastasized, surgery must be supplemented with a more systemic approach such as 
chemotherapy to significantly prolong survival. 
Subjecting solid tumors to high doses of radiation has also become a standard 
treatment for primary tumor control [7]. Ionizing radiation produces free radical capable 
of inducing single and double stranded DNA breaks and covalent crosslinks between 
DNA strands [8]. Although this activity preferentially destroys rapidly dividing cells 
(i.e., tumor cells), high radiation levels are also toxic to healthy cells. To address this 
issue, radiation treatments are commonly fractionated into multiple smaller doses 
spread over the course of weeks to allow healthy tissue time to recover and repopulate 
between treatments [9]. Radiation treatments can be applied via external beam radiation, 
which uses an acute concentrated exposure at multiple angles to maximize the dose at 
the beams’ focal point while minimizing the dose to the surrounding tissues, or 
brachytherapy, which involves precise spatial implantation of several small radioactive 
capsules throughout the tumor mass to provide a uniform and sustained level of 
radiation within the tumor for days to weeks [10]. Radiotherapy can also be enhanced by 
combining treatments with specific chemotherapeutics [11]. As radiation is least 
 4 
effective in hypoxic cells, treatment is often combined with chemotherapeutic regimens 
that increase cellular oxygenation and provide independent toxicity modalities [12]. 
 
1.2.1 Chemotherapy 
The third treatment modality is the systemic application of chemotherapeutic 
drugs. These molecules tend to prohibit or interrupt cell division, and thus prove most 
fatal to rapidly dividing cells, although their nonspecific activity can be toxic to healthy 
tissues as well. This section will briefly discuss the main classes of chemotherapeutics 
and their respective mechanisms in terms of which phase of the cell cycle they are most 
effective. Alkylating agents (chlorambucil, cyclophosphamide, and melphalan) and 
platinates (cisplatin, carboplatin, oxaliplatin) are an exception to this classification, as 
they are cell cycle nonspecific chemotherapeutics that indiscriminately induce covalent 
DNA-DNA and DNA-protein crosslinks that inhibit DNA repair and synthesis [7]. As 
this class is cell cycle nonspecific, they are commonly included in multidrug 
combination regimens to complement their cycle-specific counterparts [13, 14]. 
 As the S-phase or synthesis phase is characterized by extensive DNA replication 
prior to cell division, it provides a popular target for a variety of chemotherapeutics that 
interfere with DNA processes. Many drugs in this family are particularly toxic because 
even a few genetic abnormalities can lead to cell death. Antimetabolites, one class of S-
phase specific drugs, are comprised primarily of nucleotide analogs (Figure 1). These 
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molecules typically resemble purines (fludarabine, 6-thioguanine) and pyrimidines 
(gemcitabine, 5-fluorouracil) that prematurely terminate growing DNA chains upon 
incorporation [7]. They have also shown the ability to inhibit enzymes necessary for 
DNA synthesis, such as dyhydrofolate reductase (methotrexate), phosophoribosyl 
pyrophosphate amidotransferase (mercaptopurine), and ribonucleotide reductase 
(hydroxyurea). Anthracyclines are another class that include many S-phase specific 
drugs, including doxorubicin (the primary chemotherapeutic used throughout this 
dissertation), daunorubicin, epirubicin, and idarubicin. These drugs exhibit a variety of 
toxic mechanisms: DNA intercalation, which prevents the synthesis of DNA and RNA; 
generation of toxic free radicals; and inhibition of topoisomerases and helicases [15]. 
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Figure 1: Diagram of the cell cycle and a list of common chemotherapeutics grouped 
according to their phase toxicity. 
 
Chemotherapeutics that are most effective during M (Mitosis) phase are typically 
cytoskeletal drugs that arrest the cell in metaphase by affecting microtubule formation, a 
dynamic process that is necessary for proper chromosome alignment and cell division. 
Podophyllotoxins (etoposide) and vinca alkaloids (vincristine, vinblastine, and 
vinorelbine) block the assembly of tubulins, whereas taxanes (paclitaxel and docetaxel) 
stabilize microtubules and prevent microtubule detachment from the centromere [16]. 
By inhibiting microtubule dynamics, these drugs cause the cell to trigger apoptosis or to 
revert back to the G2-phase without dividing. 
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 The G1-phase is characterized by protein synthesis; drugs that inhibit the 
formation of amino acids, proteins, and enzymes can cause G1-phase arrest. One 
interesting example of a G1 specific chemotherapeutic is the enzyme asparaginase. Acute 
lymphoblastic leukemia (ALL) cells are unable to produce the nonessential amino acid 
asparagine, and thus must harvest asparagine from extracellular sources. Asparaginase, 
an enzyme that catalyzes the reduction of extracellular asparagine to aspartic acid and 
ammonia, selectively starves the leukemia cells because healthy cells are capable of 
generating asparagine [17, 18].  
There are a few drugs that result in cell cycle arrest in the late S-phase or G2 
(Gap-2) phase. Topoisomerase I poisons, such as camptothecin and its analogs 
(irinotecan and topotecan) bind and stabilize the Topoisomerase I – DNA complex. 
These drugs induce the formation of double stranded DNA breaks when the advancing 
replication fork collides with the stabilized complex [19]. Bleomycin, a glycopeptide 
antibiotic, also results in the arrest of cells in the early G2 phase by inducing DNA strand 
breaks, although the exact mechanism remains unknown [20]. Importantly, as the 
camptothecins and bleomycin exhibit unique mechanisms of action and display non-
overlapping toxicities with other common chemotherapeutics, they are frequently 
included in combination chemotherapy regimens. 
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1.2.2 Hyperthermia 
While not commonly recognized as a primary treatment modality in the United 
States (except for superficial tumors), the local application of mild hyperthermia 
(temperatures ranging from 39-43°C) is used as a powerful adjunctive therapy in Europe 
for the local control of a variety of cancers when used in combination with radiotherapy 
and chemotherapy [21-24]. The primary objective of this dissertation is to use externally 
applied hyperthermia to trigger the accumulation of a chemotherapeutic carrier within a 
tumor, and thus exploit hyperthermia as an externally applied stimulus. However, 
hyperthermia also induces a therapeutic response in tumor tissue, which is addressed in 
this section.  
Heating tumors to supraphysiological temperatures is not only cytotoxic, but it 
also activates several mechanisms by which tumor cells are potentiated to the primary 
treatment. The degree of cytotoxicity caused by hyperthermia is a complex function of 
the temperature, the duration of treatment, and the cell type. Generally, the rate of cell 
killing increases exponentially for every 1°C increase in temperature above 39°C; hence, 
it is possible to achieve similar cytotoxic profiles in much shorter time periods by 
slightly increasing the temperature [25]. This toxicity is primarily caused by the thermal 
denaturation or destabilization of cellular proteins. In fact, mammalian cells tend to 
develop a resistance to this effect (i.e., thermotolerance) when heated to temperatures 
below ~43.5°C by upregulating heat shock proteins that assist in protein folding [26]. 
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Fortunately, thermotolerance is a transient effect and can be avoided in the clinic by 
limiting treatment times to 1 hour and increasing the interval between treatments to 2-3 
days.  
Hyperthermia also affects the physiology of tissues by increasing blood flow and 
vascular permeability. Interestingly, while elevated temperatures substantially increase 
the blood flow in healthy tissues, this effect is suppressed in tumor tissues [27]. This 
phenomenon leads to effective thermoregulation in healthy tissues: as the temperature 
increases, the rate at which the heat is removed also increases. Tumor tissues, however, 
experience an increase in temperature without a corequisite increase in blood flow. This 
lack of thermoregulation drives tumors to higher temperatures than the surrounding 
tissues, thereby causing a higher degree of tissue and vascular damage. Mild 
hyperthermia has also been shown to promote the extravasation and deposition of 
therapeutics into the tumor interstitium. Whereas the accumulation of macromolecular 
carriers, such as monoclonal antibodies, shows a slight enhancement (2-4 fold) in the 
presence of hyperthermia [28], the penetration of nanoparticles can be greatly enhanced. 
For example, vasculature in human ovarian carcinoma xenografts (SKOV-3) that was 
impermeable to 100-nm liposomes under normothermic conditions (< 39°C) exhibited an 
exponential increase in liposome deposition for every 1°C the tumor was heated 
between 39 and 42°C [29].  
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Several phase III clinical trials spanning multiple tumor types (cancers of the 
breast, head and neck, esophagus, and cervix, as well as melanomas and glioblastomas) 
indicate that hyperthermia in combination with radiotherapy provides substantial 
benefits over radiotherapy alone without significantly increasing toxicity or tissue 
damage to the surrounding region [30]. This combined effect can be attributed to the fact 
that hyperthermia inhibits DNA repair pathways [31, 32], reduces the severity of radio-
resistant hypoxic regions throughout the tumor by enhancing tumor oxygenation [33-
35], and is particularly cytotoxic to cells in S-phase [36, 37], which display the highest 
resistance to radiation. 
Similarly, the efficacy of many chemotherapeutics is also improved at elevated 
temperatures. The degree of enhancement varies widely between different classes of 
drugs. Whereas antimetabolites such as methotrexate remain unaffected by 
hyperthermia, the effectiveness of alkylating agents and anthracyclines (doxorubicin) 
exhibit an additive increase in efficacy when heated [38, 39]. The drug classes 
nitrosoureas, platinates (cisplatin and carboplatin), and bleomycin display a synergistic 
increase in efficacy and hence represent promising candidates for delivery by 
thermoresponsive carriers.  
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1.3 Drug Delivery to Solid Tumors 
1.3.1 Overview 
One of the primary goals of drug delivery for cancer therapy is to improve the 
therapeutic index of anticancer drugs by increasing the amount of drug delivered to the 
tumor site and decreasing its exposure to healthy tissues; the therapeutic index is 
defined as the ratio of LD50 to ED50, where the median lethal dose (LD50) is defined as the 
dose necessary to cause death in 50% of a population, and the minimum effective dose 
(ED50) is defined as the smallest dose able to induce the desired effect in 50% of a 
population.  A large therapeutic index is preferable as it describes a situation in which 
the efficacious dose is far below the lethal dose.  Unfortunately, many cancer 
chemotherapeutics are hydrophobic compounds with a MW of less than 500 Da that 
have suboptimal pharmacokinetics, significant systemic toxicity and a small therapeutic 
index.  This low therapeutic index has two main causes: first, upon injection into the 
systemic blood circulation, only a small fraction of these low MW compounds 
accumulate in the body, while the bulk of the drug is rapidly cleared through the 
kidneys, taken up by the liver, or excreted through the digestive tract. Second, because 
the cellular toxicity of these molecules is correlated with drug concentration and length 
of exposure, both healthy cells and tumor tissue are subjected to the same distribution 
profile, resulting in similar toxicities. Although increasing the injected dose increases the 
amount of drug that reaches the tumor site, it also exacerbates undesirable side effects, 
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whereas reducing the dose to minimize side effects makes the drug less effective.  
Furthermore, because many of these drugs are hydrophobic they are poorly soluble in 
water, which also limits the maximum solubility of the drug and hence the amount of 
therapeutically active drug able to reach the desired site of action. Finally, many small 
molecule chemotherapeutics have been shown to display incomplete tumor coverage 
due to a variety of factors, including increased distances between blood vessels in 
tumors and poor tissue penetration of small molecule drugs, interactions between the 
drug and the extracellular matrix and cellular organelles, drug metabolism, and a high 
interstitial fluid pressure gradient combined with a lack of convection [40]. 
Engineered drug carriers provide a means to circumvent many of these issues, 
and thus improve the therapeutic index of anticancer drugs through conjugation of the 
drug to macromolecular carriers such as polymers [41, 42], proteins [43], and 
polysaccharides [44], or by encapsulation within liposomes [45], polymer micelles [46], 
and nanoscale polymer emulsions [47]. While these carriers also provide the opportunity 
for a range of delivery strategies, release mechanisms, targeting modalities, and 
pharmacokinetic profiles, the most important rationale for their use stems from the 
observation that these high molecular weight carriers improve accumulation within 
solid tumors compared to free drug via the enhanced permeability and retention (EPR) 
effect and reduce accumulation in healthy tissues [48, 49]. The EPR effect arises from the 
rapid pathological development of the tumor vasculature, which results in highly 
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porous vessel walls lacking the tight junctions found in healthy tissue [50]. These pores 
can range from 100 to 800 nm, depending on the tumor and organ environment [51], 
thereby permitting extravasation of both small and macromolecules.  Thus, many 
macromolecular drug carriers that are excluded from healthy tissues are able to 
extravasate across the leaky tumor vasculature, while the lack of lymphatic drainage in 
tumor tissue leads to enhanced retention of these delivery vehicles.  
 
1.3.2 Macromolecular Carriers 
Macromolecular polymers provide a wide array of advantages for drug delivery.  
First, they can extend the circulation half-life of the drug by simply increasing the 
apparent molecular weight of the drug [52]. This decreases the rate of clearance of the 
drug and its nonspecific absorption into systemic tissues. Extending the plasma half-life 
also increases tumor exposure and can hence increase the amount of drug that 
accumulates in the tumor by the EPR effect. Second, these carriers can specifically target 
tumor tissue, passively through the EPR effect [53, 54], or actively via targeting ligands 
[55] or application of focused mild hyperthermia to tumors [56], thereby increasing the 
efficacy and reducing the systemic toxicity of the drug. Third, for drugs that are 
covalently conjugated to a polymer, the presence of a covalent link between the drug 
and polymer provides a cleavable tether that can be tailored to release the drug in 
response to an active trigger (e.g., low pH in endo-lysosomal compartments). In the case 
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of low MW, hydrophobic drugs, conjugation to a soluble carrier can also increase the 
solubility of the drug in plasma by many orders of magnitude, enabling administration 
of higher doses [41]. In some cases, covalent conjugation of the drug to the carrier can 
also stabilize the metabolically active drug, thereby further increasing efficacy. Fourth, 
the presence of a hydrophilic corona can impart “stealth” characteristics by preventing 
opsonization by immune tissues and degradation by proteases. Some polymeric carriers 
also enhance the cytotoxicity of a drug by overcoming the cellular multidrug resistance 
exhibited by many solid tumors [57-59]. 
 
1.3.3 Active and Passive Targeting Strategies 
Macromolecular drug carriers commonly exploit both passive and active 
targeting strategies to increase the bioavailability of the drug within the tumor. Passive 
targeting utilizes the size of the carrier to passively accumulate in the tumor via the 
enhanced permeability and retention (EPR) effect [60], which results in the extravasation 
of sub-100 nm nanoparticles into the tumor and prevents their clearance. In healthy 
tissues, this passive transvascular transport of therapeutics occurs through two primary 
pathways: diffusion, in which a concentration gradient drives the molecules from an 
area of high concentration (intravascular space) to an area of low concentration 
(intratumoral environment); and convection, in which molecules move with the bulk 
solution current [61]. However, the rapid proliferation of cells within the tumoral matrix 
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combined with an impaired lymphatic drainage system results in a high interstitial fluid 
pressure (IFP) within most tumors that severely reduces convection currents from the 
vasculature into the tumor space [62]. Consequently, many treatment modalities attempt 
to generate high transvascular concentration gradients in order to best enhance diffusion 
across the vessel wall [63-65]. 
Active targeting approaches, on the other hand, typically involve decorating the 
outer surface of the nanoparticle carrier with tumor-specific ligands such as antibodies 
[66] and aptamers [67] that tightly bind receptors overexpressed by the tumor. While 
active affinity targeting remains the focus of many delivery strategies, it is limited by the 
heterogeneity of receptor expression between tumors [68] and even between patients 
diagnosed with the same cancer [69].  
 
1.3.4 Thermoresponsive Carriers 
1.3.4.1 Overview 
Thermoresponsive drug delivery systems are capable of exploiting an alternative 
active targeting approach that relies on the regional application of mild hyperthermia to 
spatially and temporally control the accumulation of a chemotherapeutic agent within a 
solid tumor. Despite their distinct features, most of these systems are designed to 
respond to hyperthermia in one of two ways: (1) carriers that physically encapsulate 
drugs, such as thermally sensitive liposomes [70, 71], polymer micelles [72], and 
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hydrogels [73, 74] typically release their therapeutic payload upon heating. These 
carriers are subdivided into fast release vehicles (release in seconds to minutes) that 
exhibit complete drug release within the first pass through the tumor vasculature, and 
slow release vehicles (minutes to hours) that exploit the EPR effect to accumulate within 
the tumor over a period of 24 hours and then release the drug within the tumor 
extravascular space upon heating. (2) Carriers that are physically conjugated to a drug, 
such as polypeptide-drug conjugates [63] and polypeptide micelles [75, 76], undergo a 
morphological or physicochemical change in response to heat to induce the 
accumulation of the carrier in the tumor extravascular space. These carriers typically 
rely on conventional cleavage mechanisms such as hydrolysis or pH to release the drug 
upon cellular uptake [76, 77]. Both targeted accumulation and triggered release are 
capable of increasing the bioavailability of the chemotherapeutic within the tumor, 
potentially reducing the tumor burden prior to resection, or even abolishing the tumor 
entirely.  
 
1.3.4.2 Elastin-like Polypeptides 
Elastin-like polypeptides (ELPs) are a class of temperature sensitive biopolymers 
based on the structural motif found in mammalian tropoelastin [78, 79]. ELPs consist of a 
repeated pentapeptide sequence (VPGXG)n, where X is any amino acid except proline. 
ELPs exhibit a thermodynamic inverse phase transition in aqueous solution at a specific 
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temperature (Tt), below which ELPs are soluble and above which ELPs become insoluble 
and phase separate into a polymer-rich coacervate. This phase transition is completely 
reversible.   
ELPs retain all the advantages of polymeric drug delivery systems, but also 
provide a number of additional benefits that are unique to genetically engineered 
biopolymers. First, because ELPs are composed of amino acids, they are non-toxic [80] 
and biodegradable [81]. Second, ELPs have a favorable pharmacokinetic profile [82]. 
Third, because ELPs are designed and synthesized using genetic engineering techniques 
[83], the molecular weights of ELPs can be precisely specified resulting in monodisperse 
polymers, parameters that are critical to tune the pharmacokinetics of polymers. In 
contrast, the MW and polydispersity of synthetic polymers is difficult to control with the 
same level of precision as recombinant peptide polymers. Fourth, their composition can 
also be precisely encoded at the gene level. This has the consequence that the degree of 
hydrophobicity and the degree of ionization of an ELP can be precisely tuned, both of 
which impact its tissue distribution and sub-cellular uptake. Control over the ELP 
sequence also allows the numbers and locations of reactive sites for drug conjugation to 
be precisely specified, which allows the architecture of an ELP-drug conjugate to be 
controlled at the sequence level. Fifth, ELPs can be easily expressed at high yield (100-
200 mg/L) from Escherichia coli and rapidly purified by exploiting their phase transition 
behavior [84, 85]. 
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As elastin-like polypeptides retain their thermal responsiveness following 
chemical conjugation, ELP-drug conjugates have been rationally designed by optimizing 
their sequence and molecular weight to exhibit a phase transition between 39°C and 
42°C, a range that is achievable through the application of mild clinical hyperthermia. 
Triggering the phase transition through the application of mild hyperthermia increased 
cellular uptake of an ELP conjugated to a fluorescent reporter in three different human 
carcinoma lines in vitro (ovarian carcinoma SKOV-3, squamous cell carcinoma FaDu, 
and cervical adenocarcinoma HeLa) compared to a soluble ELP control [86], an effect 
likely mediated by enhanced interactions between the phase-separated ELPs and the 
phospholipid membrane of the cells. Meyer et al. observed that the ELP transition could 
increase total uptake in human ovarian tumors (SKOV-3) implanted within a dorsal 
skin-fold tumor window chamber model. The window chamber allows real-time 
fluorescent measurements of the vasculature and extravascular space of an implanted 
tumor. By heating the window chamber to 42°C, they observed a 2-fold increase in the 
intratumoral accumulation of a thermoresponsive ELP conjugate over the course of one 
hour when compared to a non-heated control [87].  
To further increase the accumulation of ELP-drug conjugates within solid 
tumors, Dreher et al. proposed a cyclical heating regimen [63]. Applying localized mild 
hyperthermia to a window chamber tumor model induced the formation of small ELP 
aggregates that adhered to the vascular walls, increasing in number and size over time 
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(Figure 2). Upon cessation of hyperthermia, the rapid solubilization of the ELP 
aggregates created a steep transvascular gradient that “pumped” the ELP into the tumor 
across the interstitial fluid pressure gradient. By measuring the fluorescence as a 
function of time, the authors observed that the thermally sensitive ELP displayed a 2.8-
fold concentration increase over a non-heated control and a 1.6-fold increase over a 
heated control that lacked the phase transition.  
 
 
Figure 2: ELP response to clinical hyperthermia visualized with a dorsal skin-fold tumor 
window chamber. A thermally sensitive (green) and a thermally insensitive (red) ELP in a 
solid tumor before, during, and following hyperthermia treatment. (A) Prior to heating, the 
green and red levels were normalized to produce a uniform yellow throughout the 
vasculature. Between (B) 10 minutes and (C) 30 minutes of heating, the thermally sensitive 
ELPs began to adhere to the vasculature walls, indicated by the green punctate fluorescence. 
(D) Upon return to normothermia, the aggregates rapidly resolubilized and dissipated, 
demonstrating the reversibility of the ELP transition. The scale bar represents 100 µm in all 
images [63]. 
 
This technique was also used in vivo to induce tumor regression in a murine 
E0771 breast cancer model. Thermally sensitive ELP-doxorubicin (DOX) conjugates were 
fused to the terminal cell penetrating peptide (CPP) SynB1 to enhance cellular uptake in 
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both tumor and vasculature cells. The DOX moiety was attached through a pH-sensitive 
hydrazone linker that rapidly cleaves in the low pH environment of the late endosome 
[88, 89]. The authors observed that thermally cycling (20 min heat; 10 min cool; 4 cycles) 
the tumor following each of the four SynB1-ELP-DOX administrations (2 day intervals) 
resulted in a statistically significant four-fold reduction in tumor volume by day 14 over 
normothermia treatment [90].  
While the delivery strategies described above rely solely on the application of 
mild hyperthermia to the tumor site, the diversity in structure and composition available 
to polypeptide carriers enables elastin-like polypeptide conjugates to utilize a vast array 
of “smart” triggers in conjunction with heat, including pH-sensitivity [91], ligand 
binding [92], metal ion concentration [93], and light [94].  
 
1.3.4.3 Micelles 
Diblock polymers exhibiting a large solubility difference between the two blocks 
form core-shell micelles above their characteristic critical micelle concentration (CMC) to 
reduce the unfavorable interactions between the hydrophobic block and the aqueous 
environment. The spontaneous self-assembly of micelles creates a hydrophobic, water-
excluding core stabilized by a soluble corona. First popularized by Kataoka and 
coworkers in 1990 [95], drug-encapsulating micelles remain a common therapeutic 
delivery vehicle because they exhibit many desirable characteristics for treating solid 
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tumors. The micellar core provides a high loading capacity for small and lipophilic 
molecules (i.e., most of the chemotherapeutic drugs on the market), while the 
hydrophilic corona –when comprised of specific polymers - can extend the plasma half-
life of the vehicle by evading uptake by the RES [96]. The sub-100 nm size and narrow 
size distribution is ideal for accumulating within the tumor interstitium by the EPR 
effect and avoiding renal filtration. Actively targeted micelles – whether through the 
addition of targeting ligands or the localized application of hyperthermia or magnetic 
fields – represent a new class of drug delivery vehicles that can increase the therapeutic 
payload reaching the tumor while decreasing nonspecific uptake in healthy tissues. To 
this end, micelles have been modified through the incorporation of thermally sensitive 
polymers, resulting in two basic classes of thermosensitive micelles that can be actively 
targeted to a solid tumor: micelles with thermoresponsive coronas and micelles with 
thermoresponsive cores. 
1.3.4.3.1 Micelles with thermosensitive coronas 
The most commonly used polymer in the design of thermosensitive coronas is 
poly(N-isopropylacrylamide) (i.e., pNIPAAm). This synthetic polymer displays a 
distinct lower critical solution temperature (LCST) at 32°C; pNIPAAm is a soluble 
polymer below this temperature but undergoes a coil-to-globule phase transition above 
32°C that makes it insoluble. The LCST phase transition is thermally reversible. The 
LCST is frequently tuned by copolymerizing pNIPAAm with a hydrophilic polymer to 
increase the LCST or a hydrophobic polymer to decrease the LCST [97]. Despite the large 
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compositional diversity of thermally sensitive micelles in the literature, there are only a 
few examples that are responsive within the physiological range of 39-43°C (Table 1) [72, 
98-104].  
 
Table 1: Thermosensitive therapeutic micelles that respond to clinical hyperthermia 
Thermosensitive Corona Core Block LCST (°C) Size (nm) Therapeutic Ref 
p(NIPAAm-co-AAm) PDLLA 41 80 Docetaxel [98] 
p(NIPAAm-co-AAm) PDLLA 39.8 80 Docetaxel [72, 99] 
p(NIPAAm-co-AAm) PDLLA 39.7 80 Paclitaxel [72] 
p(NIPAAm-co-DMAAm) PDLLA 40 65 Adriamycin [100] 
p(NIPAAm-co-DMAAm) PDLLA 39 170 Adriamycin [101] 
p(NIPAAm-co-DMAAm) PCL 40.5 87 Adriamycin [101] 
p(NIPAAm-co-DMAAm) PLGA 39 75-243 Doxorubicin [102] 
p(NIPAAm-co-DMAAm) PDLLA 39.4 20 None [103, 104] 
 
 
Figure 3: Diblock micelles with thermosensitive coronas. (A) At temperatures below the 
transition temperature of the thermosensitive polymer (orange; pNIPAAm), the hydrophilic 
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thermosensitive corona and the hydrophobic core (blue; poly(ɛ -caprolactone)) spontaneously 
assemble into micelles that can encapsulate drugs. (B) At temperatures above the LCST of 
pNIPAAm, the corona collapses into a hydrophobic coacervate, thereby destabilizing the 
structure and releasing the drugs [105]. 
 
In general, these micelles encapsulate their payload at physiological 
temperatures (37°C) and accumulate within the tumor via the EPR effect (Figure 3A). 
The subsequent application of hyperthermia to the tumor tissue induces the collapse of 
the thermoresponsive corona into a hydrophobic aggregate, which both enhances 
intracellular uptake by increasing hydrophobic interactions with the cellular membrane 
and drastically increases the rate of drug release within the tumor interstitium by 
destabilizing the micelle structure (Figure 3B). The micelles listed in Table 1 release DOX 
slowly and incompletely at 37°C, a temperature below the transition temperature, but 
rapidly release DOX at and above their respective transition temperature (39-43°C). The 
release of free drug from the micelles typically increases therapeutic efficacy by allowing 
the therapeutic molecule to penetrate deeply into the tumor due to its lower molecular 
weight and higher diffusivity.  
1.2.4.3.2 Micelles with thermally sensitive cores 
Thermally sensitive micelles can also be designed with the thermoresponsive 
polymer in the core. In contrast to micelles that disassemble and release their payload in 
response to hyperthermia, micelles that contain thermoresponsive cores spontaneously 
assemble when heated. This triggered assembly is uniquely suited to allow the 
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locoregional modulation of ligand density in response to heat [75, 106, 107]. In a recent 
example of the utility of this approach, MacEwan and Chilkoti synthesized diblock ELPs 
that self-assemble into monodisperse micelles in response to a thermal trigger, wherein 
self-assembly in the narrow temperature range between 37°C (normal body 
temperature) and 42°C (highest temperature approved for mild clinical hyperthermia) 
results in the presentation of a functional cell penetrating peptide  (CPP) motif on a ELP 
nanoparticle [75]. In this system, nanoparticles were assembled by fusing two ELPs: one 
with a hydrophilic composition and one with a hydrophobic composition, resulting in a 
diblock ELP (ELPBC) that exhibited two independent LCST transitions (Tt1 = 39°C and Tt2 
= 56°C). At systemic physiological temperatures (37°C) the ELPBC was in a unimer state –
soluble polymer chains– that display five Arg residues on one end of the polymer chain 
(Figure 4A). Five Arg residues were selected because previous studies have shown that 
there is minimum threshold of six consecutive Arg residues required to create a 
functional CPP [108], so at 37°C where the ELPBC is in a unimer state, cell uptake should 
be low. When heated to the range of clinical hyperthermia (42°C) the hydrophobic ELP 
(Tt1 = 39°C) collapsed into a hydrophobic core whereas the hydrophilic ELP formed a 
soluble corona decorated with a high local density of Arg (Figure 4B). This high-density 
presentation of arginine in the heated Arg5-ELPBC resulted in an 8-fold increase in 
cellular uptake in vitro compared to the 37°C control. Uptake was negligible for ELPBCs 
without fused CPPs and CPP-ELPs that did not self-assemble [75]. The presentation of a 
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functional CPP only at 42°C, but not at 37°C opens the way to convert CPPs which are 
powerful yet promiscuous agents to promote the uptake of drugs into cells into an 
exquisitely targeted system for cancer drug delivery via the application of focused 
external hyperthermia to solid tumors. While it remains to be seen whether this strong 
enhancement of cellular uptake in vitro translates in vivo, it represents a potentially 
powerful strategy to overcome the problem of nonspecific targeting of CPPs and 
promotes the tissue specific delivery of therapeutics.  
 
 
Figure 4: Diblock micelles with thermosensitive cores. (A) A diblock ELP construct that 
consists of a conjugated drug (red circle), a hydrophobic block with a low Tt (blue), a 
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hydrophilic block with a high Tt (orange), and a dysfunctional cell penetrating peptide (CPP; 
green triangle). At physiological temperatures, the diblock is a soluble chain and the low Arg 
density on the terminus of the ELPBC does not promote cellular uptake. (B) At ~40°C, 
desolvation of the hydrophobic block results in the assembly of spherical micelles that display 
a high density of Arg restudies, thus creating a functional CPP motif on the surface of the 
nanoparticle. This results in the enhanced uptake of the nanoparticles by cells heated to the 
clinically relevant mild hyperthermia temperature of 42°C [105]. 
1.3.4.4 Vesicles 
Since their debut in 1965 [109], liposomes have comprised a substantial fraction 
of known drug delivery vehicles and currently represent one of the most extensively 
studied systems in the literature. Liposomes consist of a stable phospholipid bilayer 
encompassing an aqueous core. The aqueous compartment is capable of encapsulating 
water soluble therapeutics whereas the phospholipid membrane can solubilize lipophilic 
molecules. Incorporation of small molecule therapeutics into liposomes improves drug 
performance by extending the plasma half-life [110], increasing the solubility of the 
drug, enhancing accumulation in solid tumors via the enhanced permeability and 
retention (EPR) effect [111, 112], and shielding the drug from deactivating plasma 
proteases [113]. These benefits are also reflected in the clinic where there are currently 
multiple systems in clinical trials and on the market, including the chemotherapeutics 
Doxil® and Caelyx® (pegylated liposomal doxorubicin) and Daunoxome® (liposomal 
daunarubicin) [114]. Despite the significant increase in tumor accumulation, these 
formulations continue to display poor drug bioavailability because they suffer from 
slow and incomplete drug release. Furthermore, the extended plasma half-life of the 
drug combined with nonspecific targeting can result in a number of systemic side effects 
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such as hand and foot syndrome [115]. Using clinical hyperthermia to trigger 
thermoresponsive liposomal drug release has emerged as a viable strategy to address 
these issues and allow the rapid release of the entire drug payload within the tumor 
vasculature. 
In sharp contrast to using hyperthermia to target the drug delivery vehicle to a 
diseased site, as is the case with ELP-conjugates, thermosensitive liposomes typically use 
hyperthermia to facilitate the release of their encapsulated payload. Yatvin et al. first 
developed temperature sensitive liposomes (TSLs) by selecting phosopholipids that 
provided an acyl chain gel-to-liquid crystalline phase transition at temperatures slightly 
above body temperature (42-45°C) [116]. The melting temperature (Tm) was tuned by 
mixing dipalmitoyl phosphatidylcholine (DPPC; Tc = 41°C) with small amounts of 
distearoyl phosphatidylcholine (DSPC; Tc = 54°C). The resultant vesicles displayed a 
single transition between 42.5 and 44.5°C that was accompanied by enhanced drug 
release. 
This basic design served as a foundation for further improvements in 
thermosensitive liposomal delivery. Based on several studies demonstrating that 
grafting short polyethylene glycol (PEG) chains to the surface of liposomes enhanced the 
plasma half-life, increased liposomal stability in serum, and reduced immune system 
recognition [110, 117], Li et al. showed that these “stealth” properties could be imparted 
to TSLs without affecting the stability of the liposome or the gel-to-liquid crystalline 
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phase transition [118]. The first few generations of thermoresponsive liposomes also 
suffered from a relatively slow release rate in response to hyperthermia (15-60 min). This 
slow release prevented the drug from releasing exclusively within the tumor 
vasculature, so these liposomes were allowed to accumulate in the tumor prior to 
hyperthermia exposure. To address this limitation, lipid components such as lysolipids 
and phosphatidyloligoglycerols were incorporated into the membrane to enhance the 
degree and speed of the thermal response [64, 119].  
Needham and Dewhirst have amassed a large body of work detailing the effect 
of incorporating the micelle-forming lysolipid, monostearoyl phosphatidylcholine 
(MSPC) into a stealth DPPC membrane (Figure 5A) [64, 65, 120-124]. At the melting 
temperature (Tm) of these liposomes, the membrane coexists in two states: solid 
crystalline regions separated by liquid grain boundaries. Upon heating, the incorporated 
lysolipids migrate to the grain boundaries in high concentrations where they form 
highly curved, semispherical pores that rapidly release the encapsulated drug (Figure 
5B) [125]. In fact, these self-assembled pores enable the encapsulated doxorubicin to be 
completely released in 10-20 seconds at mild hyperthermic temperatures, essentially 
allowing the drug to be released within the transit time through the tumor vasculature 
[64]. This rapid release has shown the ability to both flood a tumor with free drug and to 
shut down the tumor vasculature [65, 121, 124]. This technology, now owned by Celsion 
and marketed as ThermoDox®, is currently undergoing a phase II clinical trial for 
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recurrent chest wall disease for breast cancer patients and phase II and III clinical trials 
for metastatic and primary liver cancers (www.celsion.com). 
 
 
Figure 5: Temperature sensitive liposomes. (A) Under normothermia, micelle-forming 
lysolipids are uniformly dispersed throughout the phospholipid bilayer, forming a 
 30 
barrier that is impenetrable to encapsulated drugs. (B) Upon exposure to 
hyperthermia, the lysolipids congregate and form large pores that enable rapid drug 
release. (C) Liposomes conjugated to soluble pNIPAAm chains. (D) When heated 
above the pNIPAAm LCST, the chains become hydrophobic and destabilize the 
membrane, promoting the release of encapsulated drugs. 
Although micelle-forming lysolipids display a remarkable ability to rapidly 
migrate to grain boundaries and form pores, they have also shown the tendency to 
desorb from the bilayer when diluted or when in the presence of acceptor lipid pools. 
This process, which is likely to occur upon in vivo administration, destabilizes the 
membrane and significantly reduces the thermal sensitivity of the liposome. As an 
alternative, Kono et al. proposed a design in which the thermosensitive polymer poly(N-
isopropylacrylamide) (i.e., pNIPAAm) was used to decorate the outer membrane of the 
liposomes Figure 5C) [126, 127]. Upon reaching the pNIPAAm LCST, the grafted 
polymer experiences a hydrophilic coil to hydrophobic globule phase transition that 
disrupts the liposomal membrane, releasing the contents (Figure 5D). These 
formulations have shown high stability in serum and minimal leakage over time [71].  
Thermally sensitive liposomes have proven capable of capturing many of the 
passive benefits associated with the co-application of hyperthermia, including increased 
tumor accumulation and enhanced drug activity, as well as the active benefits of a rapid 
drug release in a site-specific manner. The safety and efficacy of this approach in human 
trials suggests that it will be a strong challenger in the upcoming decade to many of the 
passive strategies currently used in the clinic. 
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1.3.4.5 Dendrimers 
Dendrimers are a specialized class of synthetic polymers that consist of a 
spherical topology with a well-defined tree-like architecture. Polymer branches grow 
outward from a central core in a stepwise fashion such that each new branch represents 
a new generation. Thus, dendrimers are commonly described according to the number 
of generations, or branches, that they contain, which also correspond to their 
macromolecular size. In contrast to polymeric micelles, dendrimers are single molecules. 
Their interior contains numerous nanoscopic cavities that are capable of hosting guest 
molecules [128]. The specific environment of these cavities can be tuned to favor certain 
molecules by modifying the terminal end groups of the central polymer [129]. 
Dendrimers also offer a small size distribution relative to multimolecular micelles, can 
be easily functionalized, and are stable at very high dilutions. As they do not display a 
critical aggregation concentration (CAC), they do not suffer from structure 
destabilization and premature drug release upon systemic administration as can 
multimolecular micelles.  
Stratified dendrimers are generated by growing different polymer layers off of 
the terminal end groups. Thermally sensitive dendrimers have been created in this 
manner by decorating the outer layer with pNIPAAm. Increasing the temperature above 
the LCST of the dendrimer has been shown to increase the release rate of hydrophobic 
molecules encapsulated in the core [130, 131]. These dendrimers theoretically operate in 
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a manner similar to thermosensitive micelles: the dendrimers accumulate in a solid 
tumor via the EPR effect and are then triggered to release the encapsulated drug by 
hyperthermia. One example of this mechanism is the hyperbranched block copolymer of 
H40-poly(ε-caprolactone) and poly(N-isopropylacrylamide-co-acrylamide) that 
encapsulates paclitaxel [132]. Upon the administration of hyperthermia, the release rate 
of paclitaxel doubled and the hydrophobicity of the outer layer increased cellular uptake 
of the polymer.  
Surprisingly, it is also possible to design dendrimers that release their payload in 
response to hyperthermia without triggering an LCST phase change. Chandra et al. 
demonstrate that an oligo(ethylene glycol)-grafted amidoamine can encapsulate 
doxorubicin through a series of hydrogen bond interactions [133]. While these bonds 
result in a stable encapsulation at 37°C with only a basal 10% release over 24 hours, they 
rapidly break and release doxorubicin when heated to 43°C leading to 90% release in 2-3 
hours in vitro. With the continued development of stimuli-responsive branched 
structures, this thermally triggered release mechanism will undoubtedly become more 
prominent. 
 
1.3.4.6 Hydrogels 
Polymers can be crosslinked into three-dimensional hydrogel networks that can 
absorb large quantities of water, ranging from ~ten percent to thousands of times their 
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own weight. Hydrogels have become a popular material for drug delivery for several 
reasons: (1) the crosslinks between polymers vastly increase the physiological stability of 
the gel; (2) hydrogels can be loaded with aqueous drugs or vehicles that are released in a 
sustained manner via diffusion or matrix degradation; (3) their environmental 
sensitivity can be precisely controlled through the choice of polymer; and (4) many of 
the physical properties such as elasticity, degradation rate, swelling ratio, and 
hydrophilicity can be tailored by altering polymer parameters such as block length, 
polymer, crosslinker ratio, etc.  
Recently, nanohydrogels – hydrogels that range in size from tens to hundreds of 
nanometers – have begun to receive attention in the field of drug delivery. Similar to 
many polymer micelles, they are made through common self-assembly techniques such 
as solvent emulsion, diffusion, and precipitation [134]. Nanohydrogels retain the 
material benefits of a hydrogel and gain access to the broad range of applications 
available to nanoparticles: their small size promotes cellular uptake and tumor 
accumulation while avoiding renal filtration, and the outer shell can be decorated with 
ligands to target specific tissues and stealth polymers to extend the plasma half-life by 
evading the RES.   
Thermally sensitive nanohydrogels are formed by crosslinking polymers that 
display LCST behavior, most commonly p(NIPAAm) copolymers. Nanohydrogels that 
have been tuned to respond to mild hyperthermia maintain a swelled state below the 
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characteristic transition temperature (37°C) but experience a volume phase transition 
when heated above physiological temperatures (42°C). The hydrophobic collapse of the 
polymer chains results in a rapid shrinking of the nanoparticle, aggregation, and 
deposition within the heated tissue. The reduced volume may result in the expulsion of 
the entrapped water and/or molecules within the plasma during the transit through the 
tumor and following nanoparticle deposition within the heated tissue.  
Two different p(NIPAAm) copolymers have been used in the synthesis of 
thermally sensitive nanohydrogels. Zhang et al. showed that p(NIPAAm-co-AAm) 
nanohydrogel particles with a 50 nm diameter and a volume phase transition between 
37 and 43°C were able to deliver a near-infrared fluorophore (NIRF) to a heated tumor 
[135]. No tumor accumulation was observed for the dye by itself (with hyperthermia) or 
for the nanohydrogels without hyperthermia. The same group later showed that this 
methodology could also be used to deliver the chemotherapeutics docetaxel and 5-
fluorouracil [74]. In this study, nanohydrogels loaded with docetaxel displayed 
significant tumor inhibition against the S180 murine sarcoma line (78%) when coupled 
with mild hyperthermia, compared to nanohydrogels without hyperthermia (49%) and 
free docetaxel (40%). Peng et al. synthesized p(NIPAAm)-co-poly(2-
(dimethylamino)ethyl methacrylate) (PDMAEMA) hydrogel nanoparticles that 
experienced a volume phase transition that caused the 140 nm  diameter hydrogel 
particles to shrink to 100 nm at 41°C in vivo [73]. Loaded with the highly active SN-38 
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metabolite of the chemotherapeutic, irinotecan, these nanoparticles were used to treat 
the C26 murine colon carcinoma by spacing five treatments (20 mg/kg) over 15 days. In 
combination with hyperthermia, these nanoparticles induced a significant decrease in 
the tumor burden after 30 days post-treatment compared to the nanoparticles without 
hyperthermia (2.5-fold decrease) and free irinotecan (2.5-fold decrease). The extensive 
crosslinking found throughout these hydrogel systems provides a high degree of 
stability against the large mechanical and biological stresses of circulation that simply 
cannot be matched by classical polymer micelles. This unique characteristic of nanoscale 
hydrogels, which significantly reduces premature and off-target drug release, will likely 
become a commonly adopted motif in thermally targeted systems. 
 
1.4 Conclusions and Future Perspectives 
Many active-targeting strategies rely on the unique characteristics of tumors, 
such as drug release in response to tumor pH or ligands that bind upregulated receptors 
or enzymes. While these strategies can be effective, these features dramatically vary 
between tumors and even between patients diagnosed with the same cancer. In contrast, 
thermoresponsive chemotherapeutic delivery systems in combination with focused mild 
hyperthermia have the potential to circumvent the limitations of other active targeting 
approaches. Hyperthermia mediated targeting can remotely trigger the rapid release of 
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therapeutics, induce drug accumulation, and/or enhance cellular uptake in a site-specific 
manner.  
The thermally sensitive delivery systems that have been optimized to exploit this 
strategy typically display two common traits: (1) at the physiological temperature of 
37°C, the carrier protects the therapeutic from clearance, inactivation, and harmful 
interactions with healthy tissue; and (2) at temperatures above 39°C but below 43°C, the 
carrier undergoes a significant morphological change that results in rapid drug release 
or accumulation at the target site. Both of these effects result in increased drug 
bioavailability at the site of the tumor, thereby addressing the principle limitation of 
many chemotherapeutic regimens. Although the current state of the art exclusively 
utilizes polymers displaying LCST type behavior to release drugs in response to 
hyperthermia, we anticipate that the use of UCST (upper critical solution temperature) 
polymers that are insoluble at low temperatures and soluble at high temperatures will 
soon be integrated into these smart systems. This will open up new applications such as 
micelles that simply dissociate at high temperatures to release a payload and micelles 
that invert (the hydrophobic block becomes hydrophilic and the hydrophilic block 
becomes hydrophobic) past a specific transition temperature to outwardly present a 
ligand or CPP that was previously protected in the core.  
One of the challenges in the field at the synthesis level is the fact that most 
thermally sensitive systems are not designed to display a morphological transition in the 
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clinically relevant temperature range of 39-43°C in blood where the many cosolutes 
present can influence their phase transition behavior in unanticipated ways.  Hence, 
while many such systems have been reported, very few have been shown to explicitly 
exhibit their thermal phase transition in plasma or blood. Ideally, an engineered carrier 
that responds to mild hyperthermia would experience a highly cooperative phase 
transition (1-2°C range) in blood and hence have the ability to fully release its payload 
during its transit through the tumor vasculature. The cooperativity of this transition can 
be enhanced by minimizing the polydispersity of the polymer either by recombinant 
synthesis of peptide polymers that are completely monodisperse or alternatively using 
precision polymerization techniques for the chemical synthesis of polymers with low 
polydispersity [136-139]. The continued development of thermosensitive polymers and 
approaches to thermally trigger the targeted in vivo assembly and disassembly of drug 
delivery systems promises to provide exciting new tools for cancer chemotherapy. 
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2. Seamless Cloning of Elastin-like Polypeptide Genes 
2.1 Objective and Motivation 
The purpose of this chapter is to describe a strategy that enables the rapid 
construction of highly repetitive elastin-like polypeptide genes for use in drug delivery 
applications. The ease with which synthetic genes that encode these biopolymers can be 
assembled has greatly improved over the past decade, primarily due to advances in 
molecular biology for the synthesis and assembly of genes that encode multiple repeats 
of peptide “monomers.” These advances have been motivated by the utility of 
biopolymers for a variety of applications including biomaterials [140, 141], tissue 
engineering scaffolds [142, 143], as materials for surface modification [144] and as drug 
delivery vehicles [56, 89, 145]. The driving force for the use of artificial repetitive 
polypeptides in these applications stems from the ability of genetically encoded 
synthesis to control the polypeptide sequence, architecture, molecular weight (MW), and 
polydispersity with a precision that is, as yet, unmatched by chemical polymerization.   
As a result, a number of strategies to rapidly assemble synthetic genes that 
encode repetitive polypeptides have been developed, which include PCR cloning [146, 
147], concatemerization [148], overlap extension rolling circle amplification [149], and 
seamless cloning [150-152]. Our lab previously developed a method known as Recursive 
Directional Ligation (RDL) that utilizes stepwise, recursive addition of an oligomer with 
itself, or with another compatible DNA sequence by ligation of an insert with a 
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linearized parent vector containing a copy of the same or compatible insert [83]. RDL 
has proven to be very useful for the deterministic synthesis of genes that encode large 
biopolymers with a precisely specified molecular weight. It is also a useful method for 
the synthesis of genes that encode block copolymers when the orientation, sequence, 
and molecular weight of the two blocks are critical to their function. Although this 
method for the assembly of synthetic genes for repetitive polypeptides has proven to be 
extraordinarily useful, its limitations have also became apparent to us over the last 
decade of extensive use. These limitations are: first, it is not generalizable, a priori, to 
biopolymers of any arbitrary sequence. Although our implementation of RDL exploited 
codon degeneracy to select endonucleases that would enable seamless cloning of elastin-
like polypeptides (ELPs), the endonuclease recognition sequence in RDL overlaps the 
coding region. The type II restriction enzymes used in RDL place restrictions on the 
codons (and therefore the biopolymer sequence) that can be used in the gene (Figure 
6B). Second, RDL results in a significant number of clones lacking the insert due to self-
ligation of a vector or incomplete digestion of the vector, thereby increasing the number 
of colonies that must be screened in every round of cloning. Third, the insert itself can 
self-ligate and circularize, which reduces cloning efficiency at each oligomerization step. 
Fourth, RDL requires many time-consuming cloning steps. For example, our 
implementation of RDL was designed in a pUC vector that was unsuitable for 
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expression, such that the final product –the gene oligomer of interest– had to be cloned 
into an expression plasmid following gene construction.  
To address these limitations of RDL, this chapter introduces a significantly 
improved cloning methodology – Recursive Directional Ligation by Plasmid 
Reconstruction (PRe-RDL) – to rapidly clone repetitive polypeptides of any sequence 
and length. PRe-RDL is a modified form of Recursive Directional Ligation (RDL) that 
has new features that overcome the limitations of RDL [83]. In PRe-RDL, two halves of a 
parent plasmid, each containing the desired oligomer, are ligated together, thereby 
dimerizing the oligomer and reconstituting a functional plasmid. Unlike RDL, PRe-RDL 
is applicable to any arbitrary DNA sequence (and hence any peptide sequence) and 
produces peptide oligomers with no extraneous peptides at the junction between 
repeats, because it uses type IIs endonucleases (Figure 6C). Unlike most other classes of 
endonucleases, type IIs restriction enzymes cut at a defined number of nucleotides away 
from their recognition sequence. Because the cleavage site is degenerate, it allows the 
selection of any single amino acid to join two repeats. When this amino acid is selected 
as the leading or trailing peptide of the repeated segment, the junctions become 
seamless. This feature of PRe-RDL hence addresses the inability to oligomerize any 
arbitrary peptide sequence using type II restriction endonucleases, which was a serious 
limitation of RDL. The reconstitution of a functional plasmid only upon successful 
ligation in PRe-RDL also addresses two the other limitations of RDL: the significant 
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background from self-ligation of the vector and the decreased efficiency due to 
circularization of the insert. The modular design of PRe-RDL is suitable for the rapid 
generation of any repetitive peptide sequence of a specified length, and can also be used 
to join blocks of different lengths and sequences in a predetermined order.   
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Figure 6: (A) Recursive directional ligation by plasmid reconstruction (PRe-RDL) 
[153]. One round in PRe-RDL involves: (1) purifying the ELP-containing DNA 
fragment from the parent vector that is digested with AcuI and BglI; and (2) purifying 
the ELP-containing fragment from the parent vector that is digested with BseRI and 
BglI; and then (3) ligating the two compatible halves to reconstitute the original 
vector, and thereby doubling the length of the insert. (B) Original RDL vector design 
reported by Meyer [83], with a representative pentamer sequence. The identity of the 
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capitalized base pairs are specified by the recognition site of the restriction enzyme 
listed above those nucleotides. Note that the sequence of the restriction 
endonucleases required for RDL are contained within the DNA sequence that is 
oligomerized. The vertical arrows indicate the endonuclease restriction sites. (C) PRe-
RDL vector, which utilizes the type IIs restriction enzymes, BseRI and AcuI, to 
eliminate sequence dependence upon the recognition sites. The recognition sequence 
for BseRI has been designed directly into the Shine-Delgarno ribosomal binding 
sequence (RBS; underlined), AGGAGGAG, which is required to initiate translation. 
The BseRI cleavage site (‘CC’ in this vector) is 8-bases downstream of its recognition 
site. The recognition site for AcuI, CTGAAG, is 14-bases downstream of its 
degenerate cleavage site, which is ‘GG’ in this vector. The vertical arrows indicate the 
endonuclease cleavage site on the sense strand. (D) BseRI and AcuI have 2-bp 
overhangs, which reduces intra-sequence dependence within the repeating unit to a 
single amino acid. (E) Basic design for a leader sequence to be inserted into a vector 
restricted with NdeI and BseRI [153]. 
 
2.2 Recursive Directional Ligation by Plasmid Reconstruction 
2.2.1 Selection of Restriction Enzymes 
PRe-RDL is a methodology in which two halves of a parent plasmid, each 
containing a copy of a DNA insert, are ligated together, thereby dimerizing the insert 
and reconstituting the full plasmid (Figure 6A). To implement PRe-RDL to oligomerize a 
gene directionally (i.e., head-to-tail) and with no extraneous nucleotides introduced at 
the ligation junctions, six criteria must be fulfilled in the selection of the restriction 
enzymes: (1) one restriction enzyme (RE) must be unique (RE1), i.e., only present once in 
the cloning plasmid, and is needed to linearize the vector in preparation for ligation of 
the insert. (2) The second RE is preferably unique (RE2) to the cloning vector, but if it is 
present in the plasmid, it should be present only in Region II of the plasmid, which is 
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defined as the region between RE2 and RE3, excluding the insert (see Figure 6A). (3) RE1 
and RE2 must have different recognition sequences so that their sites can be cut 
independently of each other. This last feature is essential to implement PRe-RDL, as it 
allows the isolation of the A and B fragments that together constitute an entire 
functional plasmid. (4) The two enzymes must result in compatible overhangs, with at 
least a 2 bp overhang on their 3’-end so that the 3’-cohesive “sticky” end of the A 
fragment is compatible with the 5’-sticky end of the B fragment. (5) Palindromic 
overhangs at the ends of the repeat unit must be avoided to allow for directional and 
seamless ligation. (6) The plasmid must also contain a unique restriction site (RE3) 
elsewhere on the plasmid, with overhangs that are incompatible with RE1 and RE2. This 
restriction site is the point at which the plasmid is cut into two halves, both of which 
must be unable to circularize. Although the exact location of RE3 is not critical, it would 
ideally be within the antibiotic resistance gene to further decrease viability of each half 
of the plasmid. 
We first examined all three classes of restriction endonucleases, particularly 
those that were asymmetric, to identify enzymes that are capable of fulfilling these 
requirements. Although the cleavage sites of type I restriction endonucleases are 
asymmetrically displaced from their recognition sequence, this distance is highly 
variable, reducing their usefulness for cloning. Type II enzymes cut symmetrically 
within a palindromic or interrupted palindromic sequence, either of which places local 
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sequence constraints on the biopolymer. Type IIs and type III enzymes both cut 
asymmetrically at a defined distance from their recognition sequence, thereby 
eliminating any constraints on the sequence to be oligomerized. The only difference 
between the type IIs and type III endonucleases is structural, and either class of enzymes 
is suitable for PRe-RDL [154, 155]. 
Having identified type IIs or type III restriction endonucleases as the two classes 
of enzymes with the necessary attributes to implement PRe-RDL, we narrowed the 
choice of the enzymes by examining which of the many commercially available enzymes 
would be compatible with the commercial vectors. We chose to carry out 
oligomerization directly in low-copy number expression vectors, as working with high-
copy number cloning plasmids such as the pUC series – used for RDL – proved to be 
unnecessary, thereby eliminating one cloning step. Of the various expression vectors 
that are commercially available, we solely focused on the pET system (Novagen Inc.), 
given the high expression yield of diverse ELPs and their fusion proteins in this 
expression system [84, 85, 156]. 
These six requirements were met with BseRI, AcuI, and BglI as the three 
restriction endonucleases, and pET-24a(+) as the vector. BseRI is a type IIs restriction 
enzyme, whose recognition sequence is not present in the unmodified pET-24a(+), and 
AcuI is a type IIs enzyme, whose recognition sequence of CTGAAG only occurs once in 
the unmodified vector. BseRI cuts at a degenerate site 8 bps downstream of its 
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recognition site (GAGGAG) on the coding strand, which allows any two amino acids to 
be encoded between the recognition site and the beginning of the oligomer. AcuI cuts 14 
bps downstream of its recognition site, and permits any four amino acids to be encoded 
between its recognition and cleavage site. A dsDNA cassette was designed to 
incorporate both of these restriction endonucleases and include a short, default leader 
sequence (Met) and trailer (Tyr – Stop – Stop) that would encompass the oligomer until 
the desired length was obtained (Figure 6C).  BseRI was chosen as RE1 for the 5’-end of 
the ELP because the minimal default leader sequence (Met) was shorter than the two 
amino acid limit imposed by the choice of this enzyme.  In addition, the BseRI 
recognition site could be easily incorporated into the Shine-Delgarno ribosomal binding 
site proximal to the start codon. Similarly, AcuI was selected as RE2, because the default 
peptide trailer of Tyr-Stop-Stop was shorter than the four amino acid limit imposed by 
Acu I. This dsDNA cassette  consisting of two chemically synthesized oligonucleotides 
with XbaI and BamHI compatible sticky ends was then inserted into the multiple 
cloning region of pET 24a(+) by cleaving pET 24a(+) with XbaI and BamHI and ligation 
of this insert into the linearized plasmid. AcuI also only occurs once in pET 24a(+) 
vector, within Region II (Figure 6A). Both AcuI and BseRI have different recognition 
sequences (Figure 6C), so that the first three requirements were met by this pair of REs.   
The fourth and fifth requirements were considered simultaneously. If the 
enzymes resulted in overhangs of 3 bp or less, the overhangs would be contained within 
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the sequence of a single amino acid to maintain a seamless union. Because any repetitive 
gene can be designed to repeat seamlessly by partitioning the first amino acid into two 
complementary overhangs encompassing the monomer, RE’s yielding an overhang of 3 
bp or less are generalizable to any polypeptide sequence (Figure 6D). In systems that are 
even more sensitive to overhang length, RE’s with only one bp overhangs can be 
selected, such as AlwI, BceAI and BspPI. The sixth requirement was met by the selection 
of BglI as RE3 because its recognition site occurs only once on pET 24a(+), which is on the 
opposite side of the plasmid as the site of gene oligomerization. In addition, BglI has 
incompatible overhangs with AcuI and BseRI. 
 
2.2.2 Concatemerization Provides the Initial Oligomer Reactants 
In order to decrease the number of rounds in PRe-RDL, we exploited the fact that 
the inserts in PRe-RDL can be forced to concatamerize to create larger inserts that can 
serve as the starting point for PRe-RDL. The compatibility of PRe-RDL with 
concatemerization is especially useful to minimize the number of recursive steps 
required to arrive at genes with a high degree of oligomerization. We therefore 
concatemerized the monomer ELP4 genes that encoded (GVGVP)5 to obtain a hexamer 
that encodes (GVGVP)30 (see Figure 38 in Appendix 8.1 for precise sequence). Similarly, 
the ELP2 monomer (GXGVP)10  – a 10 pentamer ELP monomer where X alternates 
between A and G in a 1:1 ratio – was concatemerized to obtain the dimer, (GXGVP)20.  
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One of the limitations of concatemerization is that it is difficult to reliably obtain a large 
number of higher order oligomers. While concatemerization of the ELP4 monomer 
provided a hexamer with no trouble, ELP2, despite several attempts only yielded a 
dimer. 
 
2.2.3 Repetitive Gene Synthesis by Recursive Directional Ligation by 
Plasmid Reconstruction 
With the products of concatemerization (ELP4-30 and ELP2-20) in hand, we next 
proceeded to recursively dimerize these sequences by PRe-RDL. The gene for ELP4-30 
was doubled in each round to create the -60, -120, and -240 mers (Figure 7A).   The ELP2 
library was  similarly recursively oligomerized starting with the gene encoding 
(GXGVP)20 (ELP2-20) to obtain the -40, -80, -160, and -320 mers after each round of PRe-
RDL (Figure 7C). After the ELP2 gene library was generated, an ‘A’ fragment of ELP2-60 
and a ‘B’ fragment of ELP2-80 were then combined to generate ELP2-240 to demonstrate 
how PRe-RDL can be used to generate intermediate length ELPs (lane 7, Figure 7C). The 
same approach can also be used to join together two different sequences to create more 
complex block copolymers. Following the synthesis of the ELP2 gene library, the ELP2 
constructs selected for expression (ELP2-80, -160, -240, and -320) were all modified with a 
leader sequence to demonstrate that PRe-RDL also enables attachment of a leader L1, or 
a trailer, in a single round of cloning in order to increase yield.  
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Figure 7: ELP4 and ELP2 libraries produced by PRe-RDL [153].  (A) ELP4 gene library 
run on an agarose gel (1%). The left lane represents a size standard ladder, with sizes 
in base pairs shown on the left. Lanes 2-11 are diagnostic digests of each construct 
(restricted with XbaI and BamHI, which flank the ELP sequence with 66 bp), with the 
length shown on the right (in base pairs) and bottom (in pentapeptides).  Lanes 2-8 
were generated using concatemerization, while 9-11 were created using PRe-RDL. (B) 
ELP4 expression library run on an SDS-PAGE gel. The left lane is the Bio-Rad 
KaleidoscopeTM Ladder, with lengths in kDa on the left. Lanes 2-6 show the expressed 
ELPs with the lengths shown on the right (in kDa) and bottom (in pentapeptides). 
The dimer in lane 4 (ELP4-60 L1T1) is indicative of disulfide bonds formed between 
the cysteine residues present in T1. (C) ELP2 gene library run on an agarose gel. Lanes 
2-3 were generated using concatemerization, whereas lanes 4-8 were formed via PRe-
RDL. (D) ELP2 expression library run on an SDS-PAGE gel. To increase expression 
yields, the ELP2 library was modified with L1 (MSKGPG) on the amino terminus 
[153]. 
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2.2.4 Plasmid Reconstruction Enables the Facile Modular Addition of 
Leading and Trailing Peptides 
In the modified PRe-RDL cloning plasmid, the default DNA leader and trailer 
sequences are restricted in length by RE1 and RE2 to 2 and 3 amino acid residues, 
respectively. While this length of leader and trailer peptide may be adequate for some 
applications, in many instances having the flexibility to append other, longer leader or 
trailer peptides with any arbitrary sequence of interest is desirable, as they can provide 
peptide sequences for targeting, encode other purification tags (e.g., an oligohistidine 
tag) or provide unique reactive groups for site-specific conjugation of the polypeptide 
with drugs or imaging agents as is described in detail in the following chapters. To 
demonstrate the feasibility of appending an arbitrary leader and trailer peptide sequence 
(Figure 8), a leader plasmid (L1) consisting of MSKGPG and a trailer plasmid (T1) 
consisting of G(CGG)8WP were generated in separate cloning vectors, identical to the 
vector used in the ELP4 library. DNA encoding these leader and trailer peptides were 
added to ELP4-60 in a two-step process: (1) The ‘A’ fragment of L1 was ligated to the ‘B’ 
fragment of the ELP4-60, and (2) The ‘A’ fragment of the L1 ELP4-60 was ligated to the ‘B’ 
fragment of T1, generating L1ELP4-60T1. Once a desired length is reached, PRe-RDL can 
be used to add leaders and trailers of unrestricted length, although the addition of a 
leader or trailer prevents further seamless dimerization of the original monomer. 
However, this procedure enables the rapid generation of a library of leaders and a 
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library of trailers that can be used to systematically modify the 5’-and 3’-ends of the gene 
encoding a repetitive polypeptide once it has been assembled. For example, the ELP2 
constructs described in the following section (ELP2 - 80, -160, -240, and -320) were 
modified with L1 in a single round of cloning. While these modified constructs cannot be 
further dimerized with themselves in a seamless manner, each could be modified at its 
3’-end, either with a library of trailers, or other compatible sequences lacking the 5’-
modification. 
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Figure 8: PRe-RDL is a modular design that allows for the combination of multiple 
libraries.  This figure demonstrates the stepwise ligation of a leader to an ELP, and 
then the ligation of a trailer to the Leader-ELP fragment.  The ligation order shown 
here is not essential; leaders were appended to the ELPs before incorporating the 
trailers, though the order could be reversed if needed [153]. 
 
2.3 Validation of the Elastin-like Polypeptide Library 
To demonstrate that this method was capable of producing ELPs similar in both 
composition and physicochemical characteristics as previous recombinant strategies 
such as Recursive Directional Ligation, we designed two ELP libraries – one that has 
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been characterized extensively (ELP4) and one new library (ELP2) – and measured their 
molecular weight and thermal properties as follows. After validating the genes by DNA 
sequencing, each of the higher molecular weight ELPs from each library were 
transformed into BL21TM cells and expressed in 4 – 6 L of media each. The ELP was then 
purified by 3-5 rounds of inverse transition cycling (ITC), followed by overnight dialysis 
into distilled, deionized water and subsequent lyophilization. Each of the ELPs 
produced between 30 – 70 mg purified protein/L media, which was gravimetrically 
quantified. The size and purity of each of the expressed ELP4 and ELP2 specimens was 
visualized by SDS-PAGE (Figure 7B, 4D). Each of the ELPs ran approximately 20% 
higher than expected, which matches previously published data [83, 157]. To further 
verify the molecular weight of each of the constructs, ELPs < 240 pentapeptides in length 
were characterized by MALDI-MS (Table 11 in Appendix 8.4). The MWs of all ELPs 
determined by MALDI-MS were close to their calculated MWs, indicating that the gene 
oligomerization in PRe-RDL proceeded as expected. 
The thermal behavior of both ELP libraries was then assessed by monitoring the 
turbidity of a solution of each ELP as a function of temperature. The linear dependence 
of the Tt on the log of concentration can be seen for ELP4 in Figure 9A. The measured Tt’s 
for the ELP4 library were then compared with the fit generated for the same ELP 
sequence by Meyer and Chilkoti [158]. This fit (Equation 1) describes the Tt dependence 
of ELP in terms of the critical Tt (Ttc; °C), the critical concentration (Cc; µM), the length (L; 
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pentapeptides) of the sequence, the concentration of the ELP (Conc; µM), and k (°C), a 
proportionality constant (this equation will be discussed in more detail in the following 
chapter.) 
(1)           𝑇𝑡 = 𝑇𝑡𝑐 +
𝑘
𝐿𝑒𝑛𝑔𝑡ℎ
ln
𝐶𝑐
𝐶𝑜𝑛𝑐
   
Despite the small sequence variation at the C-terminus (the ELP4 library contains 
a Tyr trailer instead of the Trp-Pro trailer used in Meyer’s work) the model very 
accurately predicts the measured transition temperatures (Figure 9A). The ELP2 
constructs were also characterized in PBS, but their Tt’s were above 80°C, the highest 
measurable temperature on the temperature-controlled UV-vis spectrophotometer 
available for these studies. Their inverse transition behavior was hence analyzed in PBS 
+ 1 M NaCl, which significantly depresses the Tt, allowing the thermally triggered 
transition behavior to be quantified in a temperature range that is experimentally 
accessible (Figure 9B). The Tt of ELP2 in 1 M NaCl were not fit to Meyer’s model as this 
model does not compensate for the depression in the Tt due to the addition of salt. 
Figure 9C also shows the Tt dependence on chain length at the given concentration of 25 
µM for both ELP4 in PBS, which also closely matches the data obtained by Meyer, and 
ELP2 in 1 M NaCl. 
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Figure 9: Thermal properties of the ELP4 and ELP2 series [153]. (A) ELP4 Tt as a 
function of concentration and chain length. The dashed line represents the predicted 
Tt for each ELP4 length based on Meyer and Chilkoti’s model [158]. (B) ELP2 Tt as a 
function of concentration and chain length in 1 M NaCl. The ELP2 Tt was > 80°C at 
these concentrations. 1 M NaCl was added to depress the Tt to demonstrate the 
presence of the thermal transition. (C) The ELP Tt as a function of chain length at a 
constant 25 µM ELP. ELP4 is in a PBS solution, whereas ELP2 is in 1 M NaCl in PBS. 
The dashed line represents the expected Tt for ELP4 based on the model developed by 
Meyer and Chilkoti [158]. 
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2.4 Advantages of Recursive Directional Ligation by Plasmid 
Reconstruction 
The use of three restriction enzymes in PRe-RDL has the intrinsic benefit of 
reducing background by eliminating the possibility of self-ligation of the vector. This is 
possible because BglI (RE3) is incompatible with both BseRI and AcuI, so that each half 
of the vector can only ligate to its complement, rather than itself. PRe-RDL also increases 
cloning efficiency by eliminating the possibility of circularization of the insert. It has 
been our experience that RDL [83] has a high yield (up to 80%) when dimerizing small 
inserts < 1000 bp. However, the efficiency rapidly drops to 5-30% when working with 
inserts over 1000 bp. An added inconvenience of RDL is that the cloning is performed in 
a high copy number plasmid that is not designed for expression, so that the insert must 
be transferred to an expression vector once it reaches the desired length. Because this 
final length is commonly 1500 - 2400 bp, this step can be tremendously rate limiting. In 
contrast, this issue is eliminated in PRe-RDL, because cloning is carried out in an 
expression vector. PRe-RDL has shown efficiencies of 80-100% for dimerizing inserts less 
than 1500 bp, which gradually drops to 20-50% as the insert length approaches 2400 bp. 
However, even with the longest oligomer (ELP2-320, 4800 bp, 120 kDa), the final step of 
adding a leader was near 100%, suggesting that the reduced efficiency is limited to 
joining two large moieties. 
PRe-RDL was motivated by the utility –and limitations– of RDL, and it also 
borrows from the work of Kempe et al. who used Type II palindromic endonucleases 
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[159] to recursively clone up to 64 repeats of the 11-mer peptide substance P, and Lewis 
et al. [160] who also used Type II palindromic endonucleases to recursively synthesize 
genes consisting up to 32 repeats of spider silk protein [147]. Both Kempe and Lewis 
used the similar strategy of compatible but nonregenerating restriction sites to ligate two 
halves of a parent vector, each containing the oligomer, to reconstitute the plasmid and 
thereby double the oligomer length. This method allowed for recursion because as the 
oligomers were ligated together, the restriction site internal to the oligomer was 
abolished. Although these methods displayed the low background inherent in PRe-RDL, 
each was also restricted to sequences compatible with the selected palindromic 
endonuclease restriction sites, making each not generalizable to any arbitrary peptide 
repeat. Lee et. al used the unique asymmetric cutting characteristics of type IIs 
endonucleases to eliminate sequence constraints to oligomerize a gene encoding the 
antimicrobial peptide, magainin, in an iterative strategy based upon multiple 
concatemerization reactions, although the use of 4 bp overhangs resulted in a 4 bp seam 
between each monomer [148]. Ståhl et al. also capitalized on the asymmetry of type IIs 
endonucleases to build a polypeptide comprised of two different concatemerized 
sequences, each derived from malaria blood-stage antigen [150]. In a design similar to 
our own plasmid, they eliminate extraneous amino acid residues from the N- and C-
terminus as well as the junction between inserts. Our work combines the advantages of 
these methodologies by using type IIs endonucleases to allow for directional head-to-tail 
 58 
oligomerization of the gene encoding any peptide of interest, with no extraneous 
peptides encoded at the junction between two repeats, while maintaining the ability to 
encode a biopolymer of a predetermined length. The plasmid reconstruction strategy 
also greatly increases cloning efficiency, significantly decreases background, and limits 
self-ligation of the insert, thereby increasing the efficiency of cloning by reducing the 
loss of the insert in an unproductive side-reaction.  
 
2.5 Conclusions 
This chapter presents a straightforward and general method to rapidly produce 
repetitive polypeptides of any desired sequence and length over a wide range of 
molecular weights, which proved valuable in the generation of new ELP libraries 
described in later chapters. The key to this approach is to use type IIs restriction 
enzymes to produce seamless, head-to-tail repeats of any arbitrary DNA sequence by a 
process that requires reconstitution of the plasmid in every oligomerization step, while 
avoiding the problems of poor ligation efficiency and high background that limit RDL. 
Carrying out PRe-RDL with an initial concatemerization step in an expression vector 
permitted the gene assembly of two ELP libraries up to 4800 bp in length with 3-4 fewer 
steps than required by conventional RDL. With a dimerization efficiency of 80-100%, 
PRe-RDL is also enormously efficient compared to RDL, thereby largely simplifying the 
screening process at each cloning step. This system is also flexible in that the genes for 
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other, non-repetitive peptide sequences can be appended at the two ends of the gene, 
which allows leader and trailer peptide sequences with unique functional groups to be 
incorporated at the two ends of a repetitive polypeptide. This modular strategy is used 
in later chapters to generate new CP libraries by the C-terminal fusion of short (CGG)8 
peptides. 
 
2.6 Materials and Methods 
2.6.1 Materials 
Restriction enzymes and calf intestinal phosphatase (CIP) were purchased from 
New England Biolabs (Ipswich, MA). T4 DNA ligase was purchased from Invitrogen 
(Carlsbad, CA). The pET-24a+ cloning vector was obtained from Novagen Inc. (Madison, 
WI), and all custom oligonucleotides were synthesized by Integrated DNA Technologies 
Inc. (Coralville, IA). Top10™ cells were purchased from Invitrogen (Carlsbad, CA) and 
BL21™ E. coli cells were purchased from Novagen (Madison, WI). All E. coli cultures 
were grown in TBDry™ media purchased from MO BIO Laboratories, Inc (Carlsbad, 
CA). The DNA miniprep, gel purification, and PCR purification kits were purchased 
from Qiagen Inc. (Germantown, MD). 
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2.6.2 Methods 
2.6.2.1 Modification of pET-24(+) for PRe-RDL 
1.5 µg of the pET-24a(+) vector was digested with 20 U of XbaI and 20 U of 
BamHI in NEB buffer 3 for 4 h at 37°C. The 5’ ends were dephosphorylated with 1 U CIP 
for 1 h at 37°C, and the vector was then purified using the Qiagen PCR purification kit.  
The linearized vector was eluted in 30 µL of distilled, deionized water. Two 
oligonucleotides were designed: 5’ctagaaataattttgtttaactttaagaagGAGGAGtacatatgg 
gctactgataatgatCTTCAG -3 ’ and 5’- gatcCTGAAGatcattatcagtagcccatatgtaCTCCTC 
cttcttaaagttaaacaaaattattt – 3’. This DNA sequence was designed to encode two new 
endonuclease restriction sites for BseRI and AcuI (shown in capitalized letters), as well 
as a short leader sequence (Met) and trailer sequence (Tyr – Stop – Stop). The BseRI site 
was incorporated into the Shine-Delgarno ribosomal binding site adjacent to the start 
codon (underlined). The two oligonucleotides were annealed by heating each 
oligonucleotide (50 µL at 2 µM concentration) in T4 DNA ligase buffer to 95°C for 2 min, 
then slowly cooling the solution to room temperature over 3 h. This resulted in a double 
stranded (ds) DNA with XbaI and BamHI compatible sticky ends. Ligation of the 
modified cloning insert into the multiple cloning site within pET 24a(+) was carried out 
by incubating 20 pmol of the annealed dsDNA with 0.1 pmol of the linearized vector 
with 400 U of T4 DNA ligase at 20°C for 1  h in T4 DNA ligase buffer. The product was 
transformed into Top10™ chemically competent cells, which were allowed to recover for 
1 h at 37°C in Luria broth.  The cells were then plated on TBdry™ plates that were 
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supplemented with 45 µg/mL of kanamycin.  The sequence was then confirmed by DNA 
sequencing. 
2.6.2.2 Monomer Gene Synthesis 
A synthetic gene that encodes the (GVGVP)5 peptide sequence for ELP4 was 
synthesized as two 75 nt long single stranded oligonucleotides that encoded for the 
sense and antisense strands of the gene. The two oligonucleotides were annealed by 
heating each oligonucleotide (50 µL at 2 µM concentration) in T4 DNA ligase buffer to 
95°C for 2 min, then slowly cooling the solution to room temperature over 3 h. This 
resulted in a double stranded (ds) DNA with nonpalindromic, 2 bp, 3’ overhangs. The 
same procedure was used to anneal the two 150 nt long, single stranded 
oligonucleotides that encoded the (GXGVP)10 peptide sequence for ELP2, where X  
alternates between the amino acids A and G in a 1:1 ratio. 
2.6.2.3 Concatemerization 
1.5 µg of the pET 24a(+) modified cloning vector was digested with 2 U of BseRI 
for 16 h at 37°C. The 5’ ends were dephosphorylated with 1 U CIP for 1 h at 37°C, and 
the vector was then purified using the Qiagen PCR purification kit. The linearized vector 
was eluted in 30 µL of distilled, deionized water. Ligation of concatemers was carried 
out by incubating 20 pmol of the annealed dsDNA with 0.1 pmol of the linearized vector 
with 400 U of T4 DNA ligase at 20°C for 1 h in T4 DNA ligase buffer. The product was 
transformed into Top10™ chemically competent cells, which were allowed to recover for 
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1 h at 37°C in Luria broth. The cells were then plated on TBdry™ plates that were 
supplemented with 45 µg/mL of kanamycin. A detailed procedure is shown in 
Appendix 8.9.1. 
2.6.2.4 Gene Oligomerization by PRe-RDL 
PRe-RDL was used to recursively double the ELP4 gene that encodes (GVGVP)30 
and the ELP2 gene that encodes (GXGVP)20 where X = A and G in a 1:1 ratio, which were 
obtained after a single round of concatemerization. Using the dimerization of the 30 
repeat fragment of ELP4 in the second round of PRe-RDL as an example, the designated 
‘A’ fragment was obtained by digestion of 4 µg of ELP4-30 with 10 U AcuI and 40 U BglI 
for 3 h at 37°C (see Figure 6A) in NEB Buffer 2 (New England Biolabs; Ipswich, MA). 
The ‘B’ fragment was obtained by digestion of 4 µg of ELP4-30 with 8 U BseRI and 40 U 
BglI for 3 h at 37°C in NEB Buffer 2. Both DNA digests were run on a low melting point 
agarose gel. The ‘A’ digestion resulted in 3 bands: 1586 bp, 1821 bp, and a 2341 bp (1891 
+ ELP) fragment. The 2341 bp band was excised from the gel and purified with Qiagen’s 
gel purification kit. The ‘B’ digestion resulted in 2 bands: 1891 bp, and a 3857 (3407 + 
ELP) fragment, and the 3857 bp band was  excised from the gel, purified, and eluted in 
30 µL of distilled, deionized water. Equimolar amounts of the A and B fragments at a 
total DNA concentration of 5 ng/µL in a volume of 20 µL were ligated by incubation 
with T4 DNA ligase at 20°C for 1 h. Top10™ chemically competent cells were 
transformed with the ligation product, as described previously. Escherichia coli 
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transformants were screened by colony PCR and by diagnostic restriction digests on an 
agarose gel.  Each sequence was then confirmed by DNA sequencing. A detailed 
procedure is included in Appendix 8.9.1. 
 
2.6.2.5 Cloning of Leader and Trailer Sequences 
A plasmid containing a leader sequence and a plasmid containing a trailer 
sequence were also constructed. The gene segment encoding a (CGG)8WP trailer (T1) 
was created by annealing two chemically synthesized oligonucleotides that encode this 
peptide sequence, as described previously (Monomer gene synthesis). The annealed 
oligonucleotides were inserted into the linearized pET 24a(+) expression vector using the 
same preparation protocol and insert to vector ratios as provided in the 
Concatemerization section. The DNA segment encoding a MSKGPG leader (L1) was 
similarly synthesized by annealing two oligonucleotides, which provide the ‘TA’ and 
‘CC’ overhangs that are compatible with NdeI and BseRI (Figure 6E). Because the NdeI 
restriction site is between the BseRI recognition sequence and BseRI cleavage site, 1.5 µg 
vector was first digested with 8 U BseRI for 2 h at 37°C in NEB Buffer 2. 60 U NdeI was 
then added, and the sample was incubated at 37°C for an additional 1 h. The linearized 
vector was purified using a Qiagen PCR purification kit, and eluted in 30 µL distilled, 
deionized water. Annealing of the oligonucleotides encoding L1 to yield a dsDNA 
cassette, the insertion of the cassette into the linearized vector, and transformation of the 
plasmid into Escherichia coli, proceeded as described above. Colonies were screened by a 
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diagnostic restriction endonuclease digestion using XbaI and BamHI and agarose gel 
electrophoresis, and the sequence of positive clones were confirmed by DNA 
sequencing.   
The ligation of the plasmid encoding L1 to the ELP proceeded in a manner 
similar to a typical dimerization step in PRe-RDL. The construction of the ELP4-60 L1T1 
oligomer is shown in Figure 8 to illustrate the modular process by which a leader or 
trailer gene sequence can be appended to the 5’- and 3’-end of the oligomerized gene 
that encode for peptide sequences that are distinct from the repetitive polypeptide. The 
plasmid containing the gene encoding L1 was subjected to an ‘A’ digestion (AcuI and 
BglI), resulting in 3 bands: 1586 bp, 1821 bp, and 1903 bp (1891 + leader), and the 1903 bp 
band was excised and purified, as previously described. The ELP4-60 construct was 
subjected to a ‘B’ digestion (BseRI and BglI), resulting in the 2 bands: 1891 bp and a 4307 
bp (3407 + ELP4-60) fragment. These two fragments were ligated together under the 
previously described conditions, thereby joining the leader fragment to the N-terminus 
of ELP4-60 and reforming the parent plasmid. The colonies were then screened via 
diagnostic digest and sequenced. The plasmid containing the gene for T1 was then 
subjected to a ‘B’ digestion, resulting in 2 bands: 1891 bp and 3476 bp (3407 + trailer), 
and the 3476 band was excised and purified. The L1 ELP4-60 construct from the previous 
step was then subjected to an ‘A’ digestion, resulting in three bands: 1586 bp, 1821 bp, 
and 2803 bp (1891 + L1 ELP4-60), of which the 2803 band was excised and purified. The 
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two purified fragments were ligated together, which ligated the T1 encoding DNA 
fragment at the 3’-end of the gene encoding L1 ELP4-60, forming L1 ELP4-60 T1. E. coli 
transformants were screened by colony PCR, followed by a diagnostic restriction digest, 
and positive clones were confirmed by DNA sequencing. 
2.6.2.6 Expression of Elastin-like Polypeptides 
100 ng of plasmid DNA was transformed into chemically competent Escherichia 
coli BL21TM cells (Novagen; Carlsbad, CA), and used to inoculate a 250 mL flask 
containing 50 mL TBdryTM media supplemented with 45 µg/mL kanamycin. The cultures 
were incubated on a shaker at 200 rpm overnight at 37°C. This starter culture was then 
used to inoculate 4 L flasks containing 1 L of TBdry media with 45 µg/mL kanamycin. 
The flasks were incubated on a shaker at 200 rpm for 24 h at 37°C.  This 
“hyperexpression” expression protocol relies upon the leakiness of the T7 promoter to 
express the ELP [161]. 
2.6.2.7 Purification of Elastin-like Polypeptides 
After a 24 h incubation period, the cells were centrifuged at 3000 g for 15 min in 1 
L bottles. The cell pellet was resuspended in 10 mL of PBS, and the cells were lysed by 
54 cycles of sonication for 10 s separated by 20 s intervals (Sonicator 3000, Misonix, 
Farmingdale, NY) on ice. 0.7% w/v polyethyleneamine (PEI) was added to the cell lysate 
to precipitate nucleic acid contaminants. The ELP was then purified by inverse transition 
cycling (ITC) as follows: the cell lysate was centrifuged in a 30 mL round bottom tube at 
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11,000 g for 10 min at 4°C to precipitate the insoluble fraction of cell lysate. The 
supernatant, containing soluble ELP, was then transferred to a new 30 mL round bottom 
tube and heated to 37°C. For ELP2, which has a higher transition temperature, up to 3 M 
salt was added to trigger the phase transition at 37°C. Once the solution became turbid, 
it was centrifuged at 11,000 g for 10 min at 37°C to precipitate aggregated, insoluble ELP.  
The supernatant was decanted and the pellet was resuspended in 10 mL of cold, low 
ionic strength buffer (PBS). Typically, 3-5 rounds of ITC were enough to attain > 95% 
purity, as assessed by SDS-PAGE.   
2.6.2.8 Physicochemical Characterization of Elastin-like Polypeptides 
The purified ELP constructs were characterized with SDS-PAGE, matrix-assisted 
laser desorption/ionization mass spectrometry (MALDI-MS) and UV-vis 
spectrophotometry. The ELP concentration was determined by UV-vis 
spectrophotometry (Nanodrop, Thermo Scientific, Waltham, MA) using the extinction 
coefficient of tyrosine at 280 nm (1285 M-1cm-1) or tryptophan at 280 nm (5630 M-1cm-1).  
The purity of the ELPs was determined by SDS-PAGE, using 4-20% Tris-HCl Ready 
Gels™ (Bio-Rad, Hercules, CA), which were stained with copper chloride. MALDI-MS 
was performed on a PE Biosystems Voyager-DE instrument equipped with a nitrogen 
laser (337 nm). The MALDI-MS samples were prepared in a 50% (v/v) aqueous – 
acetonitrile solution, containing 0.1% trifluoroacetic acid, using a sinapinic acid matrix.  
To characterize the inverse transition temperature (Tt) of the ELPs, the optical density at 
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350 nm (OD350) of ELP solutions were measured as a function of temperature on a UV-
visible spectrophotometer equipped with a multicell thermoelectric temperature 
controller (Cary 300, Varian Instruments, Walnut Creek, CA) as follows: an ELP solution 
in PBS, at concentrations between 1 – 100 µM, was heated from 20°C to 80°C at a rate of 
1°C/min.  The Tt was defined as the temperature that corresponds to the maximum of 
the first derivative of its turbidity profile with respect to temperature, which is 
indicative of the onset of the phase transition. 
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3. Self-Assembly of Thermoresponsive Elastin-like 
Polypeptide Nanoparticles by Drug Conjugation 
3.1 Objectives and Motivation 
Most small molecule therapeutics utilized in the clinic have poor bioavailability 
and suboptimal pharmacokinetics because of their hydrophobicity and low molecular 
weight. Engineered drug delivery vehicles seek to improve the efficacy of these 
therapeutics by increasing their solubility, extending their plasma half-life, increasing 
the amount of drug deposited in the desired tissue, and decreasing their exposure to 
healthy tissues [41]. Repackaging hydrophobic drugs by sequestering them within the 
core of soluble polymeric nanoparticles can overcome these limitations by increasing 
drug solubility; the appropriate choice of polymer can also lead to long in vivo 
circulation and improved tissue distribution as compared to the free drug [41, 88, 162, 
163]. Furthermore, the choice of stimulus responsive polymers as the carrier suggests the 
intriguing possibility of endowing these nanoparticles with thermal responsiveness in 
the clinically relevant temperature range of 37-43°C that would allow them to be 
targeted in vivo to a site of disease by externally applied, focused mild hyperthermia. 
The launching point of our attempt to rationally design drug-loaded, thermally 
targeted nanoparticles was our recent observation that the site-specific (C-terminal), 
covalent attachment of multiple copies of doxorubicin –a small molecule 
chemotherapeutic– to a chimeric polypeptide (CP) resulted in the formation of near-
monodisperse micelles [88]. Chimeric polypeptides are comprised of two components: a 
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high molecular weight elastin-like polypeptide which imparts solubility and 
thermosensitivity to the system and a short cysteine-rich motif appended to the C-
terminus of the ELP that provides eight unique drug attachment sites. The observation 
that the attachment of doxorubicin to the CP initiated micelle assembly prompted three 
questions that provided the roadmap for this chapter: (1) is the conjugation triggered 
self-assembly of a CP observed in the previous study restricted to a small set of 
compounds or does it reflect a more general propensity of CPs to undergo self-assembly 
upon conjugation to small molecules? (2) If this is indeed a general phenomenon, what is 
the mechanism that drives their self-assembly? (3) If we can uncover the rules that drive 
self-assembly, can we use this information to rationally design drug-loaded 
nanoparticles that also exhibit thermal responsiveness in the clinically relevant 
temperature range of 37-42°C under physiologically relevant conditions? 
 
3.2 Formation of Chimeric Polypeptide Amphiphiles by Chemical 
Conjugation 
To explore these questions, 14 different maleimide derivatives of small molecules 
spanning a large range of hydrophobicity were covalently attached to a CP (Figure 10A). 
These model compounds were chosen with two considerations in mind: first, they 
display a range of hydrophobicity, as reflected by their octanol-water distribution 
coefficient, Log(D) [164]. Log(D) is a common measure in the pharmaceutical industry to 
describe the solubility of a compound, and is defined as the ratio of the concentration of 
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the therapeutic in octanol to the concentration in an aqueous buffer (pH 7.4) following 
extensive mixing. Second, they all contain a reactive maleimide moiety so that they 
could be covalently coupled to the CP. The CP used in this study consists of two 
segments: a hydrophilic, biodegradable elastin-like polypeptide (ELP) segment with a 
MW of 62 kDa, and a short, 1.6 kDa cysteine-rich Cys(Gly-Gly-Cys)7 segment that 
provides eight thiol groups for conjugation of the maleimide derivatives (Figure 10A).   
The CP was overexpressed from a plasmid-borne gene in Escherichia coli and was 
purified by a nonchromatographic method, inverse transition cycling [84, 85]. The model 
compounds with Log(D) values ranging from -1 to 4 were selectively conjugated to the 
Cys residues in the CP by a Michael addition reaction. Figure 10B displays the structure 
of the model compounds, as defined by their Log(D) at pH 7.4, where higher  
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Figure 10: (A) Sequence of the chimeric polypeptide. The 62 kDa ELP segment 
of the CP consists of 160 repeats of VPGXG with the guest residue X having the 
composition Val1Gly7Ala8. The 1.6 kDa cysteine-rich sequence at the C-terminus 
provides sites for covalent conjugation of maleimide derivatives of model 
compounds. (B) Structure of the model compounds. The circle represents a visual map 
of the model compounds and their hydrophobicity as measured by the distribution 
coefficient at pH 7.4. The attachment of compounds with a Log(D) ≤ 1.5 (shown in 
blue) did not trigger self-assembly of the CP, whereas compounds with a Log(D) > 1.5 
(shown in pink) triggered the CP to self-assemble into nanoparticles [77]. 
 
values indicate greater hydrophobicity. The Log(D) was calculated with the ACD 
Labs/PhysChem Suite [50], which fragments a molecule into non-overlapping structures. 
The Log(D) value is then calculated through a summation of the hydrophobicities of the 
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individual components and their correction factors [164, 165]. Following attachment, the 
degree of conjugation was assessed by measuring the ratio of free, residual cysteine 
residues, quantified with Ellman’s reagent, and the polypeptide concentration, 
measured by the bicinchoninic acid assay, and ranged from 3.3 – 6.4 for all of the 
molecules, as listed in Table 15 in Appendix 8.7.  
 
3.3 Physicochemical Characterization of the Formed 
Amphiphiles 
Next, the spontaneous self-assembly of the conjugates were investigated by 
dynamic and static light scattering (DLS, SLS), temperature-programmed turbidimetry, 
and fluorescence spectroscopy.  
 
3.3.1 Dynamic and Static Light Scattering 
The attachment of 3-6 copies of compounds with a Log (D) < 1.5 (shown in blue 
in Figure 10B) did not trigger self-assembly of the CP, whereas compounds with a 
Log(D) > 1.5 (shown in pink) imparted sufficient amphiphilicity to the CP to trigger their 
self-assembly into nanoparticles with the conjugated molecules presumably comprising 
the hydrophobic core. The conjugates that did not trigger self-assembly had an average 
hydrodynamic radius (Rh) of 5.9 ± 0.7 nm, which was similar to the Rh of the unmodified, 
control CP. In contrast, the conjugates that formed nanoparticles had an Rh ranging from 
30 nm to 58 nm, with an average standard deviation of ~15% within each population 
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(Figure 11B). There was no correlation between the hydrodynamic size of the 
nanoparticles and the number of molecules conjugated per CP (r2 = 0.0009).  
 
Figure 11: Physical properties of CP nanoparticles. (A) CP thermal characterization. 
Transition temperature (Tt) as a function of CP concentration of CPs conjugated to 
hydrophilic compounds (blue; unimer; compounds 1-5), and hydrophobic compounds 
(red; nanoparticle; compounds 6-10, 14) compared with an unconjugated control 
(black; unimer). The thermal behavior of all 6 CP-small molecule conjugates that 
formed nanoparticles was identical, and is hence plotted together as the mean of the 
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Tt of each of the CP-small molecule conjugate, and the error bars are the standard 
deviation. The lines are linear fits to the data. (B) DLS results of the CP-conjugate of 
compound 8 with a Log(D) of 2.1, which shows the increase in Rh from ~6 nm 
corresponding to unimers prior to conjugation to the formation of nanoparticles with 
a Rh of ~33 nm after conjugation. (C) Relationship between the Tt (left Y-axis, data in 
red) and Rh (right Y-axis, data in black) as a function of Log(D) for all 14 conjugates. 
As the Log(D) increases to greater than 1.5, the particle Rh increases from the unimer 
size of 6 nm to nanoparticles with an Rh of 30 – 55 nm for different conjugates. The 
concentration dependence of the Tt (slope from A) decreases from an average value of 
-5.5 to -1.0°C/Log(concentration). The curves in (C) are solely a guide to the eye [77]. 
 
Each nanoparticle-forming conjugate was next analyzed by SLS to determine the 
number of CPs per nanoparticle and the shape factor (ρ = Rg/Rh) that describes the 
distribution of mass within the nanoparticle. The shape factors ranged from 0.69 to 1, 
indicating that there is likely a significant difference in the morphology of some of these 
nanoparticles. The precise attribution of the morphology of nanoparticles by light 
scattering is subject to some ambiguity, as the shape factor is subject to deviations 
arising from polydispersity and shape diversity within the ensemble of nanoparticles. 
Shape factors of 0.775 are indicative of spherical micelles, which is likely to be the case 
for nanoparticles with ρ values in the 0.69 to 0.8 range, while nanoparticles with shape 
factors of ~1.0 could instead be vesicles, as spherical shells have a ρ of 1.0, or 
polydisperse rods with relatively low aspect ratios [166]. The apparent coordination 
number (Z) also varied significantly, ranging from ~10-60 for the different conjugates. 
We note that the apparent coordination numbers were not corrected for the critical 
aggregation concentration (CAC) of the nanoparticles, which suggests that the numbers 
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shown in Figure 15 are the minimum coordination numbers for each nanoparticle. There 
was a trend toward larger apparent coordination numbers as the hydrophobicity of the 
conjugated molecules increased (Figure 15).  
 
3.3.2 Cryogenic Transmission Electron Microscopy 
To directly visualize the morphology and shape diversity of the nanoparticles, 
selected conjugates were imaged via cryogenic transmission electron microscopy (cryo-
TEM). The samples were imaged at 80 keV to increase the contrast between the 
environment and the nanoparticle core, which exhibited a relatively high aqueous 
content. Figure 12 shows that the conjugates with a Log(D) > 1.5 formed nanoparticle 
cores distributed throughout the ice at regular intervals (Figure 12B-F) whereas the one 
hydrophilic conjugate displayed a film devoid of any structures (Figure 12A). In 
agreement with the light scattering data, the selected conjugates primarily consisted of 
spherical nanoparticles, though there were subpopulations of worm-like micelles and 
stiff rods present in a few of the samples (Figure 13) that may explain the variability of 
the shape factor measured by light scattering. 
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Figure 12: Cryo-TEM. CP conjugates were imaged via cryo-TEM in phosphate 
buffered saline. (A) N-methoxycarbonylmaleimide (Compound 1) did not form 
nanoparticles and is displayed as a negative control. The remaining conjugates 
spontaneously formed nanoparticles: (B) n-benzylmaleimide (Compound 7); (C) n-[4-
(2-benzimidazolyl)phenyl]maleimide (Compound 9); (D) 2-maleimido fluorene 
(Compound 12); (E) n-(1-pyrenyl)maleimide (Compound 14); and (F) paclitaxel. Scale 
bars represent 100 nm [77]. 
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Figure 13: Cryo-TEM of trace amounts of non-spherical morphologies. (A-B) Arrows 
indicate both spherical (large and small) and worm-like nanoparticles present within 
the n-acridinylmaleimide sample. (C) The 2-maleimidofluorene sample contained 
rod-like morphologies. (D) CP-Paclitaxel included both spherical and worm-like 
micelles. The scale bars represent 100 nm [77]. 
 
3.3.3 Fluorescence Spectrophotometry 
Four of the conjugates that formed nanoparticles were further characterized by 
fluorescence spectroscopy using pyrene as a probe of the local hydrophobicity, which 
enables measurement of the critical aggregation concentration (CAC) of self-assembled 
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nanoparticles [167]. For each conjugate, the ratio of the first fluorescence emission peak 
(I370-373) and the third peak (I381-384) were plotted over a range of CP concentrations (Figure 
14). The ratio smoothly transitioned from a low value indicating a lipophilic 
environment into which the pyrene can partition (I1/I3 = 1.35 – 1.45) at higher polymer 
concentrations to ~1.87 at lower polymer concentrations, a ratio indicative of 
disassembly and the release of pyrene into water (Figure 14B). This two-state transition 
indicates the disassembly of the nanoparticle upon reducing the concentration below the 
CAC. The sigmoid of best fit was used to calculate the CAC, defined as the inflection 
point of the curve. For an unmodified CP, the ratio remained independent of polymer 
concentration consistent with the absence of a lipophilic compartment, indicating the 
lack of self-assembly even at higher concentrations of the CP (Figure 14C). The CAC 
ranged from ~1-30 µM for the different nanoparticles, and higher Log(D) values were 
associated with a lower CAC (Figure 14D), and thus higher stability, which qualitatively 
scales with their hydrophobicity.  
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Figure 14: Fluorescence spectroscopy. (A) Pyrene fluorescence in water. (B) Pyrene 
fluorescence of a CP conjugate of N-(4-ethylphenyl)maleimide (compound 8) as a 
function of CP concentration in water. (C) Pyrene fluorescence as a function of 
concentration of unconjugated CP (control) in water. (D) Table showing the Log(D) of 
the conjugated molecule and the critical micelle concentration (CMC) of the CP 
nanoparticle conjugates calculated from the pyrene fluorescence assay for each 
conjugate [77].   
 
3.4 Self-Assembly Alters the Phase Transition Temperature 
These data clearly demonstrate that CPs can be driven to assemble by 
conjugation to a diverse range of hydrophobic small molecules. These results are also 
notable because they clearly reveal a simple predictive rule that governs the self-
assembly of CPs based on a threshold hydrophobicity of the conjugated small molecule. 
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Although the threshold of Log(D) > 1.5 predicts whether self-assembly will occur, the 
Log(D) of the conjugated molecule does not predict the size or shape of the nanoparticle 
that is formed, as we observed significant differences in both parameters based on the 
light scattering results that are likely related to structural differences between these 
molecules. 
We also found that the phase transition behavior of the CP was altered following 
conjugation of the model compounds (Figure 11A). CPs, similar to the ELPs from which 
they are derived, display a characteristic transition temperature (Tt), below which they 
are soluble in aqueous solutions, and above which they form polydisperse micron-sized 
aggregates. This Tt is typically modulated by varying the hydrophobicity of the guest 
residue (X), with hydrophobic guest residues depressing the Tt, and hydrophilic 
residues elevating the Tt [168]. In a similar manner, as the hydrophobicity of the 
conjugated molecules increased to the assembly threshold as defined by Log(D) = 1.5, 
the Tt shifted downward, though the dependence upon concentration (the slope) 
remained uniform (Figure 11A). Upon reaching this threshold, however, the Tt was 
immediately reduced to a temperature that was near-independent of concentration, 
though we note that this transition occurs from a nanoparticle to micron-sized 
aggregates in contrast to unmodified CPs, which undergo a transition from soluble 
unimers to micron-sized aggregates. Notably, all conjugates that form nanoparticles 
display the same thermal behavior that is described by the same quantitative 
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relationship between the Tt and unimer CP concentration. The fact that all self-
assembled CP nanoparticles display the same functional relationship between their Tt 
and their solution concentration (on a unimer basis) strongly suggests that their phase 
behavior is controlled by the high and invariant local CP concentration within the 
nanoparticles and not by the total concentration of the CP in solution.  
This finding is significant because this near-independence of Tt from CP 
concentration enables the nanoparticles to maintain a very stable Tt (within 2°C) over a 
100-fold decrease in concentration that would arise from physiological effects such as 
clearance from circulation. In contrast, the CP conjugates and the unmodified CP that 
exist as unimers show a Tt shift of over 20°C within the same concentration range 
(Figure 11A). The ability of these thermoresponsive nanoparticles to maintain a constant 
thermal response over a range of concentration eliminates the need to compensate for 
the effect of dilution and clearance that would occur upon their injection into systemic 
circulation and is hence likely to be an extraordinarily useful feature in future attempts 
to thermally target these CP nanoparticles to specific tissues in vivo by the application of 
external focused hyperthermia to disease sites. 
 
3.5 Hydrophobicity as a Predictor of Assembly 
These experiments with model compounds provide a simple physical model for 
self-assembly, in that molecules with a Log(D) > 1.5 will drive self-assembly of the 
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conjugate into nanoparticles. To further investigate the predictive validity of this model, 
three small molecule therapeutics were selected for conjugation to the CP through 
heterobifunctional linkers, where one end of the linker was attached to the CP and the 
other end to a reactive moiety on the drug. We chose three drugs that spanned a range 
of LogD at pH 7.4, estimated by ACD Labs/PhysChem Suite [50]: gemcitabine (-2.2), 
oxycodone (1.2), and paclitaxel (4.0). Conjugation of gemcitabine and oxycodone did not 
trigger self-assembly of the CP, while paclitaxel conjugation led to the spontaneous 
formation of nanoparticles that were similar in size to the nanoparticles that self-
assembled by the attachment of hydrophobic small molecules to the CP (Table 2 and 
Figure 15). Conjugation of paclitaxel to the hydrophilic CP also significantly increased 
the solubility of paclitaxel in excess of 2 mM paclitaxel equivalents in PBS, which was 
ultimately limited by the viscosity of the CP solution. Cryo-TEM of the CP-paclitaxel 
nanoparticles displayed close-packed spherical nanoparticles with a dense electron core, 
whose size (measured by the core-to-core distance) was smaller than the Rh determined 
by dynamic light scattering (RTEM = 22 ± 4 nm; n = 50) (Figure 12F). This discrepancy is 
likely due to the fact that the soft CP nanoparticle corona can become significantly 
compressed under the conditions necessary to visualize the particles with cryo-TEM 
(high shear stress may be induced by blotting and the high polymer concentration) 
when compared to the very dilute conditions necessary for light scattering 
measurements. The CP-paclitaxel nanoparticles were also highly stable with a CAC ≤ 10 
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µM (Figure 16). These results are consistent with the model: gemcitabine and 
oxycodone, as predicted by the model, were too hydrophilic to drive the assembly of 
nanoparticles at pH 7.4, whereas paclitaxel, with a Log(D) of 4.0, is above the threshold 
of hydrophobicity needed to trigger self-assembly. 
 
Table 2: CP nanoparticles assembled through drug conjugation 
Drug Log(D)[a] Rh (nm) Drug/CP #CPs/NP 
Gemcitabine -2.2 5.7 5 0.9 
Oxycodone 1.2 9.7 4 1.3 
Paclitaxel 4.0 53.3 2 72.0 
[a] Log(D) was estimated using ACD Labs/PhysChem Suite.  
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Figure 15: The apparent coordination number of the 14 small molecule conjugates (●) 
(#CPs per NP) versus the Log(D) of each molecule. Above the threshold of Log(D) = 
~1.5, the number of CPs per nanoparticle (#CPs/NP) increases with hydrophobicity of 
the conjugated small molecule [Log(D)]. The blue diamond, green square, and red 
triangle markers indicate gemcitabine, oxycodone, and paclitaxel, respectively. The 
lines are drawn solely as a guide to the eye [77]. 
 
 85 
 
Figure 16: CAC of CP-Paclitaxel. The pyrene fluorescence was measured for CP-PTX 
as a function of CP concentration in PBS. The CAC was defined as the inflection point 
of the curve; CAC = 6.1 ± 0.6 µM. The dashed line represents the sigmoid of best fit 
[77]. 
 
3.6 Conclusions 
Our results are notable for several reasons. Although attachment of drugs to 
polymers has been used to develop self-assembling therapeutic formulations, this work 
departs significantly both in its conceptual novelty and scope from these previous 
studies: adriamycin was covalently conjugated to the aspartate groups in PEG4300-b-
polyaspartate (NK911), thereby assembling into 50 nm micelles [95]; the biologically 
active metabolite of irinotecan, SN-38, was attached to the glutamate chain in PEG5000-b-
polyglutamate (NK012) to form  micelles [169]; and the polyaspartate chain of PEG12000-
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b-polyaspartate was modified with 4-phenyl-1-butanol, which induced assembly and 
facilitated the noncovalent incorporation of paclitaxel into (NK105)  [170]. In these 
studies, a general route to the conjugation triggered self-assembly of the polymer by a 
range of molecules was not shown, nor did these and related studies provide a model 
that enabled a priori prediction of the propensity –or lack thereof– of a molecule to 
trigger the self-assembly of the polymer [95, 171-173]. Furthermore, none of these 
systems exhibit the thermal responsiveness observed with these CPs over a range of 
concentrations relevant for drug delivery, a feature that can be exploited for in vivo 
thermal targeting of CP-drug nanoparticles 
In conclusion, this chapter illustrates a roadmap for the rational design of highly 
soluble, thermally responsive drug-loaded nanoparticles whose properties can be 
tailored at the molecular level. We show that attachment of small molecules above a 
critical threshold of hydrophobicity trigger self-assembly of the CP into soluble 
nanoparticles ranging from 60 nm to ~100 nm in diameter. These nanoparticles are 
soluble at concentrations greater than 100 µM of CP and ~3-6 fold higher for the small 
molecules, and are stable upon dilution up to low micromolar concentrations of the CP, 
a concentration regime that is of great utility for drug delivery. These results provide a 
simple predictive model for nanoparticle formation that permits a priori screening of the 
propensity of drugs to be sequestered into the nanoparticle core solely based on their 
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Log(D) value and demonstrate that conjugation-triggered self-assembly can package a 
hydrophobic drug into soluble nanoparticles.  
 
3.7 Materials and Methods 
3.7.1 Materials 
BL21™ Escherichia coli cells were obtained from Edge BioSystems (Gaithersburg, 
MD) and were grown in TBDry™ media (MO BIO Laboratories, Inc; Carlsbad, CA). 
Chemicals used for the purification of ELPs include: IPTG (Gold Biotechnology; St. 
Louis, MO), TCEP (Thermo Scientific; Waltham, MA), and ampicillin (CalBioChem; San 
Diego, CA). Maleimide derivatives were obtained from Sigma Aldrich (St. Louis, MO). 
 
3.7.2 Methods 
3.7.2.1 Synthesis of Chimeric Polypeptides 
The ELP segment of the CP selected for conjugation to the series of small 
molecule maleimide derivatives and the therapeutics gemcitabine, oxycodone, and 
paclitaxel– was comprised of the sequence SKGPG-(XGVPG)160-WPC(GGC)7, where the 
guest residue X = Val1, Gly7, Ala8, and is hereafter referred to as ELP2*. This specific guest 
residue composition of V1A8G7 and 160 VPGXG pentapeptide repeats was chosen to 
ensure that the CP has a Tt above body temperature in the concentration range of 1-100 
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µM, a concentration range that is useful for systemic delivery of drugs. This construct 
was synthesized using recursive directional ligation, as described elsewhere [83, 88].   
3.7.2.2 Expression and Purification of Chimeric Polypeptides 
The ELP was expressed using a previously published hyperexpression protocol, 
which relies on the leakiness of the T7 promoter [161]. 50 mL cultures grown for 16 h 
were used to inoculate six 1 L flasks of TBDry supplemented with 100 µg/mL ampicillin. 
Each 1 L flask was then incubated at 37°C for 24 h and 210 rpm, after which the cell 
suspension was centrifuged at 3,000 rpm for 10 min at 4°C. Each ELP was purified using 
Inverse Transition Cycling, which has been described elsewhere [84]. Briefly, the cell 
pellet was resuspended in PBS and lysed via sonication on ice for 3 min (10 s on, 40 s off) 
(Masonix S-4000; Farmingdale, NY). Polyethyleneimine (PEI) 0.7% w/v was added to the 
lysate to precipitate nucleic acid contaminants. The supernatant was then subjected to 
multiple rounds of ITC as follows. The solution was heated to 37°C in the presence of 3 
M NaCl. The coacervate was centrifuged for 10 min at 14,000 g and 20°C, and 
resuspended in 20 mM TCEP in water, pH 7. This suspension was cooled to 4°C, and 
then centrifuged for 10 min at 14,000 and 4°C to remove any insoluble contaminants. 
Typically, 3-5 rounds of ITC generated a sufficiently pure product (>95% by SDS-PAGE). 
3.7.2.3 Purity Analysis 
Following CP purification, SDS-PAGE was performed on Biorad ReadyGels with 
a 4-20% Tris gradient. The gels were visualized by copper staining (0.5 M CuCl2). 
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3.7.2.4 Dynamic and Static Light Scattering 
Dynamic and static light scattering measurements were performed using the 
ALV/CGS-3 goniometer system (Germany). Samples for the ALV/CGS-3 goniometer 
system were prepared in PBS at 20 µM CP and filtered through 0.22 µm Millex-GV 
filters into a 10 mm disposable borosilicate glass tube (Fischer). The tube was precleaned 
by washing three times with filtered ethanol (0.2 µM cellulose acetate filter). 
Simultaneous SLS/DLS measurements were obtained at 25°C for angles between 30°-
150° at 5° increments, with each angle consisting of 3 runs for 10 s. Results were 
analyzed by partial Zimm plot analysis using ALV/Dynamic and Static FIT and PLOT 
software. 
3.7.2.5 Cryogenic Transmission Electron Microscopy  
Cryogenic Transmission Electron Microscopy was performed at the University of 
Pennsylvania in the Penn Regional Nanotechnology Facility (Philadelphia, PA). Lacey 
formvar/carbon grids (Ted Pella) were washed in chloroform to remove the formvar 
template and carbon coated with a Quorum Q150T ES carbon coater (Quorum 
Technologies, United Kingdom). Grids were cleaned with hydrogen/oxygen plasma for 
15 s using the Solarus Advanced Plasma System 950 (Gatan, Pleasanton, CA). A sample 
in the form of a 2 µl drop was deposited onto the grid and added to a Gatan Cp3 
cryoplunger (Gatan, Pleasanton, CA). The samples were blotted by hand and plunged 
into liquid ethane. Grids were transferred to a Gatan CT3500TR cryoholder (Gatan, 
 90 
Pleasanton, CA) and immediately inserted into a JEOL 2010 TEM (JEOL, Tokyo, Japan) 
operating at 80 keV. Micrographs were imaged with an Orius SC200 digital camera. 
3.7.2.6 Absorbance Spectroscopy 
The transition temperature (Tt) of each sample was calculated by recording the 
optical density at 350 nm as a function of temperature (1°C/min ramp) on a temperature 
controlled UV-Vis spectrophotometer (Cary 300 Bio; Varian Instruments, Palo Alto, CA). 
The Tt was defined as the inflection point of the turbidity plot, or the maximum of the 
first derivative. All samples were analyzed in PBS, and 3-5 different concentrations 
ranging from 1 µM to 100 µM were used for each sample. 
3.7.2.7 Fluorescence Spectroscopy 
An assay to determine the critical aggregation concentration (CAC) using pyrene 
as a probe was performed using a Cary Eclipse spectrophotometer equipped with a 
Xenon flash lamp (Varian Instruments; Palo Alto, CA). 1 µL of a stock solution of 12 mM 
pyrene (Fluka/Sigma-Aldrich; St. Louis, MO) in ethanol was diluted into 20 mL of PBS. 
Both the stock solution and the PBS mixture were sonicated for 10 min prior to use. This 
solution was used to resuspend 1-5 mg of lyophilized sample, which was then used to 
create a dilution series. Each sample was placed in a reduced volume cuvette, and 
scanned (Ex: 334; Em: 360-380, Ex slit 10 nm; Em slit 2.5 nm). Pyrene fluorescence 
displays four peaks; the intensity at the first (I1; 370-373 nm) and third peak (I3; 381-384 
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nm) were recorded. The ratio I1/I3 was plotted as a function of CP concentration. The 
CAC was defined as the inflection point of the sigmoid of best fit. 
3.7.2.8 Conjugation of the Maleimide Derivatives 
15 mg of lyophilized CP was resuspended in 800 µL of 100 mM phosphate 
buffer, pH 7.4, and spiked with an additional 100 µL of 100 mM TCEP in water, pH 7.4. 
Finally 100 µL of a 50 mM solution of each maleimide derivative in DMSO was added to 
the CP solution dropwise, and allowed to mix for 3 h (additional DMSO was added for 
compounds that were not soluble in 10% DMSO). Following conjugation, the CP was 
purified by passage through a PD10 column (SEC) and dialysis in ddH2O overnight. The 
solution was centrifuged at 13,000 g and 4°C for 10 min, lyophilized, and stored at 20°C 
for future use. 
3.7.2.9 Conjugation of Drugs to the Elastin-like Polypeptide 
The specific chemical reaction schemes and characterization protocols (NMR, 
MALDI-MS, and ESI-MS) are included Appendix 8.9.2.1 (Gemcitabine), 8.9.2.2 
(Oxycodon), and 8.9.2.3 (Paclitaxel). 
3.7.2.10 Calculation of Conjugation Ratio 
Following purification, 2-3 mg of lyophilized ELP was dissolved in 1 mL ddH2O. 
In order to break any pre-existing disulfide bonds between unconjugated cysteine 
residues, 100 µL of the conjugate was incubated with 100 µL of Immobilized TCEP 
Reducing Gel (Thermo Fisher Scientific; Rockford, IL) for 1 h at 25°C. Included spin 
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columns were utilized to separate the TCEP beads from the CP conjugates. The solution 
was then split for use in two parallel assays. To determine the CP concentration, a 96-
well bicinchoninic acid assay (Thermo Fisher Scientific) was used on a Victor3TM 
microplate reader (Perkin Elmer; Waltham, MA) at an absorbance of 560 nm. 10 µL of 
CP solution was mixed with 200 µL of BCA working reagent, incubated for 30 min at 
37°C, and was compared  to an ELP standard curve (100, 75, 50, 40, 33, 30, 25, 20, 16.7, 
15, 13.3, 10, 6.7, 5, 3.3, 1.7, 0 µM) fit to a 2nd order polynomial in order to estimate the CP 
concentration. Each conjugate was measured in triplicate. To determine the 
concentration of free thiols, a 96-well Ellman’s assay was developed for use on the 
Victor3TM microplate reader at an absorbance of 405 nm. 40 µL of an ELP solution was 
mixed with 200 µL of a working reagent (25 µM Ellman’s reagent in 100 mM phosphate 
buffer, 1 mM EDTA, pH 8.0), incubated for 2 h at 25°C, and was compared to a standard 
curve of the ELP prior to conjugation (33, 30, 25, 20, 16.7, 15, 13.3, 10, 6.7, 5, 3.3, µM). The 
available cysteines in each sample could then be calculated by determining the ratio 
between the Ellman’s assay standard curve (assumed to have 8 free cysteines / CP) and 
the Ellman’s assay sample measurement at the concentration determined by the BCA 
assay. The conjugation ratio was the difference between the number of cysteines (8 / CP) 
and the calculated number of free cysteines. 
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3.7.2.11 Determination of Nanoparticle Assembly  
The determination of whether a construct assembled into a nanoparticle or 
remained in its unimer form was based on a combination of the Rh and the transition 
behavior (Figure 11). A few samples showed a combination of unimer and nanoparticle 
at 25 µM by DLS. This could be due to the following factors: (1) micelle theory indicates 
that nanoparticles assemble above a specific threshold concentration of unimer (CMC). 
As the bulk concentration increases past this threshold, the concentration of 
nanoparticles increases while the unimer concentration remains constant. If the 
concentration (25 µM) is near the CMC, then the unimer population will be visible via 
light scattering. (2) Since assembly is induced through the conjugation of chemicals, a 
polydisperse conjugation may result in some chains that are unconjugated or below the 
hydrophobicity threshold for assembly (i.e., only 1 molecule/chain), resulting in a 
substantial unimer population in addition to a nanoparticle population (3-4 
molecules/chain). All samples reported as unimer were >80% unimer by mass, displayed 
a Tt concentration dependence of approximately -5°C/Log(concentration), and had an 
average Tt of 65°C ± 8 (over all concentrations). Samples considered nanoparticles were 
>50% nanoparticle by mass, displayed a Tt concentration dependence of approximately -
1°C/Log(concentration), and had an average Tt of 50°C ± 1.  
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4. An Empirical Model for De Novo Design of Elastin-like 
Polypeptide Transition Temperatures 
4.1 Overview 
The previous chapter describes a method to assemble chimeric polypeptide 
nanoparticles whose transition behavior is near independent from the concentration of 
the polypeptide and the properties of the attached molecules (as long as the Log(D) > 
1.5). However, because Figure 11A clearly illustrates that the transition temperature 
resides outside of the desired 39-43°C range, it was necessary to devise a strategy to re-
engineer the CP transition behavior. In fact, many applications of ELPs require the Tt to 
occupy a narrow temperature window [56, 63, 76, 174-177]. Theoretically, an ELP or CP 
can be “forced” to exhibit a Tt within a given window by using highly concentrated or 
very dilute polymer solutions, by adding kosmotropic or chaotropic salts [178], or by 
using high or low molecular weight ELPs. From a practical perspective, however, this 
strategy is not typically feasible because the MW or concentration is often set by the 
application, while the addition of other cosolutes may be impractical in many 
applications or simply impossible if the intended application of the ELP is in vivo. These 
constraints on modulating the Tt of an ELP require an alternative strategy to tune the 
transition temperature for most applications.  
   Clearly, what is needed is an algorithm that quantitatively relates the Tt to ELP 
or CP composition, MW, and concentration. A unified model that does so would allow 
users to design ELPs and CP nanoparticles de novo for a range of applications by 
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constraining one or more of the operating parameters for a given application (MW or 
concentration) to yield one or more sequences that will exhibit the desired Tt. In 
response to this need, we first developed a quantitative model that predicts the Tt of ELP 
unimers from their sequence, MW, and concentration in phosphate buffered saline 
(PBS). We term this a unified model because it “unifies” the effect of ELP composition, 
MW and concentration on the Tt of the ELP within a single analytical equation. In the 
following chapter this model is used as the basis for a second model that describes the 
transition behavior of CP nanoparticles. 
   This model describing the transition behavior of ELP unimers builds upon, but 
departs significantly from previous studies that quantified the ELP phase transition 
behavior as a function of guest residue composition. Urry used chemically synthesized 
ELPs to demonstrate that their Tt correlated with the mean hydrophobicity of the guest 
residue [168, 179, 180]. That study did not, however, examine the effect of ELP MW and 
concentration on its Tt, two variables that we know have a large impact on the 
experimentally observed Tt in solution. In response to this limitation, Meyer and 
Chilkoti developed a quantitative model describing the effects of ELP chain length and 
concentration on the Tt of three different ELP libraries comprised of a mixture of Val, 
Ala, and Gly residues at the 4th guest residue position for a range of ELP chain lengths 
[158]. MacKay then modified that model to incorporate the effects of pH on the Tt for 
ELPs that contain ionizable residues at the guest residue position [91]. These models, 
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though valuable, only predict the Tt as a function of MW and concentration within a 
single ELP sequence, and only once at least three members of that sequence with 
different MWs have been synthesized and characterized with respect to their Tt. Because 
these models did not explicitly include a term that accounts for the effect of composition 
on the Tt, their utility as a design tool is limited because the composition is the most 
useful experimental parameter to modulate the Tt. In contrast, by incorporating ELP 
composition, MW, and concentration within a single equation that predicts the Tt, the 
model developed herein will enable de novo selection of ELP sequence and molecular 
weight combinations that will display a Tt of interest within a specific range of 
concentration.  
 
4.2 Elastin-like Polypeptide Sequence Design Considerations 
To develop this model, we first limited the sequence space, as the number of 
unique ELP sequences that will exhibit a desired Tt are enormous, even if one of two 
parameters such as MW or solution concentration are fixed. This is given by the fact that 
19 natural amino acids (and many more unnatural amino acids) are available to tune the 
Tt by incorporation at the guest residue position ‘X’ in the VPGXG repeat unit. The 
number of such sequences expands enormously when using a combination of three or 
more guest residues. We also restricted the choice of guest residues to a binary 
combination of amino acids to minimize the sequence order related complexity in phase 
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behavior because the complexity that sequence order creates can unpredictably alter the 
Tt [158]. Choosing a binary composition also has the benefit that it can be easily 
numerically encoded for modeling purposes.  
We hence narrowed the composition of the two guest residues to alanine (Ala) or 
valine (Val) at the guest residue position. We selected Ala and Val as the specific guest 
residues for two reasons: (1) because a major focus of our efforts is to design ELPs that 
would exhibit Tt’s in the physiological temperature range, we surmised that copolymer 
ELPs ranging from 100% Ala to 100% Val at the guest residue position would yield 
multiple copolymers that exhibit Tt’s between 30-45°C for a range of MWs and ELP 
concentrations, given that the Tt of their homopolymers span this range [180]; and (2) the 
side chains of Ala and Val are aliphatic and thus will not display a sensitivity to pH. 
Although the ability to tune the Tt by pH is potentially valuable [93], it adds an 
unnecessary degree of complexity to model development at this stage.  
With these parameters fixed, we recombinantly synthesized eight ELP libraries in 
Escherichia coli (the gene sequences are shown in Figure 38 in Appendix 8.1 and the gene 
libraries are shown in Figure 41 in Appendix 8.2). Each ELP library consists of a set of 
ELPs of constant composition as defined by the fraction of Ala at the guest residue 
(reminder is Val) with members in that library only differing in their MW, consisting of 
15, 30, or 60 kDa (40, 80, and 160 pentapeptides, respectively; Figure 44 in Appendix 8.3). 
The guest residue composition defined by the fraction of Ala steps across from 0 (solely 
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Val guest residue) to 1 (solely Ala guest residue) in increments of 0.1 or 0.2 across the 
eight ELP libraries. After expression in Escherichia coli, the 24 unique ELPs were purified 
to homogeneity; details of their physical characterization (SDS-PAGE and MALDI-MS) 
are contained in Appendices 8.3 and 8.4, respectively. 
We next fixed the solution conditions that the model was developed for by 
choosing phosphate buffered saline (PBS) as the solvent, as most applications of ELP are 
likely to be in biotechnology or medicine wherein PBS is the buffer of choice. We then 
measured the Tt of all 24 members of these 8 ELP libraries in PBS for a range of ELP 
concentrations (Figure 46 in Appendix 8.5). The experimentally measured Tt’s of these 
ELPs were used to develop a quantitative model that incorporates the effects of ELP 
MW, ELP concentration, and guest residue composition within a single equation.  
 
4.3 Development of a Mathematical Model to Describe the 
Elastin-like Polypeptide Transition Temperatures 
The first step in building the model was to quantify the effect of composition on 
the Tt of ELPs. Each ELP composition library followed the relationship previously 
developed by Meyer and Chilkoti [158] to describe the transition behavior of ELPs 
(average r2 = 0.987 ± 0.018): 
(1) 𝑇𝑡 = 𝑇𝑡𝑐 +
𝑘
𝐿𝑒𝑛𝑔𝑡ℎ
ln
𝐶𝑐
𝐶𝑜𝑛𝑐
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where the Tt depends on the chain length (Length, number of pentapeptide repeats) and 
polymer concentration (Conc, µM), as well as three parameters specific to each ELP 
composition: the critical transition temperature Ttc (°C), the proportionality constant k 
(°C·pentapeptides), and the critical concentration Cc (µM) (Equation 1). The Ttc 
represents the transition temperature for a given composition at a critical limit –high 
ELP concentration and chain length – at which point these two parameters no longer 
affect the Tt, and thus likely represents the lowest critical solution temperature of the 
system. The parameter Cc is the corresponding theoretical polypeptide concentration 
that would be required to achieve Ttc. Finally, the parameter k indicates the 
concentration and length dependence of the Tt: larger values signify that the transition 
temperature is more sensitive to concentration fluctuations or changes in chain length.  
 
Table 3: Summary of multivariate fits to Equation 1 for eight ELP compositionsa 
ƒ Alanine Ttc (°C) k (°C·pentapeptides) Cc (µM) r2 n 
1 54.3 (1.4) 623.0 (36.1) 844 (209) 0.98 30 
0.9 44.7 (2.0) 507.0 (53.1) 2412 (1311) 0.95 30 
0.8 39.3 (0.8) 484.7 (21.3) 2005 (442) 1.00 15 
0.7 33.8 (0.6) 433.7 (16.3) 2748 (547) 1.00 15 
0.6 29.9 (0.6) 387.0 (16.1) 3684 (851) 1.00 15 
0.5 27.7 (0.6) 316.9 (15.3) 6219 (1822) 0.99 30 
0.2 22.9 (0.2) 201.2 (5.0) 13573 (2307) 1.00 30 
0 20.2 (0.1) 144.1 (3.4) 22130 (3786) 1.00 30 
aData fit to Equation 1 and reported as estimate (standard error). 
‘n’ represents the number of measurements per fit. 
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These three parameters were simultaneously determined for each compositional 
library using a multivariate regression fit to Equation 1. The fits, summarized in Table 3, 
were based on a range of MWs (40, 80, and 160 pentapeptide repeats) and five ELP 
concentrations (100 to 5 µM). The ELP libraries are labeled according to their 
composition, which is defined by the fractional alanine content (ƒAlanine).  For example, 
a value of 1.0 indicates that the guest residue composition consists exclusively of 
alanine, and a value of 0.2 indicates that the compositional ratio is 2 alanine to 8 valine.  
We found that the parameters could be calculated with reasonable certainty with the 
exception of Cc, which showed a high level of variation that is likely due to its derivation 
from a logarithmic ratio.  
To elucidate the relationship between the ELP composition and the three 
parameters (Ttc, k, and Cc), each parameter was plotted as a function of ƒAlanine (Figure 
17). These plots revealed that the empirical relationship between the composition and Ttc 
(r2 = 0.947), k (r2 = 0.989), and Cc (r2 = 0.959) fit the exponential form Aeb·ƒAlanine, where A 
and b are constants. 
It is not entirely surprising that these parameters show a quantitative correlation 
with the ELP composition. Urry demonstrated that the critical transition temperature 
(Ttc) was influenced by the mean hydrophobicity of the guest residue composition [181]. 
We have also observed that the Tt’s of hydrophobic ELPs are less dependent on the 
concentration (hence smaller k values) than the Tt’s of hydrophilic ELPs. Meyer and 
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Chilkoti consolidated these observations by demonstrating that the parameters were 
related across three ELP libraries; they observed that k varied linearly with Ttc, whereas 
Cc varied as a power function with Ttc [158]. Although only three compositions were 
sampled and the ELP hydrophobicity was approximated by the Ttc (instead of the 
sequence, as demonstrated here), the postulated relationships are supported by this data 
set. As Ttc and k follow the form eƒAlanine, k as a function of Ttc generates a near-linear 
correlation (Figure 18; r2=0.929). Cc, on the other hand, is approximated by e-ƒAlanine, which 
signifies that Cc as a function of Ttc (eƒAlanine) yields a power function (Cc ≈ Ttc-1) (r2=0.938). 
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Figure 17: Relationship between the composition and the three parameters defined in 
Eq. 1. (A) Ttc, (B) k, and (C) Cc as a function of ƒAlanine. Data are reported as mean ± 
standard error. The dashed lines represent the best fit of the form Aeb·ƒAlanine [182]. 
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Figure 18: Parameters k (red; right axis; r2 = 0.929) and Cc (black, left axis; r2 = 0.938) as 
a function of Ttc. Data reported as estimates ± standard error. The dashed lines 
represent curves of best fit for k (linear) and Cc (power function) [182]. 
 
With these relationships validated, this exponential form was substituted for 
each parameter in Eq. 1 to yield Eq. 2: 
(2) 𝑇𝑡 = 𝐴𝑒
𝑏∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒 +
𝐶𝑒𝐷∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒
𝐿𝑒𝑛𝑔𝑡ℎ
ln(
𝐸𝑒𝐹∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒
𝐶𝑜𝑛𝑐
) 
where A-F are non-zero constants and ƒAlanine represents the ratio of alanines to the 
total number of guest residue positions. For fitting purposes, Eq. 2 was then simplified 
with logarithmic identities to yield Eq. 3:  
(3) 𝑇𝑡 = 𝐴𝑒
𝑏∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒 +
𝐶𝑒𝐷∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒
𝐿𝑒𝑛𝑔𝑡ℎ
[ ln(𝐸) + 𝐹 ∗ 𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒 − ln(𝐶𝑜𝑛𝑐)]  
Eq. 3 was used to perform a global multivariate regression analysis (n = 120) on 
the data to yield the empirical relationship between the Tt, chain length, concentration, 
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and composition for all synthesized guest residue combinations of Ala and Val 
(Equation 4):  
(4) 𝑇𝑡 = 16.8𝑒
1.1∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒 +
181.5𝑒1.2∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒
𝐿𝑒𝑛𝑔𝑡ℎ
[ ln(12881.2) − 2.3 ∗ 𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒 − ln(𝐶𝑜𝑛𝑐)] 
 A 3-dimensional surface plot of this model, holding the ELP concentration constant 
(Figure 19A) illustrates the wide range of Tt’s available to ELPs of varying length and 
composition. This model describes 99.4% of the observed variability in the Tt over all 24 
unique ELP constructs (Figure 19B) in PBS. Also evident from these data is the inverse 
relationship of Tt with chain length (Eq. 4); higher molecular weight ELPs exhibit lower 
Tt’s than smaller ELPs at the same composition and concentration. This graph indicates 
that there are several ELPs with a Tt above 100°C. Each Tt > 80°C in PBS (the temperature 
limit of our UV-Vis spectrophotometer) was linearly extrapolated from the Tt of the ELP 
at three different NaCl concentrations, which is known to quantitatively depress the Tt 
of ELPs as a function of NaCl concentration [178]. Finally, while this relationship holds 
true in PBS, the model does not apply to transition temperatures in different solvents, 
such as FBS. If this model was desired, the data points would have to be collected in FBS 
and fit to equation 3, as the transition temperatures of longer hydrophobic ELPs are 
affected less by the presence of cosolutes and salt than shorter hydrophilic ELPs. 
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Figure 19: (A) A 3-dimensional plot of the predicted Tt landscape for the Ala and Val 
superfamily of ELPs at 25 µM in PBS. (B) Predicted versus observed Tt for a global fit 
of eight ELP sequences across 3 molecular weights and 5 concentrations in PBS 
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(r2=0.993; n=120). (C) Predicted versus observed Tt for 3 additional sequences (A[0.2]-
20, A[0.5]-140, and A[0.8]-240) not included in the original data set. These three ELPs 
showed a high fidelity to the model (r2=0.999, slope = 0.95) [182]. 
 
4.4 Validation of the Model against Elastin-like Polypeptide Size 
Variants 
To test the robustness of the model, three ELPs were synthesized with molecular 
weights that were not included in the original data set (shown in Table 12 in Appendix 
8.4).  Figure 19C shows that the model accurately predicts (r2=0.999; n=15) the transition 
temperatures for ELPs with MWs that are larger (240 pentamers), smaller (20 
pentamers), and in-between (120 pentamers) the molecular weights used to construct the 
model. Finally, this model was used to develop Appendix 8.6 (Table 14), which provides 
possible combinations of sequence (ƒAlanine = 0 to 1 with a 10% Ala step size) and 
length (pentamers = 20 to 200 with a 10 pentamer step size) to achieve a specific Tt at a 
specified concentrations (1 to 1000 µM) in PBS. This resource provides a clear starting 
point for designing ELPs for specific thermoresponsive applications.  
 
4.5 Advantages of a Predictive Model for Elastin-like Polypeptide 
Transition Temperatures 
The selection of ELPs that exhibit a Tt within a specific temperature window has 
historically relied upon trial-and-error. The Meyer and Chilkoti model [158] was the first 
to quantitatively model the Tt of ELPs as a function of ELP chain length and 
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concentration. However, the model incorporated 3 parameters that could only be 
determined once the ELP was synthesized and its inverse transition behavior 
characterized. While the resulting relationship proved very useful in predicting the 
transition behavior of ELPs with different MWs within the same family, the absence of a 
defined “sequence” variable did not allow the a priori prediction of the Tt of new ELP 
sequences. The MacKay and Chilkoti model [91] expanded upon the Meyer and Chilkoti 
model by incorporating the Henderson-Hasselbalch equation to predict the relative 
quantities of protonated and nonprotonated residues. By splitting each of the 3 
parameters into protonated and nonprotonated parameters (for a total of 6 parameters), 
the MacKay model is able to predict the Tt of ELPs within a specific sequence family at a 
specific pH. While the third design parameter is useful in exploiting the pH behavior of 
charged ELPs, like the Meyer model it remains limited to a single ELP family at a time.  
The Meyer model can be applied in situations where the ELP library has already 
been generated and the user wants to know how changing the length or concentration 
will influence the Tt of a construct within that particular ELP library. The MacKay model 
also requires that the ELP library be constructed and characterized, and can be used to 
predict how length, concentration, or pH will influence the transition temperature of 
new constructs within that library. Because the model presented here is constructed 
from multiple separate ELP libraries, the user is able to predict how the length, 
concentration, and sequence will influence the transition temperature of entirely new 
 108 
libraries as long as the sequence is contained within that ELP superfamily (X=Ala and/or 
Val). This greatly increases the sequence space that can be screened for ELPs with the 
desired thermal behavior. 
The most important finding of this study is that each of the three parameters 
defined in the Meyer model can be described as an analytical function of the sequence, 
represented by the fraction of alanines in the guest residue position. This new feature of 
the model eliminates the need to express and characterize ELPs prior to predicting their 
Tt and thereby provides an a priori predictive tool for the design of ELPs in the 
superfamily of constructs containing Val or Ala guest residues. While this compositional 
limitation restricts the compositions available for designing new ELPs, we purposely 
selected Ala and Val because they exhibit transition temperatures that are far removed 
from each other, maximizing the coverage over the physiologically relevant temperature 
range that is of greatest interest to us. This is evident when observing the predicted 
range of Tt for ELPs of different MW at a specific concentration (100 µM): 40 pentamers 
(38.8 – 89.4°C); 80 pentamers (27.8 – 69.9°C); and 160 pentamers (22.3 – 60.2°C).  
This study also sheds light on the limitations of previous models that 
investigated whether the Tt’s of heterogeneous ELPs (heteropolymers composed of two 
or more different guest residues with a pseudorandom distribution of guest residues 
across the ELP’s primary amino acid sequence) could be calculated by linearly 
interpolating between the Tt of two or more homogeneous ELPs (homopolymers), and 
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then weighing each homopolymer ELP Tt by the mole fraction of the guest residue 
composition in the heteropolymer. The implementation of this method, however, has 
been met with conflicting results [158, 181]. This study conclusively demonstrates that 
the Tt of heteropolymer ELPs cannot be calculated in this manner. Figure 20 illustrates 
that the Tt for any combination of Ala and Val is clearly depressed from the linear 
interpolation between the Tt of the two homopolymer ELPs. While this particular set of 
conditions (80 pentamers at 25 µM) yields a maximum departure of ~5°C from the linear 
interpolation, the departure is inversely proportional to concentration and length. This 
study only examined the combination of two specific amino acids; it remains unknown 
to what degree other guest residue combinations will be affected, although it is our 
opinion that this error will be greatest when mixing guest residues of vastly different 
hydrophobicities. We hypothesize that the Tt is not simply dependent upon the mean 
hydrophobicity of the guest residue composition as previously proposed [181], but is 
actually determined by the specific sequence of the guest residues [183] and the 
difference in hydrophobicity between the guest residues. This hypothesis is currently 
under investigation.  
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Figure 20: (A) The global fit of the ELP Tt’s for ELP constructs with a chain length of 
80 pentapeptides and at 25 µM ELP concentration (red line) as a function of 
composition. The black dashed line represents a linear interpolation between the Tt’s 
of two homopolymer ELPs composed with 100% Ala or Val as their guest residue. (B) 
Error, defined as the departure of the linear interpolation from the global curve of 
best fit in degrees Celsius as a function of the fractional Ala content of the ELP [182]. 
 
4.6 Potential Improvements to the Model 
Although this model is a useful step forward in the design of ELPs, more 
remains to be done. Examination of Appendix 8.6 shows that although regions of the 
matrix of Tt as a function of ELP concentration is populated by ELPs with a range of 
MWs, there are regions in that matrix that are sparse in terms of available ELPs.  In 
particular, constructs that display low Tt’s at small MW and dilute conditions and 
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constructs that display high Tt’s at large MW and concentrated conditions are absent 
from the matrix. This is because at the extremes of MW and ELP concentration, this 
model is fundamentally limited by the properties of the Val (low Tt’s) and Ala (high Tt’s) 
homopolymers. Future studies will address this limitation by expanding this model by 
the synthesis and characterization of ELPs with other combinations of hydrophobic 
(Leu, Ile) and hydrophilic amino acids (Ser, Gly) that will provide additional ELPs to 
populate these regions of the matrix.  
This model could also be combined with the MacKay model to explore the pH 
sensitivity (in the physiological range) of the superfamily of ELPs constructed with 
glycine and histidine, for example. Finally, it should be noted that a similar model 
developed for other binary systems would not require 8 families of ELPs prior to 
constructing the Tt landscape of the superfamily. In fact, this model can be recreated 
with little to no loss of information with only 3 ELP families (the two endpoints and the 
midpoint: 0%, 50%, and 100% Ala) across 3 molecular weights and 5 concentrations 
(n=45). The resultant model predicts the Tt’s of all eight families with high accuracy (r2 = 
0.992; slope of predicted Tt versus observed Tt = 1.002; n=120).     
 
4.7 Conclusions 
The model presented in this chapter is the first to quantitatively correlate the Tt 
of a set of Ala and Val containing ELPs with an explicit compositional variable, its MW, 
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and concentration. This allows the a priori prediction of the Tt of any ELP consisting of a 
combination of Ala and Val at the guest residue position across a range of ELP MWs and 
concentrations in PBS. This simple analytical model provides researchers with an easy 
tool that can be implemented as an Excel™ (Microsoft Inc.) macro for the design of ELPs. 
The model will enable de novo design of ELPs wherein given a desired Tt in physiological 
buffer, the model will provide a set of ELPs (sequence and length combinations) that 
will exhibit that Tt across a specific concentration regime, thereby greatly facilitating the 
design of new ELPs. One of its most useful applications is likely to be in the design of 
ELPs that exhibit a Tt in aqueous solution under physiologically relevant conditions, 
thereby greatly facilitating their use in medicine and biotechnology. 
 
4.8 Materials and Methods 
4.8.1 Materials 
Restriction enzymes, calf intestinal phosphatase (CIP), and T4 DNA ligase were 
purchased from New England Biolabs (Ipswich, MA). The pET 24a(+) cloning vector was 
purchased from Novagen Inc. (Madison, WI), and all custom oligonucleotides were 
synthesized by Integrated DNA Technologies Inc. (Coralville, IA). The DNA miniprep, 
gel purification, and PCR purification kits were purchased from Qiagen Inc. 
(Germantown, MD). EB5α™ and BL21™ Escherichia coli cells were obtained from Edge 
BioSystems (Gaithersburg, MD) and were grown in TBDry™ media (MO BIO 
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Laboratories, Inc; Carlsbad, CA). Chemicals used for the purification of ELPs include: 
IPTG (Gold Biotechnology; St. Louis, MO) and kanamycin (CalBioChem; San Diego, 
CA). 
 
4.8.2 Methods 
4.8.2.1 Elastin-like Polypeptide Synthesis and Nomenclature.  
The synthetic genes for ELPs were assembled from chemically synthesized 
oligomers (IDT Inc.) by plasmid reconstruction recursive directional ligation (PRe-RDL) 
as described in Chapter 2 [153]. The oligomers used to construct each compositional 
library are described in Appendix 8.1. The ELP nomenclature used throughout this 
chapter is A[55]-Y, where X represents the fraction of alanine (A) in the guest residue 
composition (rest, valine (V)), and Y represents the length of the ELP in pentamers. 
4.8.2.2 Expression of Elastin-like Polypeptides 
BL21(DE3) cells transformed with an ELP-containing plasmid were used to 
inoculate a 250 mL flask containing 50 mL TBDry media supplemented with 45 µg/mL 
kanamycin. This flask was incubated on a shaker overnight at 200 RPM and 37°C before 
being used to inoculate six 4-L flasks containing 1 L of TBDry media, supplemented with 
45 µg/mL kanamycin. These cultures were incubated on a shaker at 200 RPM at 37°C for 
6 h, treated with 0.2 mM IPTG, and grown overnight. 
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4.8.2.3 Purification of Elastin-like Polypeptides 
Escherichia coli expression cultures were centrifuged in 1 L bottles at 4°C for 10 
min and 3,000 g to concentrate the cells. The supernatant was discarded and the cell 
pellet was resuspended in 10 mL PBS. The cells were placed on ice and were lysed via 
sonication for 3 min (10 s on, 40 s off) (S-4000 Misonix Sonicator; Farmingdale, NY). 
Polyethyleneamine (PEI; 0.7% w/v) was added to the lysate to precipitate nucleic acid 
contaminants, and the remaining cell debris was removed from the solution following 
centrifugation at 14,000 g for 10 min at 4°C. The ELP was then purified by two cycles of 
inverse transition cycling with minor modifications. The supernatant was heated to 60°C 
for 10 min, thereby inducing the ELP phase transition and precipitation of contaminant 
proteins, then immediately placed on ice to redissolve the ELP. Protein debris was 
removed by another centrifugation step (14,000 g, 10 min, 4°C). The supernatant 
(containing soluble ELP) was heated to 37°C, and NaCl crystals were added to a final 
concentration of 1-3 M to induce the ELP phase transition. ELP aggregates were 
precipitated by centrifugation (14,000 g, 10 min, 25°C), and the supernatant was 
discarded. The ELP was then resuspended in PBS, cooled, and centrifuged (14,000 g, 10 
min, 4°C) to remove any remaining insoluble contaminants. This cycle (starting at the 
60°C incubation) was repeated once more to yield the final product. The product was 
then dialyzed overnight in ddH2O and lyophilized. 
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4.8.2.4 Analysis of Elastin-like Polypeptides 
The purity of the ELPs was visually determined by SDS-PAGE, using 4-20% Tris-
HCl Ready Gels (Bio-Rad, Hercules, CA) stained with CuCl2 (0.5 M) (Appendix 8.3). 
MALDI-MS was performed with a PE Biosystems Voyager-DE instrument, equipped 
with a nitrogen laser (337 nm). Samples were prepared in a 50% (v/v) aqueous 
acetonitrile solution that contained 0.1% trifluoroacetic acid. The samples were analyzed 
in a sinapinic acid matrix, and all measured ELP masses were within a 0.5% margin of 
error (Appendix 8.4). 
4.8.2.5 Thermal Turbidimetry 
The optical density at 350 nm (OD350) of each ELP was measured as a function of 
temperature on a UV-vis spectrophotometer equipped with a multicell thermoelectric 
temperature controller (Cary 300, Varian Instruments; Walnut Creek, CA). ELP solutions 
in PBS ranging in concentration from 2 to 100 µM were heated at a rate of 1°C/min. The 
Tt was defined as the inflection point of the turbidity plot. To measure transition 
temperatures above 80°C, the ELPs were diluted into known quantities of NaCl in PBS 
(0.25, 0.5, 0.75, 1.0, 1.5, 2.0, or 2.5 M NaCl) to lower the Tt. A linear extrapolation of the Tt 
as a function of NaCl concentration for each ELP concentration was then used to 
estimate the transition temperatures in PBS [184, 185].  
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4.8.2.6 Data Analysis  
Non-linear regression analysis was performed with IBM SPSS Statistics 19.0 
(SPSS, Chicago, IL). MATLAB (MathWorks; Natick, MA) was used to generate the 3-
dimensional plot of the predicted Tt as a function of composition and chain length. 
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5. Development of Drug-Loaded Chimeric Polypeptides 
Micelles that Respond to Clinical Mild Hyperthermia 
5.1 Motivation 
Previous publications from our lab show that intravenously injected, thermally 
responsive ELP unimers allow thermal targeting of solid tumors by the application of 
mild hyperthermia to a solid tumor. This was achieved by tuning the ELP transition 
temperature between 39°C (slightly above physiological temperature) and 42°C (the 
temperature achieved with mild clinical hyperthermia) [186].  Because the physiological 
temperature is below the Tt, the ELP circulates systemically as a soluble unimer; upon 
reaching a heated tumor in which the temperature is above the Tt, the ELP undergoes its 
inverse phase transition and forms micron-sized aggregates that adhere to the tumor 
vasculature [187]. The localized aggregation of ELP in a tumor has been shown to 
increase uptake through two separate mechanisms. First, upon cessation of 
hyperthermia, the resolubilization of the ELP aggregates creates a steep transvascular 
concentration gradient that drives ELP extravasation into the tumor by diffusion. This 
effect was amplified by thermally cycling tumors in a two-step process: (1) inducing the 
accumulation of ELP aggregates by the application of mild hyperthermia to the 
implanted tumors; and (2) redissolving the ELP aggregates by turning off hyperthermia, 
which leads to an increase in drug accumulation within the tumor compared to passive 
diffusion under normothermic conditions or to a single cycle of hyperthermia [188]. 
Second, by complementary cell culture studies, we have previously shown that the 
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combination of hyperthermia and thermally triggered aggregation of ELP unimers 
increases cellular uptake by 2-fold in vitro, mediated through the interactions of the 
hydrophobic microscopic ELP aggregates with the cell membrane [189].  
While these results were encouraging, two limitations needed to be solved to 
move this system into relevant preclinical animal models. First, the in vivo 
demonstration of thermal targeting with ELPs was performed with polypeptides that 
lacked a relevant therapeutic cargo (typically fluorophores or radionuclides were used 
in these studies) and these markers were attached at low conjugation ratios (< 1 wt%) to 
a single reactive site on the ELP [57, 187-190].  We solved this problem by converting the 
ELP into a chimeric polypeptide by appending a drug conjugation peptide segment that 
provides a tunable number of reactive sites (typically 8 per CP, though this number can 
be increased at will) so as to increase the number of drug molecules conjugated per 
polypeptide chain.   
The second problem –that of the steep dependence of the ELP transition 
temperature on ELP concentration– was more critical, as it only provides a narrow 
temporal window in which focused mild hyperthermia of tumors could be applied, 
especially if repeated cycles of hyperthermia were required to increase the accumulation 
of the ELP within a tumor. This is because the temperature required to trigger 
aggregation of the ELP steeply increases as the ELP concentration within the blood is 
reduced through renal clearance, degradation, and normal tissue or tumor uptake. Once 
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the transition temperature increases above the hyperthermic tumor temperature (42°C) 
because of dilution effects, the ELP loses its thermal targeting capability. The self-
assembly of a CP into nanoparticles upon the attachment of drugs provides a solution to 
this problem, as these drug-loaded nanoparticles display almost no dependence on 
concentration in their thermal phase behavior and enable a useful amount of drug (~5 
wt%) to be loaded into the nanoparticle via chemical conjugation, a strategy that we 
have previously shown provides a nanoparticle formulation of Dox that is highly potent 
in vivo [191]. However, in that study, the CP-Dox nanoparticle was not designed for 
thermal targeting and consequently had a Tt that was far too high to be useful for tumor 
targeting by mild hyperthermia. To address this limitation, this chapter demonstrates 
that the CP can be redesigned to display a thermally triggered phase transition from 
nanoparticles to microscopic aggregates in vivo in response to mild hyperthermia, 
without compromising drug loading, stability, cytotoxicity, or in vivo pharmacokinetics 
and biodistribution. These attributes will finally allow us to exploit thermal targeting for 
the in vivo delivery of chemotherapeutics to solid tumors in relevant preclinical animal 
models. 
 
5.2 Development of a Mathematical Model to Describe the Phase 
Transition of Chimeric Polypeptide Nanoparticles 
Because the CP conjugates analyzed in Chapter 3 displayed an in vivo transition 
temperature (Tt) of ~50°C, we had to design new CPs that would be responsive within 
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the desired physiological range of 39-42°C. To this end, we created a series of CPs by 
appending the drug attachment domain (Cys-Gly-Gly)8 to the C-terminus of each ELP 
listed in the Chapter 4. The drug attachment domain consists of eight cysteines that 
provide unique reactive thiols for site-specific conjugation and seven digylcine spacers 
that reduce steric hindrance between the conjugated molecules. We selected the 
maleimide derivative n-benzylmaleimide for conjugation to the drug attachment sites 
because it displays sufficient hydrophobicity to drive assembly of CP nanoparticles, and 
the reaction is rapid, low cost, and can be performed in a single step. The thermal 
properties of the 24 unique CP nanoparticles formed by n-benzylmaleimide attachment 
were then measured with respect to CP concentration and fit to Eq. 3 via multivariate 
analysis to determine the values of Ttc, k, and Cc (Table 4).  
 
Table 4: Summary of multivariate fits to Equation 1 for CP nanoparticlesa 
ƒAlanine Ttc (°C) k (oC·pentapeptides) Cc (µM) r2 n 
1 45.7 (0.3) 63.6 (7.6) 4.0E+05 (5.2E+05) 0.99 15 
0.9 40.4 (0.5) 49.3 (13.3) 2.7E+06 (9.3E+06) 0.97 15 
0.8 37.6 (0.2) 35.0 (6.2) 4.4E+07 (1.2E+08) 0.99 15 
0.7 33.7 (0.2) 37.8 (4.7) 9.9E+06 (1.6E+07) 0.99 15 
0.6 31.0 (0.2) 36.4 (4.1) 1.4E+07 (2.1E+07) 0.99 15 
0.5 28.7 (0.2) 23.4 (4.7) 1.5E+09 (5.5E+09) 0.99 15 
0.2 23.4 (0.2) 16.5 (4.6) 7.8E+08 (3.9E+09) 0.98 15 
0 20.8 (0.2) 22.6 (3.9) 1.8E+05 (3.1E+05) 0.98 15 
aData fit to Equation 1 and reported as estimate (standard error). 
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Because the baseline transition temperature Ttc represents the lowest attainable 
transition temperature for a given composition once length and concentration effects are 
saturated (the lowest critical solution temperature), the value for a given CP 
nanoparticle should not significantly deviate from that of the parent ELP. As expected, 
we observed that the Ttc values for the nanoparticles remained statistically 
indistinguishable from those of the unimer sequences (p > 0.25; pair-wise t-test, 7 DOF). 
We have also shown that CP-drug nanoparticles are highly insensitive to changes in the 
bulk polymer concentration because the local polymer concentration within the 
nanoparticle is high and invariant, suggesting that the nanoparticles should display a 
lower k value [76]. In fact, when compared with the unimer values, the nanoparticles 
exhibited an average 11-fold reduction in k. This reduction provides a distinct advantage 
when designing CPs to display a specific Tt. For example, the ELP unimers examined in 
Chapter 4 exhibit an average ΔTt of 17.0 ± 12.4°C upon a 20-fold change in concentration, 
whereas the complement CP nanoparticles exhibit an average ΔTt of 2.0 ± 0.9°C upon a 
25-fold change in concentration. This demonstrates that while ELP unimers can be 
designed to display a specific thermal behavior within a defined concentration window, 
CP nanoparticles can be designed to transition in response to a specific temperature over 
a large range of concentrations. Finally, the parameter Cc, the theoretical concentration 
corresponding to the Ttc, was again highly variable due to its derivation from a 
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logarithmic ratio. The exceptionally large values were a byproduct of reducing the 
parameter k while maintaining the Ttc. 
The global dataset for the CP-drug nanoparticles was fit to Eq. 3, which yielded 
the following empirical model:  
(5) 𝑇𝑡 = 20.0𝑒
0.8∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒 +
17.1𝑒1.2∗𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒
𝐿𝑒𝑛𝑔𝑡ℎ
[ ln 6.4𝑥106 − 0.4 ∗ 𝑓𝐴𝑙𝑎𝑛𝑖𝑛𝑒 − ln(𝐶𝑜𝑛𝑐)] 
where fAlanine represents the guest residue composition of the ELP domain in terms of 
alanine (rest valine), Length represents the chain length of the polypeptide in 
pentapeptide units, and Conc represents the solution concentration of the CP. 
Similar to the model developed for ELP unimers, the CP nanoparticle model also 
described 99% of the variability in the data (Figure 21A; r2=0.994; n=120). While the 
distribution of the constructs follows a similar pattern to the global unimer fit (Figure 
19A), the CP nanoparticle range is much smaller (64.8 - 21.2°C) than the ELP unimer 
range (135.8 - 23.1°C). This model demonstrates that CP-nanoparticles display a thermal 
behavior that is not only predictable and tunable, but also much less susceptible to 
concentration fluctuations than ELP unimers. This model enables the selection of specific 
molecular weight and composition pairs that display sharp phase transitions in response 
to specific temperatures in PBS (Figure 21B). 
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Figure 21: (A) Predicted versus observed transition temperatures for a global 
fit of CP nanoparticles in PBS (r2=0.994; n=120). The CP nanoparticles were generated 
through the conjugation of n-benzylmaleimide to the C-terminal cysteine residues. 
(B) The model was used to predict the composition and length of a family of 
thermally responsive (39-42°C) CP nanoparticles (shown in red) at a concentration 
regime typical of CP drug delivery applications (25 µM). 
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Despite the utility of this model for the prediction of transition temperatures in 
phosphate buffered saline, it was essential to examine the thermal behavior of the CP 
nanoparticles in a relevant medium. This is necessary because the ions and proteins in 
serum lower the transition temperature from the values measured in PBS [187]. In order 
to mimic the vascular environment, we measured each of the CP nanoparticles in 90% 
fetal bovine serum (FBS) at a fixed concentration of 50 µM (Figure 22). We were able to 
screen the phase transition behavior of nanoparticles generated by attaching the model 
compound n-benzylmaleimide because the transition profiles between these 
nanoparticles and those generated through the attachment of other compounds such as 
n-pyrenylmaleimide and doxorubicin remained nearly indistinguishable (less than 1°C) 
in 90% FBS (Table 5), which suggests that the curves in Figure 22 can be used to predict 
transition temperatures for a variety of CP conjugates in vivo. It can also be seen that the 
three CP-drug nanoparticles selected for doxorubicin attachment (indicated by arrows in 
Figure 22) represent potential compositions at each length (40, 80, and 160 pentamers) 
that can be used to induce a nanoparticle-to-aggregate transition in conditions of mild 
hyperthermia.  
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Figure 22: Observed (markers) transition temperatures for CP nanoparticles 
(conjugated to n-benzylmaleimide) in 90% FBS. Dashed lines represent the best 
exponential fit. Black dashed lines demarcate the targeted range of hyperthermia (39 
to 42°C). Indicated constructs (↓) represent those selected for additional in vivo 
thermal targeting studies. 
 
Table 5: Phase transition temperature of three CP nanoparticles of varying molecular 
weight in 90% FBS in response to conjugation to three compounds  
  
Observed Tt (°C, 50 µM) a 
ƒAlanine Length N-Benzylmaleimide N-Pyrenylmaleimide Doxorubicin 
1 160 42.7 (0.6) 43.2 (0.1) 42.9 (1.1) 
0.8 80 40.5 (0.2) 40.7 (0.1) 39.8 (0.4) 
0.6 40 40.5 (0.7) 40.8 (0.2) 39.8 (0.3) 
aData reported as estimate (standard error) 
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5.3 Screening Physicochemical Properties of Chimeric 
Polypeptide Nanoparticles as a Function of Chain Length 
The model presented in Figure 21 (transition temperatures in PBS) and Figure 22 
(transition temperatures in 90% FBS) indicates that there are numerous combinations of 
chain length and sequence capable of transitioning within the narrow temperature 
window of 39-43°C. To narrow the field of candidates, we selected chimeric 
polypeptides of three different molecular weights (15, 30, and 60 kDa) from within this 
thermal window for three reasons: first, these specific chain lengths were generated in 
the recursive cloning process and required no further processing prior to expression and 
purification. Second, these sizes span the range of the chimeric polypeptides used to 
construct the mathematical model. Lastly, this size range also supplies polypeptides that 
are both above (60 kDa) and below (30 and 15 kDa) the estimated renal filtration cutoff, 
which has consistently played a strong role in the plasma clearance of macromolecular 
carriers [192, 193].  
 
5.3.1 Light Scattering Analysis 
To examine how chain length influences the physicochemical properties of the 
nanoparticles, each of these constructs were separately conjugated to the 
chemotherapeutic doxorubicin via an acid labile heterobifunctional linker to drive self-
assembly into nanoparticles and enable the rapid intracellular release of the drug once 
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exposed to the low pH of the late endosome [88]. Upon conjugation, the CPs 
spontaneously assembled into micelles with a hydrodynamic size that linearly 
correlated with chain length (Figure 23). Static light scattering analysis indicated that the 
average number of chains per micelle (calculated by dividing the absolute molecular 
weight of the assembled structure by the polypeptide molecular weight) was inversely 
proportional to the chain length, with the micelles comprised of 160 pentamer units 
displaying 13 chains per structure, the 80 pentamer units 18 chains per structure, and the 
40 pentamer units 45 chains per structure. 
 
 
Figure 23: Light scattering analysis of CP-Dox nanoparticles. Points in red represent 
the hydrodynamic radius, and the points in black represent the average number of 
CPs per nanoparticle as calculated by dividing the absolute molecular weight of the 
micelle by the molecular weight of the CP. 
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5.3.2 In Vitro Cytotoxicity 
After verifying that doxorubicin conjugation initiated the formation of micelle 
structures, we next examined how chain length affected cytotoxicity in vitro. C26 cells 
isolated from a murine colon adenocarcinoma were exposed to CP-Dox nanoparticles 
over a wide range of concentrations (0.001 to 60 µM Dox equivalents) for a period of 72 
hours. Following this incubation period, a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was performed 
to measure the metabolic viability of the cells as measured by the IC50, or the 
concentration of drug necessary to inhibit cellular proliferation by 50%. We observed 
that chain length did not significantly alter the measured IC50 (Free Dox: 0.2 ± 0.1 µM; 40 
pentamer construct: 2.6 ± 0.8 µM; 80 pentamer construct: 1.7 ± 0.5 µM; and 160 pentamer 
construct: 1.5 ± 0.2 µM). However, similar to other systems that rely on chemical 
conjugation (rather than physical encapsulation), conjugation to the CPs resulted in an 
approximately 11-fold reduction in activity compared to free doxorubicin [88, 194, 195]. 
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Figure 24: In vitro toxicity against a C26 murine colon carcinoma line for (A) free 
doxorubicin, (B) A[0.6]-40-Dox, (C) A[0.8]-80-Dox, and (D) A[1]-160-Dox. Data shown 
as mean ± SD averaged over three independent experiments. The dashed line 
represents the best fit of the equation Viability = 1 / (1 +  (CDox/IC50)p), where CDox is the 
effective Dox concentration in the well, the IC50 measures the necessary dose to 
inhibit cell proliferation by 50%, and p represents the slope of the sigmoidal curve. 
 
5.3.3 Pharmacokinetic Analysis 
To determine the pharmacokinetic parameters of the CP-Dox nanoparticles, the 
plasma doxorubicin concentration was longitudinally tracked over a period of 48 hours 
following systemic administration to mice via tail vein injection (Figure 25A). We found 
that these nanoparticles followed a two compartmental model (Figure 25B), signifying 
 130 
that plasma drug concentration declined biexponentially as two first order processes: 
distribution and elimination [196]. Immediately following injection into the central 
compartment (comprised of the blood, extracellular fluid, and highly perfused tissues 
such as the liver and kidneys) the drug is considered homogeneously distributed. In the 
α-phase (distribution phase), the drug concentration in the central compartment rapidly 
diminishes by partitioning into the surrounding tissue (the peripheral compartment). 
While excretion does occur in the distribution phase, this effect is generally negligible in 
comparison to the net transfer of drug to the peripheral tissues. In the β or elimination 
phase, the drug concentration in the peripheral compartment has already reached 
equilibrium with the central compartment, and the amount of drug in both tissues 
declines as a first order process due to elimination. In the model shown in Figure 25B, 
drug elimination is assumed to occur from the central compartment because the 
kidneys, responsible for renal excretion, and the liver, responsible for metabolic 
degradation of the drug, are both highly perfused organs. 
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Figure 25: Pharmacokinetic parameters of CP-Dox micelles. (A) Plasma concentration 
of doxorubicin-loaded chimeric polypeptide nanoparticles following systemic 
administration into mice. The data points represent mean ± SD (n=3) and the dashed 
lines represent the curves of best fit to the two compartment model by SAAM II. 
Significance (one-way ANOVA, Tukey post-hoc) was calculated for A[0.6]-40-Dox and 
A[0.8]-80-Dox against the A[1]-160-Dox for all time points. *p<0.05 and **p<0.005 (B) 
Diagram of a two compartmental model. (C) Compartmental analysis of CP-Dox. The 
theoretical drug concentration in the plasma and tissue compartments for A[0.6]-40-
Dox and A[1]-160-Dox as a function of time. 
 
Table 6: Half-life and area under the curve of CP-Dox micelles of varying sizea 
Parameter 
 
A[0.6]-40 A[0.8]-80 A[1]-160 
elimination half-life β t1/2 [hr] 9.6 (0.4) 12.1 (1.0) 15.5 (0.9) 
area under the curve AUC [µM hr] 1202.9 (42.8) 2690.5 (119.6) 3734.6 (112.3) 
aData represent the mean (SD) of the best fit parameters determined by SAAM II. 
 
Table 6 indicates that chain length does play a significant role in the 
pharmacokinetics of CP-Dox micelles, with the 160 pentamer construct exhibiting a β 
elimination half-life of 15.5 hours, followed by the 80 pentamer construct at 12.1 hours, 
and the 40 pentamer construct at 9.6 hours (see Table 16 in Appendix 8.8 for the 
complete list of parameters). However, the most descriptive parameter for determining 
the efficacy of a given treatment is the area under this curve (AUC), as it describes the 
total drug exposure of an area over the time course of the experiment. Similar to the 
half-life, the AUC was the greatest for the longest chain length (160 pentamers) and 
decreased to 72% for the 80 pentamer construct, and 32% for the 40 pentamer construct. 
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Figure 25C illustrates the theoretical distribution of the 160 pentamer and 40 
pentamer construct in the plasma and tissue compartments as a function of time. 
Interestingly, the theoretical doxorubicin concentration in the peripheral tissues rises to 
a maximum of 53 µM over a period of approximately 4.7 hours for the 160 pentamer 
construct, but rapidly peaks to 78 µM in only 2.4 hours for the 40 pentamer construct. In 
fact, the 40 pentamer construct preferentially partitions into the peripheral compartment 
to such a degree that within the first 1.5 hours following administration, the majority of 
the delivered doxorubicin exists within the peripheral compartment. This is in contrast 
to the 160 and 80 pentamer constructs, which establish a two compartmental equilibrium 
in which the plasma concentration is consistently higher than the tissue concentration.  
 
5.3.4 Biodistribution Analysis 
Following pharmacokinetic analysis, it was necessary to validate the 
biodistribution of the three conjugates with the intent to select the conjugate with the 
lowest instance of accumulation within the heart and general off-target toxicity. 
Reduction of the doxorubicin levels in the heart is particularly critical as 
cardiomyopathy is the primary dose-limiting factor for doxorubicin treatment in the 
clinic. As it was unknown whether inducing the phase transition within the tumor 
would influence the biodistribution of the drug, the mice were administered CP-Dox via 
tail vein injection, and the tumor, which was inoculated on the right flank of the mouse, 
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was immediately heated to 42°C via water bath for 1 hour. The mice were sacrificed 24 
hours following administration and the doxorubicin concentration within the tissue was 
quantified via a fluorescent plate assay. 
 
 
Figure 26: Doxorubicin concentration in select tissues 24 h following tail vein 
administration of doxorubicin loaded micelles assembled from 40, 80, and 160 
pentamer chain lengths. Immediately following injection, the tumor-bearing leg was 
heated to 42°C for 1 h. The data represent the mean ± SD. 
 
Figure 26 illustrates the doxorubicin load in each of the seven primary tissues 
examined 24 hours following administration. In general, accumulation was correlated 
with chain length, with higher molecular weight constructs showing a decrease in 
accumulation. This effect was most notable in the kidneys, which exhibited a marked 
decrease in accumulation when comparing the 40 pentamer construct (81 ± 17 %ID/g) to 
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the 80 (33 ± 6 %ID/g) and the 160 (5 ± 1 %ID/g). Compared to the 40 pentamer construct, 
the 160 pentamer conjugate also demonstrated a 33% reduction in liver accumulation 
and a 40% reduction in heart accumulation, supporting the results observed in the two 
compartmental pharmacokinetic model. Future studies would benefit from performing 
bone marrow analysis, as this also represents a primary target of doxorubicin toxicity 
[197]. 
The finding that micelles assembled from chains of varying molecular weight 
exhibit an altered pharmacokinetic and biodistribution profile suggests that the 
molecular weight of the individual chains comprising the higher order structure is a 
critical design parameter. This observation is likely a result of continual renal filtration 
of the single chain polymer, whose molecular weight is below the estimated renal 
filtration cutoff of 50 kDa for both the 40 (15 kDa) and 80 (30 kDa) pentamer constructs, 
as noncovalently assembled higher order systems exist in dynamic equilibrium with 
their single chain components. In fact, this phenomena has been observed in a variety of 
systems including diblock micelles [198] and multisubunit enzymes [199].  
These data, in combination with the pharmacokinetic profile indicate that 
micelles constructed with higher molecular weight chains retain doxorubicin in the 
plasma for a longer period of time (longer half-life), thereby increasing the overall 
exposure of the tumor vasculature to the drug (higher AUC). Furthermore, they also 
exhibit a lower concentration of drug within the tissue compartment, thus reducing 
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systemic toxicity. In particular, the high overall toxicity associated with significant drug 
accumulation in the kidneys suggest that the 160 pentamer construct will provide both 
an enhanced anti-tumor effect over shorter chain lengths and a significant reduction in 
off-target toxicities. Hence, we selected the 160 pentamer chain length for use in all 
following studies. 
 
5.4 Validation of the In Vivo Micelle Phase Transition 
Following selection of the 160 pentamer construct for further examination, it was 
necessary to confirm that the micelles would reversibility phase separate in vivo within 
the thermal window of 39-43°C. To accomplish this, we utilized a dorsal skin fold tumor 
window chamber model, which allows the visualization of the tumor vasculature in real 
time using an epifluorescent confocal microscope. We examined three chimeric 
polypeptide micelles: (1) a hydrophilic control with a chain length of 160 pentamers and 
a guest residue composition of X=Ala1Gly1. This micelle phase separates at 50°C in 
physiological media, and hence should not display thermal sensitivity within the range 
of 39-43°C. (2) A thermally responsive formulation of 160 pentamers and a guest residue 
ratio of X=Ala9Val1 that phase separates at 39°C in physiological media, and (3) a 
thermally responsive formulation of 160 pentamers and a guest residue of Ala that 
displays a phase transition at 42°C. Each of the CPs were labeled on the amino-terminus 
with a rhodamine dye derivative, which supplies red fluorescence and did not perturb 
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assembly or the transition temperature. The CPs were assembled into spherical micelles 
through the attachment of n-pyrenylmalemide to the unique cysteines localized to the 
carboxy-terminus. Pyrenylmalemide was selected over doxorubicin for two reasons. 
First, doxorubicin supplied the presence of a second, albeit weak, fluorophore that 
quenched rhodamine fluorescence (data not shown). Second, as the CP formulation 
extravasated into the tumor extracellular matrix, doxorubicin was released from the 
micelle, leading to an increase in background signal that further reduced image quality. 
A large molecular weight (2 MDa) dextran conjugated to fluorescein was co-
injected with the CP micelles to provide a distinct green vascular mask.  The color 
balance was then adjusted to provide a yellow overlay in the presence of both soluble 
green dextran and soluble red CP micelles. As the control CP has a transition 
temperature higher than 42°C, it is homogenously distributed throughout the 
vasculature at both 37 and 42°C (Figure 27A, B). In contrast, the thermally responsive CP 
micelle formulation, which phase separates at 39°C, is soluble at 37°C, as observed by 
the homogenous yellow overlay. However, as the tumor is heated to 42°C, the CP 
demonstrates a rapid and robust phase separation into micron-sized hydrophobic 
spheroids seen throughout the vasculature (Figure 27C, D). We also observed that the 
degree of phase separation could also be controlled through the transition temperature. 
Figure 27E shows the rhodamine-labeled CP micelle channel for A[1]-160, which 
displays a transition temperature at 42°C. While this thermal stimulus was sufficient to 
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induce a response (image taken after 30 minutes of heating), it was not nearly as robust a 
response as seen by A[0.9]-160 (image taken after 10 minutes of heating), which displays 
a transition temperature of 39°C.  
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Figure 27: In vivo visualization of the phase transition in response to heat. A control 
CP micelle formation with a transition temperature of 50°C remained soluble when 
heated to (A) 37°C and (B) 42°C for 10 min each. A thermally responsive micelle 
formulation that transitions at 39°C remains soluble at (C) 37°C for 10 min but phase 
separates at (D) 42°C (image taken after 10 min). The red CP-rhodamine channel for 
(E) A[1]-160 (Tt = 42°C) held at 42°C for 30 min and (F) A[0.9]-160 (Tt = 39°C) held at 
42°C for 10 min. Scale bars represent 100 nm. 
 
With a clear phase separation occurring selectively between 39 and 42°C, we next 
examined whether the phase transition was reversible under physiological conditions. 
Figure 28 shows images of the green (fluorescein-dextran) and red (CP-rhodamine) 
channels as the temperature is slowly ramped from 37 to 42 to 37°C. At 37°C, the CP 
micelles are homogeneously distributed throughout the vasculature. As the temperature 
approaches 42°C, the micelles coalesce into discreet hydrophobic aggregates (visualized 
by the punctate red fluorescence) that fully dissipate upon cooling.  
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Figure 28: Confocal images of tumor vasculature containing 2 MDa dextran (green) 
and CP-Rhodamine (red) as the vasculature is heated from 37 to 42°C and then cooled 
back to 37°C. The scale bars represent 100 nm. 
 
 142 
5.5 Triggering the Phase Transition to Induce Drug 
Accumulation within a Solid Tumor 
Finally, it was necessary to examine whether triggering the phase transition 
increased drug accumulation within the tumor. To test this hypothesis, we administered 
the same control (Tt=50°C) and thermoresponsive (39°C) CP-Dox formulations as 
described above to Balb/c mice bearing a murine C26 colon carcinoma in their hind leg. 
Each treatment was then subdivided into three experimental cohorts: mice receiving (1) 
no thermal therapy; (2) one hour of hyperthermia applied by submerging the hind leg of 
the mouse in a water bath heated to 42°C; and (3) one hour of hyperthermia divided into 
six intervals of 10 minutes of heat followed by 10 minutes without heat (Figure 29). The 
mice were sacrificed 2 hours following administration of the drug, and the Dox 
concentration in the tumor was measured via a fluorescent plate assay. Surprisingly, one 
hour of hyperthermia increased the accumulation of Dox within the tumor by 50% for 
both CP-Dox constructs, signifying that the effects of hyperthermia - and not the phase 
transition - dominated the biodistribution of the CP carrier under these conditions. 
However, when the same one hour of hyperthermia was divided into six separate 
heating and cooling cycles, the control CP showed the same ~50% increase in 
accumulation while the thermoresponsive CP exhibited a 160% increase (p<0.001).  
We hypothesize that because the physiological temperature is below the Tt in 
systemic circulation, the CP circulates as a soluble nanoparticle; upon reaching a heated 
tumor in which the temperature is above the Tt, the CP undergoes its inverse phase 
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transition and forms micron-sized aggregates that adhere to the tumor vasculature. 
Upon cessation of hyperthermia, the rapid resolubilization of the CP aggregates creates 
a steep transvascular concentration gradient that drives CP extravasation into the tumor 
by diffusion. This hypothesis suggests that the accumulation of drug positively 
correlates with the number of heating and cooling cycles, and thus it may be possible to 
further augment the efficacy of this strategy by simply increasing the number of cycles. 
This is currently under investigation. 
In addition to doxorubicin taken up by tumor cells upon CP-Dox extravasation 
across the vasculature, it is also possible that the tumor endothelial cells will experience 
vascular damage and perfusion shut down following such high levels of exposure to 
doxorubicin. Although the thermally sensitive liposome formulations that typically 
observe this effect are capable of achieving much higher vascular concentrations of 
doxorubicin [124], the phase separated CP-doxorubicin is in direct contact with sections 
of the vasculature for the length of the hyperthermia treatment (Figure 27D, E). Future 
studies may use window chamber analysis to quantitatively determine whether phase 
transitioned CP-Dox similarly alters vasculature health and perfusion. 
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Figure 29: Tumor biodistribution of a thermally responsive and a control CP-Dox 
nanoparticle formulation following two heating schedules. Mice were sacrificed 120 
min following drug administration. * p < 0.05. 
5.6 Conclusions 
In this chapter, we demonstrate that the micelle-to-aggregate transition 
temperature of CP nanoparticles can be predicted by their sequence, chain length, and 
concentration, and visually confirm that the phase separation is reversible and occurs 
within the narrow temperature range of 39-43°C in vivo. Cyclically heating the tumors 
following injection of the thermoresponsive CP-Dox formulation resulted in 
significantly enhanced drug accumulation over non-thermally responsive formulations 
and over thermally responsive and non-responsive controls subjected to hyperthermia 
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without cycling. We hypothesize that this increase is due to the creation of a steep 
transvascular CP-Dox concentration gradient upon cooling that is capable of pumping 
the soluble conjugate across the vascular and interstitial fluid pressure barrier. These 
results suggest that thermally cycling tumors will provide a significant boost in efficacy 
for thermally responsive CP nanoparticles. This hypothesis is currently under 
investigation. 
 
5.7 Materials and Methods 
5.7.1 Materials 
Restriction enzymes, calf intestinal phosphatase (CIP), and T4 DNA ligase were 
purchased from New England Biolabs (Ipswich, MA). The pET 24a(+) cloning vector was 
purchased from Novagen Inc. (Madison, WI), and all custom oligonucleotides were 
synthesized by Integrated DNA Technologies Inc. (Coralville, IA). The DNA miniprep, 
gel purification, and PCR purification kits were purchased from Qiagen Inc. 
(Germantown, MD). EB5α™ and BL21™ Escherichia coli cells were obtained from Edge 
BioSystems (Gaithersburg, MD) and were grown in TBDry™ media (MO BIO 
Laboratories, Inc; Carlsbad, CA). Chemicals used for the purification of ELPs include: 
IPTG (Gold Biotechnology; St. Louis, MO), TCEP (Thermo Scientific; Waltham, MA), 
and kanamycin (CalBioChem; San Diego, CA). 
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5.7.2 Methods 
5.7.2.1 Chimeric Polypeptide Synthesis and Nomenclature 
The synthetic genes for CPs were assembled from chemically synthesized 
oligomers (IDT Inc.) by plasmid reconstruction recursive directional ligation (PRe-RDL) 
as described in Chapter 2. The oligomers used to construct each compositional library 
are described in Appendix 8.1. The CP nomenclature used throughout this chapter is 
A[X]-Y, where X represents the fraction of alanine (A) in the guest residue composition 
(rest, valine (V)), and Y represents the length of the CP in pentamers. Each CP contains 
an N-terminal (CGG)8 domain that can be covalently conjugated to drugs (e.g., A[X]-Y 
Dox indicates the covalent conjugation of Dox to the unique Cys residues in the (CGG)8 
domain). 
5.7.2.2 Expression of Chimeric Polypeptides 
BL21(DE3) cells were transformed with an CP-containing plasmid and were used 
to inoculate a 250 mL flask containing 50 mL TBDry media supplemented with 45 
µg/mL kanamycin. This flask was incubated on a shaker overnight at 200 RPM and 37°C 
before being used to inoculate six 4-L flasks containing 1 L of TBDry media, 
supplemented with 45 µg/mL kanamycin. These cultures were incubated on a shaker at 
200 RPM at 37°C for 6 h, treated with 0.2 mM IPTG, and grown overnight. 
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5.7.2.3 Purification of Chimeric Polypeptides 
Escherichia coli expression cultures were centrifuged in 1 L bottles at 4°C for 10 
min and 3,000 g to concentrate the cells into a pellet. The supernatant was discarded and 
the cell pellets were resuspended in a total of 10 mL PBS. The cells were placed on ice 
and were lysed via 3 min of sonication (10 s on, 40 s off) (S-4000 Misonix Sonicator; 
Farmingdale, NY). Polyethyleneamine (PEI; final concentration of 1% w/v) was added to 
the lysate to precipitate nucleic acid contaminants, and the remaining cell debris was 
removed from the solution following centrifugation at 14,000 g for 10 min at 4°C. The 
ELP was then purified by two cycles of inverse transition cycling with minor 
modifications. The supernatant was heated to 60°C for 10 min, thereby inducing the CP 
phase transition and precipitation of contaminant proteins, then immediately placed on 
ice to redissolve the CP. Protein debris was removed by centrifugation (14,000 g, 10 min, 
4°C). The supernatant (containing soluble CP) was heated to 37°C, and NaCl crystals 
were added to a final concentration of 1-3 M to induce the CP phase transition. CP 
aggregates were precipitated by centrifugation (14,000 g, 10 min, 25°C), and the 
supernatant was discarded. The CP was then resuspended in 20 mM Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP, pH 7.4), cooled, and centrifuged (14,000 
g, 10 min, 4°C) to remove any remaining insoluble contaminants. This cycle (starting at 
the 60°C incubation) was repeated once more to yield the final product. The product was 
then dialyzed overnight in ddH2O and lyophilized. 
 148 
5.7.2.4 Analysis of Chimeric Polypeptides 
The purity of the CPs was visually determined by SDS-PAGE, using 4-20% Tris-
HCl Ready Gels (Bio-Rad, Hercules, CA) stained with CuCl2 (0.5 M) (Appendix 8.3).  
5.7.2.5 Conjugation of Molecules to Chimeric Polypeptides 
15 mg of lyophilized CP was resuspended in 800 µL of 100 mM phosphate 
buffer, pH 7.4, and spiked with an additional 100 µL of 100 mM TCEP in water, pH 7.4. 
To generate the CP nanoparticles used to build the model, 100 µL of a 50 mM solution of 
n-benyzlmaleimide in DMSO was added to the CP solution dropwise, and allowed to 
mix for 3 h at room temperature. To generate fluorescent micelles, 0.2 mg of Rhodamine 
Red-X succinimidyl ester (Life Technologies; Carlsbad, CA) dissolved in 100 µL of 
DMSO was added to the CP solution dropwise, and allowed to mix for 3 h at room 
temperature. 3 mg of n-pyrenylmaleimide in 100 µL of DMSO was then added to the 
CP-Rhodamine solution dropwise, and allowed to mix for an additional 16 h at room 
temperature. Following conjugation, the CP conjugate was centrifuged at 13,000 g and 
4°C for 10 min and purified by passage through a size exclusion column (PD10, GE 
Healthcare) and dialysis in ddH2O overnight. The solution was then lyophilized and 
stored at 20°C for future use. 
5.7.2.6 Thermal Turbidimetry 
The optical density at 350 nm (OD350) of each CP was measured as a function of 
temperature on a UV-vis spectrophotometer equipped with a multicell thermoelectric 
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temperature controller (Cary 300, Varian Instruments; Walnut Creek, CA). CP solutions 
in PBS ranging in concentration from 2 to 100 µM were heated at a rate of 1°C/min. The 
Tt was defined as the inflection point of the turbidity plot. To measure the transition in 
90% fetal bovine serum (FBS), a 500 µM CP solution was diluted 10-fold into the FBS 
solution. 
5.7.2.7 Conjugation of Doxorubicin 
The conjugation of Dox to the CPs was performed as described elsewhere [88] 
with slight modifications. Dox was conjugated to the unique cysteine residues located 
on the C-terminus of the CP using the heterobifunctional linker n-β-maleimidopropionic 
acid hydrazide (BMPH; Pierce Biotechnology, Rockford, IL) in a two-step process. First, 
Dox (215 mg) and BMPH (100 mg) were codissolved in 100 mL of anhydrous methanol 
spiked with 100 µL of trifluoroacetic acid. This solution was stirred for 16 h at 20°C in 
the dark, dried using rotary evaporation, and then resuspended in 20 mL methanol. In 
the second step, this solution was immediately added dropwise to a solution containing 
the CP. Prior to this reaction, the CP was purified as described previously, incubated in 
a high capacity endotoxin removal resin (Thermo Scientific) for 2 h, and passed through 
a 0.2 µm filter. The CP solution was then incubated in 50 mM TCEP for 1 h at 20°C to 
eliminate disulfide crosslinking. Phase separation was triggered by the addition of 
crystallized NaCl to a final concentration of 1-3 M to remove excess TCEP and 
concentrate the CP solution. The pellet was then resuspended to a final concentration of 
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8.6 µmoles of CP in 10 mL of phosphate buffer (100 mM phosphate, 1 mM EDTA, pH 
7.4). This solution was stirred for 3 h at 20°C in the dark, spiked with 1 mL of 100 mM 
TCEP (dissolved in water, pH 7), and then stirred for an additional 16 h. To purify the 
CP-Dox product, the methanol was first evaporated under a constant stream of N2 to a 
total of 10 mL. A solution of 5 M NaCl was added to the CP-Dox solution to trigger 
phase separation (a 1:1 ratio was usually sufficient). This solution was centrifuged (5000 
g, 10 min, 25°C), and the supernatant was discarded. The CP-Dox pellet was 
resuspended in PBS and centrifuged once more to remove any insoluble reactants (14000 
g, 10 min, 25°C). Finally, the CP was purified from any remaining free drug reactants by 
passing the solution through a size exclusion column (PD10, GE Healthcare), dialyzing 
for 24-48 h (MWCO = 10-12 KDa) in 5 mM ammonium carbonate (pH 8.0), and 
lyophilizing for later use.  
The degree of Dox conjugation to the CP was measured for each sample by 
resuspending 10-20 mg of lyophilized CP-Dox in 1 mL of PBS, and then dividing the 
concentration of Dox, determined via absorbance spectroscopy, by the concentration of 
CP. The CP concentration was determined gravimetrically on the lyophilized sample by 
adjusting for the added mass from the attached Dox-linker. 
5.7.2.8 In Vitro Cytotoxicity 
C26 murine colon carcinoma cells were maintained in complete media consisting 
of RPMI-1640 supplemented with 10% FBS, 4.5 g L-1 D-glucose, 10 mM HEPES, and 1 
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mM sodium pyruvate. Cells were maintained at 37°C and 5% CO2 and passaged every 3 
days. In vitro cytotoxicity was determined through the use of a colorimetric assay. 5x103 
C26 cells were seeded per 100 µL media on BD FalconTM 96-well cell culture plates (BD; 
Franklin Lakes, NJ) and allowed to adhere for 24 h. The cell media was then removed 
and replaced with 120 µL complete media containing Dox or CP-Dox nanoparticles. The 
cells were incubated for 72 h at 37°C, after which 20 µL of CellTiter 96 AQueousTM 
(Promega; Madison, WI) 3-(4,5,-dimethyl2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) reagent was added to each well. The cells were 
incubated for an additional 30 min, and the absorbance of the solution was measured at 
490 nm with a Victor3 microplate reader (Perkin Elmer; Waltham, MA). To calculate the 
IC50, the data was fit to the equation: Viability = 1 / (1 +  (CDox/IC50)p), where CDox is the 
effective Dox concentration in the well, the IC50 measures the necessary dose to inhibit 
cell proliferation by 50%, and p represents the slope of the sigmoidal curve.   
5.7.2.9 Pharmacokinetic Analysis 
All animal experiments were done in accordance with Duke University's 
Institutional Animal Care and Use Committee. CP-Dox (15 mg Dox equivalents/kg body 
weight) was intravenously administered via tail vein into Balb/c mice. 10 µL blood was 
collected at select time points (40 s, 2 min, 5 min, 1 h, 2 h, 4 h, 8 h, 24 h) and diluted into 
100 µL of heparin (1000 U/mL) in PBS. The samples were centrifuged (1000 g, 5 min, 
4°C) to remove the red blood cells, and the Dox was released from the CP by incubating 
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10 µL of plasma in 490 µL of acidified isopropanol (75 mM HCl, 90% isopropanol) for 16 
h at 4°C. The solution was loaded into a 96-well microplate in triplicate (125 µL per 
well), and Dox fluorescence was determined using a Victor3 microplate reader (485 nm 
excitation, 590 nm emission). Plasma concentration was fit to a two compartment model 
to determine the pharmacokinetic parameters using SAAM II software (University of 
Washington, Seattle, WA). 
5.7.2.10 Biodistribution Analysis 
Balb/c mice were inoculated with C26 tumors on their right hind leg (2.5x106 cells 
in 30 µL). Once the tumors reached ~100 mm3 (approximately 9 days following 
inoculation), the mice were anaesthetized with 50 mg/kg body weight of nembutol (i.p. 
administration), and administered CP-Dox (15 mg Dox equivalents/kg body weight) via 
tail vein injection. The mice were placed in a custom hyperthermia holder with a rectal 
temperature probe to monitor the core body temperature and a plastic shield to prevent 
direct skin contact with the heated water. The mice were placed in a water bath set to 
43°C, such that the tumor bearing leg was submerged just far enough to completely 
cover the tumor mass. A fan was used to regulate the body temperature.  
To determine whole body biodistribution (Figure 26), the mice were exposed to 1 
h of continuous hyperthermia and were sacrificed 24 h following CP-Dox 
administration. To elucidate the effect of thermal cycling on tumor accumulation, mice 
were exposed to various hyperthermia schedules (Figure 29) and were sacrificed 2 h 
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following CP-Dox administration. Tissues were collected (heart, lungs, kidney, spleen, 
liver, muscle, and tumor), and 75-100 mg of tissue was weighed and suspended in 1 mL 
of acidified isopropanol (75 mM HCl, 90% isopropanol). The solution was homogenized 
using 2 mm Zirconia beads and a Beadbeater-16 (Biospec, Bartlesville, OK) for 120 secs. 
The samples were incubated at 4°C for 16 h in the dark to release conjugated Dox. The 
samples were then centrifuged (4°C, 10 min, 14000 g), and the supernatant was 
fluorescently assayed as described in the pharmacokinetic analysis. Untreated tissues 
were similarly extracted and used to create a background curve (fluorescent counts / mg 
tissue) to compensate for tissue autofluorescence.  
5.7.2.11 Window Chamber and Microscopy 
Nude mice were anaesthetized with a cocktail of ketamine and xylazine (100 
mg/kg ketamine, 10 mg/kg xylazine, i.p.) and implanted with a dorsal skin fold window 
chamber. A titanium chamber was surgically implanted over a 1-cm circular incision in 
the dorsal skin fold. FaDu human squamous carcinoma cells at a concentration of 2x106 
cells in 30 µL of high glucose MEM was injected near the center of the window in the 
opposing layer of skin. The incision was then covered with a circular glass coverslip. All 
studies were performed 9-10 days following surgery, once the tumor reached a diameter 
of 2-3 mm. 
To image the tumor vasculature, the mice were anaesthetized with 50 mg/kg 
body weight of nembutol and placed laterally recumbent upon a custom microscopy 
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stage that enabled heating of the window chamber. The tail vein was cannulated and 100 
µL of 5 mg/mL 2 MDa dextran-fluorescein isothiocyanate (Invitrogen) was injected, 
followed by 200 µL of 425 µM CP nanoparticles (target plasma concentration of 50 µM) 
labeled with Rhodamine RedTM-X Succinimidyl Ester (Invitrogen). The temperature of 
the stage was maintained at 37°C (physiological temperature) or 42°C (temperature 
achieved through mild hyperthermia). Images were taken with a Zeiss 780 upright 
confocal microscope. Data were obtained using two channels, in which dextran-
fluorescein isothiocyanate was used to define the vasculature, and the rhodamine 
channel was used to view the distribution of CP nanoparticles. Upon injection of CPs at 
37°C, fluorescent levels were adjusted to provide a yellow overlay. 
5.7.2.12 Data Analysis  
Non-linear regression analysis was performed with IBM SPSS Statistics 19.0 
(SPSS, Chicago, IL). MATLAB (MathWorks; Natick, MA) was used to generate the 3-
dimensional plot of the predicted Tt as a function of composition and chain length. 
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6. Highly Asymmetric Polypeptide Amphiphiles that 
Spontaneously Assemble into Unexpected 
Morphologies 
6.1 Motivation 
Self-assembly is a process by which amphiphilic components spontaneously 
interact in solution to form hierarchical structures, such as spherical and worm-like 
micelles, vesicles, disks, and sheets. Self-assembled systems have been studied 
extensively in recent decades due to their high degree of versatility; in particular, 
polymeric systems have been used in a variety of applications, including drug delivery 
[46, 75, 76, 88, 200], sensing [201], electronics [202, 203], and separation science [204]. The 
most common amphiphiles in these applications are block copolymers, in which two or 
more polymers with varying degrees of hydrophobicity are covalently linked. However, 
with the recent advances in controlled radical polymerization methods such as 
reversible addition-fragmentation chain transfer polymerization (RAFT), it is now 
possible to create highly asymmetric amphiphiles through end-functionalization of 
homopolymers with specifically tailored hydrophobic moieties, such as alkyl chains 
[205-207]. While these homopolymers are still able to self-assemble in aqueous solution, 
their geometries – and potentially the structural properties of their assemblies – may be 
quite distinct from those of classical block copolymers. 
In this chapter, we investigate the structural properties of homo-biopolymer 
amphiphiles that have been end-functionalized using recombinant methods by 
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genetically fusing a variety of short hydrophobic peptides of precise sequence and 
length to the carboxy-terminus of an elastin-like polypeptide. Previous chapters describe 
a remarkably simple approach to building nanoscale thermoresponsive carriers out of 
these biopolymers for the targeted delivery of therapeutics by functionalizing the 
carboxy-terminus of a thermoresponsive elastin-like polypeptide with a short (CGG)8 
domain. The eight cysteine residues - unique to the polypeptide sequence - provide sites 
to which small molecule therapeutics can be covalently attached. We demonstrated that 
the fate of the polypeptide conjugate is inextricably tied to the hydrophobicity of the 
attached molecules; when the hydrophobicity is greater than a threshold value of 
LogD=1.5, the amphiphilic chimeric polypeptides assemble into sub-100 nm spherical 
micelles that retain the thermoresponsive behavior of the parent elastin-like 
polypeptide.  
This simple assembly mechanism hints at a larger set of self-assembling 
polypeptides that may be able to access a range of morphological diversity unobtainable 
through stochastic chemical conjugation. The proposed structure of these highly 
asymmetric amphiphiles follows the motif: (M)SKGPG – (VPGαG)n – (XGy)z, where α 
represents the guest residue composition in the elastin-like polypeptide sequence, n is 
the number of pentameric repeats, X is the identity of the amino acid hydrophobe 
responsible for driving self-assembly, y is the number of glycine (G) spacers, and z is the 
number of repeats of the C-terminal assembly domain. We hoped that by sampling a 
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subset of this population, we would be able to better understand how the composition of 
the assembly domain influences the phase transition behavior and physicomechanical 
properties of the structure (i.e., the size, stability, and morphology). 
 
6.2 Physicochemical Characterization of Asymmetric 
Amphiphiles 
Recombinant synthesis techniques were used to construct a series of asymmetric 
amphiphiles with a short assembly domain genetically fused to the carboxy-terminus of 
an elastin-like polypeptide (Figure 43, Appendix 8.2). The amphiphiles were 
transformed into Escherichia coli, purified using inverse transition cycling, lyophilized, 
and stored at -20°C for future use. Despite exploiting recombinant synthesis techniques, 
the compositional space necessary to screen all possible C-terminal peptide domains 
capable of driving assembly was immense; hence, we focused on a narrow but 
morphologically rich subset of the domains of the basic form (XGy)z, where X represents 
a number of hydrophobic amino acids selected from Urry’s hydrophobicity index [180], 
y represents the number of glycine spacers and was varied between 0, 1, and 2, and z 
represents the number of assembly domain repeats, which was set at eight for all 
examined constructs (Table 7). All elastin-like polypeptide domains were comprised of 
the sequence (VPGAG)n, where the number of pentapeptide repeats ‘n’ varied between 
40, 80, and 160. A C-terminal tyrosine was included to facilitate absorbance based 
protein quantification (Figure 40, Appendix 8.1). Following purification, matrix-assisted 
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laser desorption/ionization mass spectrometry (MALDI-MS) was performed on each of 
the constructs to confirm their molecular weight (Appendix 8.4). In an attempt to 
understand the rules governing nanoparticle assembly, we then examined each 
construct with a variety of qualitative and quantitative techniques, including thermal 
turbidimetry, fluorescent spectroscopy, cryogenic transmission electron microscopy, 
static and dynamic light scattering, and single particle size analysis. 
 
6.2.1 Thermal Behavior 
We have previous shown that the thermal behavior of elastin-like polypeptides is 
exquisitely sensitive to its composition [182], attached proteins [84, 208] or compounds 
[77], as well as polymer concentration [158, 182], ionic strength [178], and the presence of 
solvents. In striking similarity to the thermal behavior of chimeric polypeptide 
conjugates seen in Figure 11A of Chapter 3, as the hydrophobicity of the fused assembly 
domain (Figure 30A) increases according to Urry’s scale of hydrophobicity [180], the 
transition temperature of the construct decreases. In fact, thermal turbidimetry was 
sufficient to separate the constructs into two populations. The first population, 
comprised of the residues Leu, Ile, His, and Tyr, is primarily monomeric, and thus is 
characterized by transition temperatures that vary according to both hydrophobicity 
and the polymer concentration in solution (Figure 30B). As illustrated in Figure 31, 
however, the His and Leu constructs also contain a small fraction of assembled 
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nanoparticles. The absorbance increase, shown in Figure 31A, is indicative of the 
nanoparticle-to-globule phase transition, as it is both significantly lower than the unimer 
transition and does not show the same degree of concentration dependence (Figure 31B), 
whereas the second increase in absorbance represents the unimer-to-globule phase 
transition.  
While many of the genetically encoded amphiphiles remained monomeric, the 
hydrophobic Trp and Phe domains spontaneously assembled into higher order 
structures whose transition behavior is approximated by the mathematical model 
developed for micelle formation in Chapter 5 (see the red dashed line in Figure 30B). 
Although this model was designed to predict the assembly of spherical micelles, we 
hypothesized that it could be applied to other higher order structures as they all exhibit 
a high local polypeptide concentration. This hypothesis was corroborated by the fact 
that the model also accurately predicts the transition temperature of constructs with 
lengths of 40 and 80 pentamers modified with the (FGG)8 domain (see dashed lines in 
Figure 32A). 
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Figure 30: (A) Sequence and (B) transition behavior of ELPs that have been genetically 
fused to a C-terminal assembly domain. Black and red dashed lines represent the 
predicted transition temperature of the A[1]-160 construct as a unimer and micelle, 
respectively. 
 
  
Figure 31: (A) Thermal turbidimetry profile at 100 µM amphiphile concentration. 
Arrows indicate discrete transition temperatures. (B) Transition behavior as a 
function of concentration for the genetically encoded amphiphiles containing an 
(LGG)8 or (HGG)8 domain. 
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 Surprisingly, we observed that the number and distribution of glycine residues 
within the assembly domain can play a potent role in the assembly and transition 
temperatures of these asymmetric amphiphiles. For assembly domains comprised of 
tyrosine residues, for instance, incorporating 2 glycine spacers constrains the amphiphile 
to a monomeric form, thereby resulting in a high transition temperature that strongly 
depends on concentration (Figure 32B). Reducing the number of glycines between 
hydrophobic residues to a single residue or none at all results in the assembly of 
nanoparticles with low transition temperatures that are near-independent of 
concentration. This effect is most likely due to the hydrophilicity of the glycine residue: 
as the number of glycine residues decreases from 2 to 1, the overall hydrophobicity of 
the assembly domain surpasses the threshold necessary to induce nanoparticle 
assembly. It is also possible that the number of glycine residues controls the secondary 
structure of the assembly domain, which has demonstrated the ability to significantly 
enhance core interactions and stabilize structures. For instance, pH has been shown to 
trigger the transition of a poly(L-glutamic acid) block from a hydrophilic random coil to 
a hydrophobic alpha helix, thereby inducing the formation and stabilization of vesicles 
[209]. It is clear, however, that not all systems are affected by the presence or absence of 
glycine residues equally; assembly domains comprised of phenylalanine residues, for 
example, are sufficiently hydrophobic to assemble into structures with 0, 1, or 2 glycine 
spacers (Figure 32C). 
 162 
 
 163 
Figure 32: Thermal behavior of highly asymmetric polypeptides. (A) Transition 
temperatures of ELPs of varying size fused to C-terminal (FGG)8 domains. Dashed 
lines represent the predicted transition behavior of assembled complexes according to 
Equation 5. (B) The number of glycine residues in the assembly domain can play a 
potent role in the transition behavior of asymmetric polypeptides with Tyr assembly 
domains but (C) plays almost no role in constructs with Phe assembly domains.  
 
6.2.2 Nanoparticle Size Analysis 
 Dynamic light scattering was performed on each of the constructs to verify self-
assembly. The unimeric domains comprised of Leu, Ile, His, and Tyr were comprised of 
random coils approximately 6 nm in radius (Figure 33A), with Leu and His displaying a 
second population (5-10% of total mass) at 39.4 ± 2.5 nm and 70.0 ± 8.3 nm, respectively 
(Table 7), in close agreement with thermal turbidimetry measurements (Figure 31). In 
contrast, the assembly-inducing domains generated nanoparticles whose hydrodynamic 
radii ranged from 30 to 90 nm (Figure 33B). As it is unlikely that spherical micelles can 
display diameters of ~180 nm, these values suggest that at least a few amphiphiles are 
assembling into more complex structures such as vesicles or worm-like micelles. 
 As the ionized form of tyrosine (Tyrpka = 11.3) is 10 times more hydrophilic than 
neutral tyrosine, the A[1]-160-(YG)8 construct offered a unique opportunity to affirm that 
assembly is primarily driven by the hydrophobicity of the assembly domain. Upon 
increasing the pH to 12, the vast majority of the A[1]-160-(YG)8 constructs disassemble 
into unimers (Figure 33C) because the now charged tyrosinate residues could not 
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maintain a hydrophobic core, whereas the A[1]-160-(FGG)8 constructs, which do not 
display a pKa within this range, remain unaffected by the increase in pH (Figure 33D). 
 
Figure 33: Dynamic light scattering of genetically encoded amphiphiles. (A) Rh 
distribution of A[1]-160-(IGG)8 and (B) A[1]-160-(WGG)8. (C) A[1]-160-(YG)8 constructs 
dissociate at pH > pKaTyr because the pH-mediated conversion from tyrosine to 
tyrosinate vastly increases the hydrophilicity of the domain. (D) A[1]-160-(FGG)8 
constructs do not dissociate at high pH because phenylalanine residues do not 
become charged at high pH values. 
 
Static light scattering was used to calculate the coordination number Z, or the 
number of amphiphiles per nanoparticle. The unimer domains measured between 1 and 
13 amphiphiles/structure; as static light scattering is an ensemble technique, the 
coordination number reflects the weighted average between the assembled 
nanoparticles and the single chains (Table 7), thereby providing a coordination number 
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that neither reflects the unimeric state or nanoparticle state. This artifact explains the 
high coordination numbers for both the Leu and His domains, in accordance with the 
fact that thermal turbidimetry and dynamic light scattering indicated the coexistence of 
unimers and nanoparticles. The remaining nanoparticles displayed a wide range of Z, 
from weak aggregates (10 amphiphiles/NP) to nanoparticles (100-500 amphiphiles/NP) 
to what are likely large aggregates (1653 amphiphiles/NP). 
 
Table 7: Results of size analyses on genetically encoded amphiphiles 
Amphiphile MW g·mol-1 Z Rha (nm) Rb (nm) Assembly 
A[1]-160-(IGG)8 1.35E+05 2 6.5 ± 0.8 n.d. No 
A[1]-160-(LGG)8 3.93E+05 6 6.1 ± 0.7 n.d. Noc 
A[1]-160-(HGG)8 8.33E+05 13 6.7 ± 0.7 n.d. Noc 
A[1]-160-(YGG)8 5.99E+04 1 6.6 ± 0.8 n.d. No 
A[1]-160-(FGG)8 6.89E+06 111 42.8 ± 9.9 53.5 ± 4.8 Yes 
A[1]-160-(WGG)8 2.64E+07 426 80.6 ± 35.6 76.0 ± 12.1 Yes 
A[1]-160-(YG)8 2.47E+07 399 72.7 ± 13.1 71.0 ± 8.9 Yes 
A[1]-160-Y8 6.40E+05 10 27.9 ± 3.0 n.d. Yes 
A[1]-160-(FG)8 4.68E+06 76 33.0 ± 4.9 54.5 ± 5.5 Yes 
A[1]-160-F8 1.03E+08 1653 91.4 ± 9.7 73.0 ± 6.3 Yes 
A[1]-80-(FGG)8 9.00E+06 290 35.3 ± 4.3 55.5 ± 6.0 Yes 
A[1]-40-(FGG)8 8.62E+06 575 30.9 ± 2.6 54.5 ± 5.4 Yes 
a Rh was determined with dynamic light scattering.  
b R was determined using tunable resistance pulse sensing.  
c Indicates partial assembly (~5% by mass).  
Z Represents the coordination number, or the number of polypeptides per nanoparticle. 
n.d. Indicates that the measurement was not performed. 
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Figure 34: Nanoparticle size measured with tunable resistive pulse sensing (TRPS). 
(A-B) Pulsatile increases in measured resistance as nanoparticles flow through pores 
creates blockade events (white arrows) whose amplitude is proportional to the 
nanoparticle diameter. (C) A[1]-160-(FGG)8 and (D) A[1]-160-(YG)8 as measured with 
TRPS (red, left axis) and dynamic light scattering (blue, right axis). 
  
As light scattering relies on ensemble analysis, the measured sizes are highly 
subject to contamination. In fact, as intensity is proportional to radius6, small quantities 
of large aggregates can completely screen the presence of smaller structures, and sample 
polydispersity can greatly skew the measured size of the nanoparticle. To verify the 
sizes determined with dynamic light scattering, we used a particle-by-particle analysis 
technique that relies on tunable resistive pulse sensing (TRPS; Figure 34A). The 
 167 
instrument is equipped with a sensors that measure the magnitude of transient changes 
in the ionic current flow caused by single nanoparticles traversing the pore (known as 
blockade events; Figure 34B). As the magnitude of the blockade event correlates to the 
size of the particle, the physical particle size can be measured following calibration 
against known standards. We found that the Rh and particle distribution determined 
with light scattering closely resembled the physical particle size measured using tunable 
resistive pulse sensing (Table 7). TRPS is, however, constrained by the quality and pore 
sizes of the available sieves. As the smallest pore size available measured diameters 
between 70 and 200 nm, there were five constructs whose sizes could not be determined 
(n.d.). The radial distribution of two representative constructs determined by both DLS 
and TRPS are shown in Figure 34C-D. 
 
6.2.3 Fluorescence Spectrophotometry 
Fluorescence spectrophotometry using pyrene as a probe was used to sample the 
hydrophobicity of the inner core of the self-assembled structures. As described in detail 
in Chapter 3, plotting the ratio of the pyrene fluorescence at 370-373 nm to the 
fluorescence at 381-384 nm against the concentration of the amphiphile yields a two-
state curve that quantitatively describes the thermodynamic stability of the 
nanoparticles, termed the critical aggregation concentration (CAC). Herein we define the 
inflection point of the two state curve as the CAC, which is listed for each of the 
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constructs in Table 8. Constructs that do not provide a lipophilic environment into 
which pyrene can partition exhibit a fluorescent pattern independent from amphiphile 
concentration as the fluorescence spectrum of pyrene in water does not change with the 
concentration of the amphiphile. 
Figure 35A indicates that of the three most hydrophobic assembly domains, the 
(YGG)8 domain was unable to induce assembly, whereas the (WGG)8 and (FGG)8 
domains were sufficiently hydrophobic to self-assemble into structures. Surprisingly, the 
(FGG)8 domain formed a more hydrophobic core than (WGG)8 – seen by the lower I1/I3 
ratio at high concentrations – despite the fact that tryptophan is more hydrophobic than 
phenylalanine. While this anomaly is not fully understood, it is possible that the smaller 
phenylalanine side chain allows higher packing densities or facilitates more π-π 
stacking interactions. We also observed that decreasing the molecular weight of the ELP 
domain from 60 to 30 to 15 kDa only slightly increased the hydrophobicity and stability 
of the (FGG)8 core (Figure 35B, Table 8). 
Although we anticipated that greater numbers of hydrophilic glycine residues in 
the core would decrease core hydrophobicity and stability, this interaction turned out to 
be more complex. For instance, the presence or absence of glycines did not significantly 
affect the hydrophobicity or stability of the phenylalanine domains. However, it did 
play a pivotal role within the tyrosine domains. In agreement with thermal turbidimetry 
and light scattering analysis, the (YGG)8 domain was unable to induce structure 
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formation, as observed by the absence of a concentration dependence in the I1/I3 ratio. 
However, by halving the core glycine content to (YG)8, the domain was able to drive the 
assembly of nanoparticles with a clearly defined hydrophobic core. Upon total 
elimination of the assembly domain glycine residues (Y8), the pyrene assay indicates the 
complete absence of a hydrophobic core, although thermal turbidimetry, light scattering, 
and tunable resistive pulse sensing indicate that nanoparticles remain the predominant 
species. It is possible that this particular domain drives the formation of aggregates that 
lack a defined core rather than the core-shell structures observed for the other domains, 
although the structure cannot be fully elucidated without a discriminating technique 
such as small angle x-ray scattering or small angle neutron scattering. These studies are 
currently ongoing. 
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Figure 35: Fluorescence spectrophotometry of genetically encoded amphiphiles. 
Pyrene analysis of (A) ELPs fused to a series of (XGG)8 domains, (B) a series of ELPs 
of various molecular weights fused to an (FGG)8 domain, (C-D) Pyrene curves of a 
series of (C) phenylalanine-based and (D) tyrosine-based assembly domains fused to 
an ELP. 
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Table 8: Critical Aggregation Concentration and Core Hydrophobicity of Genetically 
Encoded Amphiphiles determined via fluorescence spectrophotometry 
Amphiphile CAC (µM) Minimum I1/I3 
A[1]-160-(IGG)8 n.d. n.d. 
A[1]-160-(LGG)8 n.d. n.d. 
A[1]-160-(HGG)8 n.d. n.d. 
A[1]-160-(YGG)8 n.d. n.d. 
A[1]-160-(FGG)8 0.9 ± 0.1 1.26 
A[1]-160-(WGG)8 3.1 ± 0.4 1.41 
A[1]-160-(YG)8 13.0 ± 1.3 1.40 
A[1]-160-Y8 n.d. 1.73 
A[1]-160-(FG)8 2.5 ± 0.2 1.31 
A[1]-160-F8 1.3 ± 0.1 1.28 
A[1]-80-(FGG)8 0.7 ± 0.1 1.20 
A[1]-40-(FGG)8 0.4 ± 0.0 1.19 
n.d. not determined 
 
6.2.4 Cryogenic Transmission Electron Microscopy 
To determine the morphologies of the different assemblies, it was necessary to 
perform cryogenic transmission electron microscopy (cryo-TEM). The samples were 
imaged at a high concentration (200 µM amphiphile) and a low voltage (80 keV) to 
increase contrast between the buffer and the highly hydrated polypeptide chains. We 
observed that many of these highly asymmetric amphiphiles formed unexpected 
morphologies (Figure 36). In contrast to conjugation-driven assembly, which yielded 
spherical micelles, genetically encoded amphiphiles spontaneously assembled into 
spherical micelles, worm-like micelles, and even vesicles. Most of the samples were 
 172 
dominated by spherical and worm-like micelles (Figure 36A-D), where the lengths of the 
worms ranged from an average 57 nm to 170 nm and the thickness of the inner core 
averaged 8 nm (Table 9). Two of the constructs (A[1]-160-(FGG)8 and A[1]-160-(WGG)8) 
also displayed significant quantities of vesicles (Figure 36E-F) with average radii of 45.4 
and 31.3 nm, respectively, and a shell thickness of approximately 7.5 nm. It is not 
surprising to observe an equilibrium between various morphologies, as it has been 
shown to exist in a variety of polymersome systems [210, 211]. However, we still do not 
fully understand why some constructs only seem to form worm-like micelles (e.g., A[1]-
40-(FGG)8) and why others seem to only form vesicles (e.g., A[1]-160-(WGG)8). These 
studies are currently ongoing. 
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Figure 36: Cryogenic transmission electron microscopy of genetically encoded 
amphiphiles. Many of the genetically encoded amphiphiles were predominantly 
comprised of spherical and worm-like micelles, including: the (A) A[1]-160-(YG)8, (B) 
A[1]-160-(FGG)8, (C) A[1]-80-(FGG)8, and (D) A[1]-40-(FGG)8 constructs. (E) A[1]-160-
(FGG)8 and (F) A[1]-160-(WGG)8 were the only samples to also contain spherical 
vesicles. All samples were imaged at 200 µM. Scale bars represent 100 nm. 
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Table 9: Physical characteristics of self-assembled structures via cryogenic-
transmission electron microscopy.  
 
Worm-like Micelles Vesicles 
Construct Length (nm) Membrane (nm) Radius (nm) Membrane (nm) 
A[1]-40-(FGG)8 56.6 ± 26.0 6.5 ± 1.5 n.d. n.d. 
A[1]-80-(FGG)8 63.5 ± 25.4 6.5 ± 1.5 n.d. n.d. 
A[1]-160-(FGG)8 110.2 ± 34.0 10.0 ± 1.7 45.4 ± 16.9 7.9 ± 1.3 
A[1]-160-(WGG)8 n.d. n.d. 31.3 ± 11.7 7.0 ± 1.2 
A[1]-160-(YG)8 169.0 ± 39.9 9.9 ± 1.8 n.d. n.d. 
n.d. : not determined because these structures were not observed 
Data reported as mean ± standard deviation, with a minimum of 25 measurements. 
 
6.2.5 Pharmacokinetics of Genetically Encoded Amphiphiles 
To determine whether the in vivo properties of these homo-biopolymers benefit 
from spontaneous self-assembly, two genetically encoded amphiphiles and a single 
chain ELP were injected into the mouse tail vein, and the plasma concentration was 
tracked longitudinally over 24 hours via an N-terminal conjugated fluorophore. The two 
selected amphiphiles, A[1]-160-(FGG)8 and A[1]-160-(YG)8, were similar in both 
molecular weight and nanoparticle size (Table 7). However, the A[1]-160-(FGG)8 
construct displayed a critical aggregation concentration of approximately 0.9 µM (56 
times lower than the initial concentration of 50 µM), whereas the A[1]-160-(YG)8 
construct displayed a CAC of 13.0 µM, only ~4 times lower than the initial 
concentration. The plasma concentration of each construct was fit to a two-compartment 
model (Figure 37), and their pharmacokinetic parameters were calculated (Table 17, 
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Appendix 8.8). Within the first 2 hours, the injected amphiphiles partitioned out of the 
plasma in an effort to establish a dynamic equilibrium between the plasma and tissue 
compartments, resulting in the rapid decline of the plasma concentration. As the plasma 
concentration approached the CAC of the A[1]-160-(YG)8 construct, the nanoparticles 
began to dissociate into unimers. Thus, while this construct exhibited all of the 
characteristics of nanoparticles ex vivo, it displayed an elimination half-life and an area 
under the curve (AUC) that was indistinguishable from that of a single chain control in 
vivo (Table 10). In contrast, the A[1]-160-(FGG)8 construct, which remained assembled 
into stable nanoparticles to concentrations below 1 µM, did not dissociate upon in vivo 
administration and thus displayed an elimination half-life of 16 hours (75% longer than 
the control) and an AUC of 628 µM·h (90% higher than the control). This suggests that 
the phenylalanine-based constructs may provide a distinct biological advantage when 
delivering therapeutics as they will remain circulating longer and provide a higher 
exposure levels than the tyrosine-based constructs. 
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Figure 37: Plasma concentration of two genetically encoded amphiphile assemblies 
compared to a single chain ELP as a function of time. The data points represent mean 
± SD (n=3) and the dashed lines represent the curves of best fit to the two 
compartment model by SAAM II. Significance (one-way ANOVA, Tukey post-hoc 
test) was calculated for A[1]-160-(FGG)8 and A[1]-160-(YG)8 against the A[1]-160 
control for all time points. **p<0.005 
 
Table 10: Pharmacokinetic parameters of two genetically encoded amphiphiles 
following plasma injection 
Parameter 
 
A[1]-160 A[1]-160-(FGG)8 A[1]-160-(YG)8 
elimination half-life  [hr] 9.1 (0.5) 16.0 (2.6) 10.9 (1.0) 
area under the curve [µM hr] 332.1 (9.9) 628.0 (40.1) 329.7 (19.1) 
aData represent the mean (SD) of the best fit parameters determined by SAAM II. 
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6.3 Conclusions 
This chapter illustrates a very simple approach to build morphologically rich 
structures by genetically end-functionalizing a water soluble homopolypeptide with a 
short hydrophobic domain of precise length and composition. We observed that the 
assembled structures were highly sensitive to the composition of the assembly domain. 
Typically, the morphology of self-assembled systems are a composite of multiple factors, 
including the composition of the polymers, the concentration in solution, polymer-
solvent interactions, and most importantly, the size ratio of the hydrophilic to the 
hydrophobic block, known as the hydrophilic fraction [210]. As a general rule, when this 
fraction exceeds 60%, polymer diblocks tend to form spherical micelles. Polymers favor 
worm-like micelles between 45% and 55%, and vesicles are constrained to the narrow 
region between 25% and 45% [212]. The unexpected finding with this system is that 
worm-like micelles and vesicles form when the hydrophilic fraction is as high as 97%, a 
regime that would classically only allow a spherical micellar structure. Surprisingly, 
many of these systems were also extremely stable despite their degree of asymmetry. In 
fact, we were able to show that one of the constructs demonstrated a significant increase 
in both the plasma half-life and systemic exposure in vivo compared to a single chain 
control. 
We have found that many of the assembly domains utilizing the aromatic amino 
acids – tyrosine, phenylalanine, and tryptophan – assemble into structures that are 
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sensitive to the number of glycine residues between the hydrophobes. The (YGG)8 
domain, for instance, remains monomeric, while the (YG)8 domain drives worm-like 
micelle formation and the Y8 domain induces the formation of nanoscale aggregates. The 
hydrophilic fraction does not seem to play a significant role in the (FGG)8 domain 
morphologies in the hydrophilic fraction regime of 97% (chain length n=160) down to 
94% (n=80) or 88% (n=40), although only the longest chain length (n=160) was observed 
to induce the formation of vesicles in equilibrium with the worm-like and spherical 
micelles observed within the n=40 and 80 samples.  
We elected to use elastin-like polypeptides as the principal component of these 
structures for several reasons: (1) they undergo a soluble-to-insoluble phase above a 
specific temperature that can be specifically tuned to occur within a narrow (2°C) 
temperature window that has prompted their use in a variety of biomedical applications 
including the delivery of protein [84, 208] and chemical therapeutics [76, 77, 88]; (2) they 
are designed on the genetic level, providing precise control over their molecular weight 
as well as the number and distribution of reactive sites along the polymer chain; (3) they 
are biodegradable [81] and non-toxic [80]; and (4) they can be expressed at high yield 
from Escherichia coli and rapidly purified by exploiting their phase transition behavior 
[84, 85].  
ELPs also retain their unique thermal behavior upon fusion to proteins and 
peptides, and thus provide a useful platform to construct environmentally responsive 
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polypeptide amphiphiles. The fusion of a hydrophobic peptide to one end of the soluble 
polypeptide generates amphiphilic molecules with the capacity to assemble into 
complex structures that can then collapse into a hydrophobic aggregate in response to 
subtle temperature triggers.  
Although many of the rules dictating the physicomechanical characteristics of 
structures assembled with these hydrophobic domains remain unknown, it is our hope 
that this work provides a starting point to exploit the versatility of these genetically 
encoded domains for a diverse range of drug delivery and biomedical applications. 
 
6.4 Materials and Methods 
6.4.1 Materials 
Restriction enzymes and T4 DNA ligase were purchased from New England 
Biolabs (Ipswich, MA). All custom oligonucleotides were synthesized by Integrated 
DNA Technologies Inc. (Coralville, IA). The DNA miniprep and gel purification kits 
were purchased from Qiagen Inc. (Germantown, MD).  EB5α™ and BL21™ Escherichia 
coli cells were purchased from Edge BioSystems (Gaithersburg, MD).  All Escherichia coli 
cultures were grown in TBDry™ media purchased from MO BIO Laboratories, Inc 
(Carlsbad, CA).  Kanamycin was purchased from CalBioChem (San Diego, CA). 
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6.4.2 Methods 
6.4.2.1 Synthesis of asymmetric polypeptides  
The highly asymmetric amphiphiles were synthesized from purchased oligomers 
using plasmid reconstruction recursive directional ligation (Figure 43, Appendix 8.2) 
[213]. The asymmetric amphiphiles described in this chapter are of the form: SKGPG-
(AGVPG)n-(XGz)8-Y, where the polypeptide length n (40, 80, or 160), the number of 
glycine spacers y (0, 1, or 2) , and the identity of the hydrophobic residue X are 
systematically varied (Figure 40, Appendix 8.1).  
6.4.2.2 Expression and purification of asymmetric amphiphiles 
Each construct was expressed using a previously published hyperexpression 
protocol, which relies on the leakiness of the T7 promoter [161]. 50 mL cultures were 
grown overnight and used to inoculate 1 L flasks of TBDry supplemented with 45 
µg/mL kanamycin. The flasks were then incubated at 37°C for 24 h and 190 rpm. Each 
construct was purified using a modified Inverse Transition Cycling protocol [84], where 
the solution was never heated above room temperature due to the irreversible thermal 
nature of a few of the constructs. Briefly, the cell suspension was centrifuged at 3,000 
rpm for 10 min at 4°C, the cell pellet resuspended in PBS and then lysed via sonication 
on ice for 3 min (10 s on, 40 s off) (Masonix S-4000; Farmingdale, NY). Polyethyleneimine 
(PEI) 0.7% w/v was added to the lysate to precipitate nucleic acid contaminants. The 
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supernatant was then subjected to multiple rounds of ITC as follows. The solution was 
transitioned on ice through the addition of 3 M NaCl. The coacervate was then 
centrifuged for 10 min at 14,000 g and 20°C, the supernatant decanted, and the pellet 
resuspended in phosphate buffer. This suspension was cooled to 4°C, and then 
centrifuged for 10 min at 14,000 and 4°C to remove any insoluble contaminants. 
Typically, 3-5 rounds of ITC generated a sufficiently pure product (>95% by SDS-PAGE). 
6.4.2.3 Thermal Characterization.  
Turbidity profiles were obtained for each of the constructs by recording the 
optical density as a function of temperature (1°C/min ramp) on a temperature controlled 
UV-Vis spectrophotometer (Cary 300 Bio; Varian Instruments; Palo Alto, CA). The Tt 
was defined as the inflection point of the turbidity profile. Samples were measured in 
phosphate buffered saline solution at five different solution concentrations between 1 - 
100 µM. 
6.4.2.4 Light Scattering Analysis 
Dynamic light scattering was used to determine the hydrodynamic radius (Rh) of 
the various constructs at 25°C and 25 µM amphiphile concentration using a Dynapro 
plate reader (Wyatt Technology; Santa Barbara, CA), following filtration through 0.22 
µm Millex-GV filters (Millipore; Billerica, MA). The data was analyzed with a 
regularization fit for Raleigh spheres. Static light scattering measurements were 
performed using the ALV/CGS-3 goniometer system (Germany). Samples for the 
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ALV/CGS-3 goniometer system were prepared in PBS at 25 µM and filtered through 0.22 
µm Millex-GV filters into a 10 mm disposable borosilicate glass tube (Fischer). 
Measurements were obtained at 25°C for angles between 30°-150° at 5° increments, with 
each angle consisting of 3 runs for 10 seconds. Results were analyzed by partial Zimm 
plot analysis using ALV/Dynamic and Static FIT and PLOT software. 
6.4.2.5 Tunable Resistive Pulse Sensing 
Lyophilized samples were resuspended in phosphate buffered saline to a 
concentration of 50 µM and filtered through 0.22 µm Millex-GV filters. 40 µL of the 
sample was loaded onto a qNano (Izon; Christchurch, New Zealand) instrument 
equipped with 50 – 150 nm pores (A[1]-160-(FGG)8, A[1]-160-(FG)8, A[1]-80-(FGG)8, and 
A[1]-40-(FGG)8) or 100-300 nm pores (A[1]-160-(YG)8, A[1]-160-F8, and A[1]-160-
(WGG)8). Samples were measured for at least 30 seconds and a minimum of 500 
blockade events were recorded per sample. Samples were calibrated against known 
standards (Izon) for the same stretch and voltage. 
6.4.2.5 Fluorescence Spectroscopy 
An assay to determine the critical aggregation concentration (CAC) using pyrene 
as a probe was performed using a Cary Eclipse spectrophotometer equipped with a 
Xenon flash lamp (Varian Instruments; Palo Alto, CA). 1 µL of a stock solution of 12 mM 
pyrene (Fluka/Sigma-Aldrich; St. Louis, MO) in ethanol was diluted into 20 mL of PBS. 
Both the stock solution and the PBS mixture were sonicated for 10 minutes prior to use. 
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This solution was used to resuspend 1-5 mg of lyophilized sample, which was then used 
to create a dilution series. Each sample was placed in a reduced volume cuvette, and 
scanned (Ex: 334; Em: 360-380, Ex slit 10 nm; Em slit 2.5 nm). Pyrene fluorescence 
displays four peaks; the intensity at the first (I1; 370-373 nm) and third peak (I3; 381-384 
nm) were recorded. The ratio I1/I3 was plotted as a function of CP concentration. The 
CAC was defined as the inflection point of the sigmoid of best fit. 
6.4.2.6 Cryogenic Transmission Electron Microscopy  
Cryogenic Transmission Electron Microscopy was performed at the University of 
Pennsylvania in the Penn Regional Nanotechnology Facility (Philadelphia, PA). Lacey 
formvar/carbon grids (Ted Pella) were washed in chloroform to remove the formvar 
template and carbon coated with a Quorum Q150T ES carbon coater (Quorum 
Technologies, United Kingdom). Grids were cleaned with hydrogen/oxygen plasma for 
15 s using the Solarus Advanced Plasma System 950 (Gatan, Pleasanton, CA). A 200 µM 
sample in the form of a 2 µl drop was deposited onto the grid and added to a Gatan Cp3 
cryoplunger (Gatan, Pleasanton, CA). The samples were blotted by hand and plunged 
into liquid ethane. Grids were transferred to a Gatan CT3500TR cryoholder (Gatan, 
Pleasanton, CA) and immediately inserted into a JEOL 2010 TEM (JEOL, Tokyo, Japan) 
operating at 80 keV. Micrographs were imaged with an Orius SC200 digital camera. 
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6.4.2.7 Pharmacokinetic Analysis 
All animal experiments were done in accordance with Duke University's 
Institutional Animal Care and Use Committee. Genetically encoded amphiphiles labeled 
with an N-terminal Alexa Fluor® 488 sulfodicholorphenol ester (Invitrogen; Carlsbad, 
CA) were intravenously administered via tail vein into Balb/c mice (400 µg/g body 
weight). 10 µL blood was collected at select time points (40 s, 5 min, 30 min, 2 h, 4 h, 8 h, 
24 h) and diluted into 100 µL of heparin (1000 U/mL) in PBS. The samples were 
centrifuged (1000 g, 5 min, 4°C) to remove the red blood cells. The solution was loaded 
into a 96-well microplate in triplicate (25 µL per well), and the fluorescence was 
determined using a Victor3 microplate reader (485 nm excitation, 535 nm emission). 
Plasma concentration was fit to a two compartment model to determine the 
pharmacokinetic parameters using SAAM II software (University of Washington, 
Seattle, WA). 
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7. Conclusions and Future Directions 
The polypeptide platform described in this thesis represents a modular and 
robust drug delivery vehicle. Its size and stability in serum enable it to accumulate in 
solid tumors by the enhanced permeability and retention effect, and its unique thermal 
behavior allows the carrier to exhibit a rapid and reversible phase transition from 
nanoparticle to insoluble aggregate in serum. While the studies presented herein 
demonstrate a significant increase in tumor drug accumulation in response to cyclic 
heating, there are a variety of different paths future researchers may explore to improve 
the efficacy and versatility of this system. 
  
7.1 Designing Novel Sequences Based on Elastin-like 
Polypeptides  
This thesis demonstrates that the transition temperature of elastin-like 
polypeptide drug carriers (unimers and nanoparticles) can be precisely determined 
through the composition, chain length, and concentration of the polypeptide [182]. 
While the combination of valines and alanines in the guest residue position was 
carefully selected to provide nanoparticles that transition between 37 and 42°C for the 
chain lengths of 40, 80, and 160 pentapeptides, it is possible that others will (1) require 
smaller or larger ELPs or CPs to display a unimeric or micellar transition temperature 
outside of the range provided by these two residues, (2) require constructs that display 
pH and thermal sensitivity, or (3) want to predict the transition temperature of 
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zwitterionic sequences. In the first case, the selection of aliphatic binary residue 
combinations such as glycine and leucine would provide a large transition temperature 
range while avoiding complicating effects such as charge, π-π stacking, and pH. Recent 
works by MacKay show that single chain ELPs comprised of serine residues exhibit very 
peculiar thermal behaviors that would not be conducive to modeling by any of these 
equations, as the intermolecular hydrogen bonding seems to eliminate both length and 
concentration dependence of the transition temperature of unimeric ELPs [214]. For this 
reason, glycine was selected as it is likely hydrophilic enough for most purposes and 
should not alter the innate tendencies of most ELP chains. If pH sensitivity is desired, a 
combination of histidines and glycines may provide ELPs that both transition in a wide 
range of physiological temperatures as well as exhibit a pH dependence that is 
appropriate for physiological triggers. In this case, it would be possible to combine 
Equation 3 with the MacKay model [91] in an effort to incorporate the Henderson-
Hasselbalch relationship such that the predicted transition temperature would depend 
on sequence, chain length, concentration, and solution pH. In the final case, 
combinations of lysines and glutamates or arginines and glutamates would yield 
zwitterionic ELPs, though the transition temperatures would likely be quite high due to 
the presence of charged residues.  
When it is necessary to design constructs that exhibit a phase transition within a 
narrow temperature or pH range, constructing a predictive model similar to Equation 4 
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and 5 can eliminate much of the guesswork. While Chapters 4 and 5 show models 
constructed from 8 independent libraries (24 constructs total), many of these libraries 
did not influence the outcome of the model. In fact, we observed that the Ala-Val system 
only required three ELP libraries (3 different molecular weights per library, 9 constructs 
total) to fully predict the transition temperatures of the ELP superlibrary: 100% guest 
residue A, 100% guest residue B, and the 50:50 mixture of the two guest residues (45 
measurements, r2=0.992). When designing future sequence combinations, it would be 
logical to first generate these three foundational libraries with which to build the model, 
then only build the libraries with the desired properties. 
 
7.2 Improving the Pharmacokinetic Profile of Chimeric 
Polypeptide Nanoparticles 
One of the more interesting and unanticipated behaviors in vivo was that the 
pharmacokinetics of chimeric polypeptides was primarily determined by the chain 
length of the monomeric polymer rather than the size of the nanoparticle. CP 
nanoparticles with chain lengths measuring between 15 and 30 kDa, for instance, were 
rapidly cleared by the kidneys, whereas CP nanoparticles formed with 60 kDa chains 
exhibited a much longer plasma half-life and little to no kidney uptake. Despite forming 
large (30-60 nm diameter) micelles, in vivo, the fate of these CPs were tied to the fate of 
the polymer molecular weight. To be clear, that does not mean that the micelle and the 
single chain polymer show the same half-life, rather that micelles with shorter chains 
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experience drastically shorter half-lives than nanoparticles with longer chains. This was 
a peculiar finding because the in vivo thermal behavior of the nanoparticles clearly 
indicates that a significant portion of these structures remained fully formed even hours 
after injection. We hypothesized that this effect may be due to the equilibrium that self-
assembled structures maintain with their unimeric counterparts; when the unimeric 
structures display a molecular weight below the renal filtration cutoff, the kidneys are 
able to continuously clear the unimers from circulation. To circumvent this effect, it may 
be possible to increase the stability of the circulating micelles through internal core 
crosslinking by incorporation of lysines [215], lysines and glutamines [216], cysteines to 
exploit disulfide crosslinking [200], or noncanonical amino acids using residue specific 
incorporation technologies [217].  
Crosslinking and stabilizing the nanoparticle may enable a higher degree of 
control over the size of the micelles by permitting the use of even smaller chain CPs 
without the associated poor pharmacokinetic profile. CP-Dox micelles comprised of 15 
kDa, 30 kDa, and 60 kDa chains exhibited increasing diameters of 30, 38, and 54 nm, 
respectively. Although it is possible that the 30 nm micelles improved the penetration 
depth of the drug into the tumor, their biodistribution profile (high kidney 
accumulation) precluded their use in mice. As we hypothesized that this trait may be 
due to the continuous, renal-induced clearance of single chain polymers from the serum, 
crosslinking may prevent this poor pharmacokinetic profile. Finally, it is unlikely that 
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core crosslinking will significant reduce the amount of released drug within the tumor. 
CP nanoparticles remain highly solvated in the core; once a drug is released due to 
changes in pH or hydrolysis, it is unlikely that a soluble CP carrier will be able to inhibit 
the diffusion of the free drug. 
 Others have also shown that diblock micelles tend to display pharmacokinetic 
profiles that are tied to the molecular weight of the polymer [198]. It may be possible to 
extend the plasma half-life of these diblocks by designing the hydrophobic core with an 
ELP composed primarily or partially of hydrophobic amino acids such as 
phenylalanines, tyrosines, or tryptophans. Chapter 6 demonstrates that only a few of 
these amino acids are necessary to direct assembly of stable nanoparticles; a core that is 
rich in these amino acids may be much more stable than a core rich in valines [208] or 
isoleucines [198], and thus be able to withstand the mechanical stress of circulation. 
  
7.3 Strategies to Improve Treatment Efficacy 
 A simple strategy to enhance the antitumor effect of CP-drug conjugates would 
be combination therapy. There are a large number of chemotherapeutic drug 
combinations (a few of which are mentioned in Chapter 1) that synergistically enhance 
tumor toxicity. As the degree of synergy is typically tied to the molar ratio of the two (or 
more) chemotherapeutics, it is important to precisely control this ratio to limit the 
number of experimental variables. For instance, a logical next step would be to examine 
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the efficacy of CP-Doxorubicin and CP-Paclitaxel in combination, two constructs that 
have been extensively characterized. The two primary delivery routes are to (1) co-inject 
CP-Dox and CP-PTX at a predetermined ratio, and (2) inject a single CP conjugated to 
two drugs simultaneously. While the first strategy enables the ratio of the two drugs to 
be held constant across experiments by simply adjusting the injection ratio of the two 
conjugates, the second strategy requires precision control over the conjugation ratio of 
both drugs across multiple batches, and thus will likely confound the outcome of 
repeated in vivo studies.  
 All of the CP-drug conjugates that our group has developed to this point exploit 
unique cysteine residues as drug attachment sites. However, there are a number of 
situations in which an orthogonal chemistry may be required for site-specific 
conjugation. For instance, using cysteines for drug attachment sites would not be 
advisable if the CP chain or an attached peptide ligand contained cysteine residues, or if 
two different drugs were being conjugated to the same CP chain. In either case, it would 
be worth exploring the incorporation of noncanonical amino acids as they can provide 
completely orthogonal click chemistries such as azides and aldehydes [218]. Carboxyl 
and amine chemistry, while available through natural amino acids such as glutamates 
and lysines, are not preferred because the polypeptide would require site-specific 
protection and deprotection of the carboxy- and amino-terminus to prevent polypeptide 
polymerization. 
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7.4 Asymmetric Polypeptide Amphiphiles 
Finally, the chapter discussing genetically encoded amphiphiles opens many 
possibilities to explore the rules governing how these short peptides induce extreme 
morphological variability once appended to their respective biopolymer and how they 
can be harnessed to provide useful drug carriers. One possibility would be to utilize 
these hydrophobic domains in combination with drug attachment domains to induce the 
formation of thermally responsive spherical micelles, worm-like micelles, or vesicles 
despite carrying a hydrophilic drug that would not normally drive assembly. Although 
hydrophilic drugs do not suffer from insolubility in vivo, they still display poor 
pharmacokinetics that could be greatly improved through chemical conjugation to 
nanoparticles or thermally targeted nanoparticles. Preliminary data does indicate that 
this new class of nanoparticle is feasible, as we have shown that the hydrophilic 
chemotherapeutic gemcitabine does not drive assembly when conjugated to a (CGG)8 
domain, but does not interfere with the assembly of a (YG)6-(CGG)8 domain upon 
conjugation. While the attachment of gemcitabine is not the driving force for assembly, 
the drug still reaps the same benefits from an improved pharmacokinetic and 
biodistribution profile as hydrophobic drugs (Chapters 3 and 5). It may also be 
fascinating to explore whether other morphologies (toroids, for instance) can be 
constructed through the use of noncanonical amino acids or if the conjugation and 
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assembly domains can be merged into the same residues, such as p-
propargyloxyphenylalanine (tyrosine + alkyne) or p-acetylphenylalanine (phenylalanine 
+ aldehyde) [218]. 
A number of questions remain concerning the morphology of these genetically 
encoded amphiphiles. While we have characterized many of the amphiphiles with a 
variety of techniques, they have not shed any light on whether secondary structure 
formation within the assembly domains plays a role in morphological variety. Future 
studies could include circular dichroism (CD) and fourier transform infrared 
spectroscopy (FTIR) to directly measure secondary structure interactions, and electron 
paramagnetic resonance (EPR) to determine the degree of solvation of the ELP chain.   
It would also be interesting to explore the in vitro and in vivo differences induced 
by simply changing the morphology from spheres to worms to vesicles. For example, 
various systems have shown significant differences between micelles and worms in the 
pharmacokinetic profile [219, 220] and in the primary organs targeted [221-223], as well 
as differences in the quantities and mechanisms of cellular uptake [224, 225], although in 
many of these experiments it can be difficult to tease out whether the changes are due to 
differences in morphology or absolute size. Branching from this work, one could 
compare the pharmacokinetic and biodistribution profiles of spherical micelles 
assembled via conjugation of hydrophobic molecules such as pyrenylmaleimide and the 
worm-like micelles observed in the (YG)8 genetically encoded amphiphile system by 
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appending a small fraction of hydrophilic fluorophores on the N-terminus of the ELP 
chains. It would also be feasible to instead use the attachment of doxorubicin to A[1]-
160-(CGG)8 to induce the formation of spherical micelles and compare the 
pharmacokinetic and biodistribution profiles of the drug directly against A[1]-160-(YG)8-
(CGG)8-doxorubicin, although it is unknown whether the attachment of doxorubicin will 
perturb the assembly of worm-like micelles.  
In summary, this thesis describes a novel method for the construction of highly 
repetitive polypeptides and a model to predict their phase transition behavior based on 
their composition, chain length, and concentration. These constructed polypeptides were 
assembled into thermoresponsive micelles through the attachment of drugs that display 
a minimum threshold hydrophobicity, and were shown to display an in vivo transition 
temperature within the narrow range of 37-42°C. Finally, we demonstrated that these 
thermally responsive micelles induced a 2.6 fold increase in tumor drug accumulation 
by thermal cycling. It is our hope that this work will serve as a foundation for others to 
develop new thermally responsive sequences and find new uses for these versatile 
polypeptides. 
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8. Appendices 
8.1 Gene sequences 
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Figure 38: Gene sequence of ELP unimers. The ELP constructs consist of a leader 
sequence (MSKGP) followed by the ELP sequence. The methionine is cleaved during 
expression. A short trailer was included (Y… or WP..) to permit A280 nm protein 
quantification. The repeat unit n=4, 8, and 16 represent the 40, 80, and 160 pentamer 
sequences, respectively [182]. 
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Figure 39: Gene sequence of ELP micelles that assemble through drug conjugation. 
The ELP constructs consist of a leader sequence (MSKGP) followed by the ELP 
sequence. The methionine is cleaved during expression. A short cysteine-rich trailer 
was appended to the C-terminus (CGG)8WP to both allow site specific drug 
conjugation to the unique cysteine residues and permit A280 nm protein quantification 
via the tryptophan reside (ɛ = 5630 mol-1cm-1). The repeat unit n=4, 8, and 16 represent 
the 40, 80, and 160 pentamer sequences, respectively. 
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Figure 40: Gene sequence of genetically encoded amphiphiles. The ELP constructs 
consist of a leader sequence (MSKGP) followed by the ELP sequence. The methionine 
is cleaved during expression. The repeat unit n=4, 8, and 16 represent the 40, 80, and 
160 pentamer sequences, respectively. Each assembly domain is shown with both the 
shorthand notation and the actual sequence, followed by a single tyrosine that allows 
A280 nm protein quantification (ɛ = 1290 mol-1cm-1).  
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8.2 Gene Libraries 
 
Figure 41: ELP unimer gene libraries. ELP genes were run on a 1% agarose gel and 
stained with Sybr Safe (Invitrogen). The left and right lanes represent a size standard 
ladder (1 KB DNA Ladder, New England Biolabs) with the length (kb) shown on the 
left. The remaining lanes represent diagnostic digests of the constructs restricted with 
BamHI-HF and XbaI (hence appending 66 bp of flanking sequences to each band). 
The composition of the guest residue ratio and the expected length of the ELP 
constructs (shown in pentamers and basepairs) are displayed on the bottom [182]. 
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Figure 42: CP gene libraries. CP genes were run on a 1% agarose gel and stained with 
Sybr Safe. The left and right lanes represent a size standard ladder with the length 
(kb) shown on the left. The remaining lanes represent diagnostic digests of the 
constructs restricted with BamHI-HF and XbaI (hence appending 66 bp of flanking 
sequences to each band). The composition of the guest residue ratio and the expected 
length of the ELP constructs (shown in pentamers and basepairs) are displayed on the 
bottom. 
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Figure 43: Genetically encoded amphiphile gene libraries. The amphiphile genes 
were run on a 1% agarose gel and stained with Sybr Safe. The left and right lanes 
represent a size standard ladder with the length (kb) shown on the left. The 
remaining lanes represent diagnostic digests of the constructs restricted with BamHI-
HF and XbaI (hence appending 66 bp of flanking sequences to each band). The 
composition of the morphogenic domain and the expected length of the amphiphiles 
(shown in basepairs and elastin-like polypeptide pentamers) are displayed on the 
bottom. 
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8.3 Protein Expression Libraries  
 
Figure 44: ELP unimer expression libraries. Proteins purified by 2-3 cycles of inverse 
transition cycling were run on an SDS-PAGE gel and stained with CuCl2. The left 
lane is the Bio-Rad Kaleidoscope Protein Ladder, with the molecular weights (in kDa) 
shown on the left. The remaining lanes represent the purified proteins with the guest 
residue ratio (composition), and length (pentamers and kDa) shown beneath their 
respective lanes [182]. 
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Figure 45: ELP micelle expression libraries. Proteins purified by 2-3 cycles of inverse 
transition cycling were run on an SDS-PAGE gel and stained with CuCl2. The left 
lane is the Bio-Rad Kaleidoscope Protein Ladder, with the molecular weights (in kDa) 
shown on the left. The remaining lanes represent the purified proteins with the guest 
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residue ratio (composition), and length (pentamers and kDa) shown beneath their 
respective lanes. The dimer and trimer bands that appear above the primary band are 
indicative of the formation of cysteine-cysteine disulfide bonds between the drug 
conjugation domains of different ELP chains. 
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8.4 MALDI-MS  
Table 11: MALDI-MS results for ELP1 and ELP2 libraries constructed with PEe-RDL.  
Molecular weights could not be accurately determined (n.d.) for species larger than 
160 pentapeptides.  Theoretical masses were determined by inputting the theoretical 
amino acid composition of the peptide into the exPASy Proteomics Server [226], 
which then outputs the sum of the isotopically averaged mass of each individual 
amino acid [153]. 
 
Length (Pentamer) Expected (g/mol) Measured (g/mol) Error (%) 
ELP4 
30 12465.7 12476.2 0.1 
60 24750.3 23524.9 -5.0 
60 L1T1 26914.7 26965 0.2 
120 49319.4 49309.3 0.0 
240 98457.7 n.d. n.d. 
ELP2 
80 L1 30561.1 30502.7 -0.2 
160 L1 60514.6 59539.6 -1.6 
240 L1 90468 n.d. n.d. 
320 L1 120421.5 n.d. n.d. 
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Table 12: MALDI-MS results for ELP unimers. Theoretical masses were determined 
by inputting the theoretical amino acid composition of the peptide into the exPASy 
Proteomics Server [226], which then outputs the sum of the isotopically averaged 
mass of each individual amino acid [182]. 
ƒAlanine Length (pentamer) Expected (g/mol) Measured (g/mol)  Error (%) 
1 40 15864.9 15833.4 -0.20 
1 80 31122.2 31034.5 -0.28 
1 160 61636.7 61425.2 -0.34 
0.9 40 15977.1 15966.7 -0.07 
0.9 80 31346.6 31265.1 -0.26 
0.9 160 62085.6 61916.6 -0.27 
0.9 240* 93618.0 93486.7 -0.14 
0.8 40 16209.5 16169.7 -0.25 
0.8 80 31691.2 31604.0 -0.28 
0.8 160 62654.6 62467.7 -0.30 
0.7 40 16321.7 16273.2 -0.30 
0.7 80 31915.6 31855.2 -0.19 
0.7 160 63103.5 62908.3 -0.31 
0.6 40 16433.9 16384.5 -0.30 
0.6 80 32140 32049.6 -0.28 
0.6 160 63552.3 63405.1 -0.23 
0.5 40 16546.1 16513.4 -0.20 
0.5 80 32364.5 32269.0 -0.30 
0.5 120* 48182.8 48140.9 -0.09 
0.5 160 64001.2 63799.0 -0.32 
0.2 20* 8685.1 8713.0 0.32 
0.2 40 16762.6 16728.7 -0.20 
0.2 80 32917.6 32861.4 -0.17 
0.2 160 65227.6 65148.3 -0.12 
0 40 16987 16924.5 -0.37 
0 80 33366.5 33265.9 -0.30 
0 160 66125.3 65983.2 -0.21 
*Lengths followed by an asterisk were not used in the construction of the model 
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Table 13: MALDI-MS results for genetically encoded amphiphiles. Theoretical 
masses were determined by inputting the theoretical amino acid composition of the 
peptide into the exPASy Proteomics Server [226], which then outputs the sum of the 
isotopically averaged mass of each individual amino acid. 
Trailer Length Expected Measured  Error (%) 
Control 160 61636.7 61425.2 -0.34 
(IGG)8 160 63454.8 63495.7 0.06 
(LGG)8 160 63454.8 63434.1 -0.03 
(HGG)8 160 63646.7 64147.3 0.79 
(WGG)8 160 64039.3 n.d. n.d. 
(YGG)8 160 63855 63852.6 0.00 
(YG)8 160 63398.5 63463.5 0.10 
Y8 160 62942.1 63027.8 0.14 
(FGG)8 160 63727 63760.9 0.05 
(FG)8 160 63270.6 63319.6 0.08 
F8 160 62814.1 n.d. n.d. 
(FGG)8 80 33212.4 33233.3 0.06 
(FGG)8 40 17955.1 17959.9 0.03 
n.d.: not determined 
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8.5 Thermal Profiles 
 
Figure 46: Thermal properties for ELP unimer libraries. The measured transition 
temperatures for each of the three molecular weights synthesized (40, 80, and 160 
pentamers) as a function of ELP concentration for each ELP library. The three data 
sets shown in green represent the three ELP constructs designed to test the fidelity of 
the model at molecular weights other than 40, 80, and 160 pentamers. The dashed 
lines represent the predicted transition temperatures derived from the ELP unimer 
model (Equation 4) [182]. 
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Figure 47: Thermal properties for ELP micelle libraries. Each ELP construct was 
conjugated to n-benzylmaleimide and purified, at which point the transition 
temperature was measured as a function of ELP concentration. The dashed lines 
represent the predicted transition temperatures derived from the ELP micelle model 
(Equation 5). 
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8.6 Transition Temperatures of ELP Unimers 
Table 14: ELP compositions and lengths necessary for designing ELP unimers with a 
specific transition temperature (rounded to the nearest 1°C) at select concentrations in 
PBS. The ELP nomenclature is A[X]-Y, where X represents the fraction of alanine (A) 
in the guest residue composition (rest, valine (V)), and Y represents the length of the 
ELP in pentamers [182]. 
 
 
 
Tt 1 uM 5 uM 10 uM 25 uM 50 uM 100 uM 250 uM 500 uM 1000 uM
19 A[0]-180
A[0]-200
20 A[0]-200 A[0]-160 A[0]-140
A[0]-180 A[0]-160
A[0]-200
21 A[0]-200 A[0]-160 A[0]-140 A[0]-100
A[0]-180 A[0]-120
A[0.1]-180
A[0.1]-200
22 A[0]-200 A[0]-180 A[0]-160 A[0]-140 A[0]-120 A[0.1]-140
A[0]-200 A[0]-180 A[0.1]-180 A[0.1]-160
A[0.1]-200
23 A[0]-200 A[0]-180 A[0]-160 A[0]-140 A[0]-120 A[0]-100 A[0]-80
A[0.1]-200 A[0.1]-160 A[0.1]-140 A[0.1]-100
A[0.1]-180 A[0.1]-160 A[0.1]-120
A[0.1]-200 A[0.2]-200
24 A[0]-200 A[0]-180 A[0]-160 A[0]-140 A[0]-120 A[0]-100 A[0]-80 A[0]-60
A[0.1]-200 A[0.1]-180 A[0.1]-140 A[0.1]-120 A[0.2]-140
A[0.2]-180 A[0.2]-160
A[0.2]-200 A[0.2]-180
25 A[0]-200 A[0]-180 A[0]-160 A[0]-140 A[0]-120 A[0.1]-140 A[0.1]-120 A[0.1]-100 A[0.1]-80
A[0.1]-200 A[0.1]-180 A[0.1]-160 A[0.2]-180 A[0.2]-160 A[0.2]-120
A[0.2]-200
26 A[0]-180 A[0]-160 A[0]-140 A[0]-120 A[0.1]-160 A[0]-100 A[0]-80 A[0.1]-80 A[0.2]-100
A[0.1]-200 A[0.1]-160 A[0.2]-200 A[0.1]-100 A[0.2]-120 A[0.3]-160
A[0.1]-180 A[0.2]-160 A[0.2]-140 A[0.3]-180
A[0.3]-200
27 A[0]-140 A[0.1]-180 A[0]-100 A[0.1]-120 A[0.2]-140 A[0]-60 A[0.1]-60
A[0.1]-180 A[0.1]-140 A[0.2]-160 A[0.2]-100 A[0.2]-80
A[0.1]-200 A[0.2]-180 A[0.2]-180 A[0.3]-180 A[0.3]-120
A[0.2]-200 A[0.3]-200 A[0.3]-140
28 A[0]-160 A[0.1]-160 A[0]-120 A[0]-100 A[0.1]-120 A[0]-80 A[0.1]-80 A[0.3]-140 A[0]-40
A[0.1]-200 A[0.1]-160 A[0.1]-140 A[0.2]-160 A[0.1]-100 A[0.2]-120 A[0.3]-160 A[0.3]-100
A[0.2]-180 A[0.2]-140 A[0.3]-180 A[0.4]-200
A[0.2]-200 A[0.3]-200
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29 A[0]-140 A[0]-120 A[0.1]-140 A[0.1]-120 A[0]-80 A[0.2]-120 A[0]-60 A[0.1]-60 A[0.2]-60
A[0.1]-180 A[0.2]-200 A[0.2]-180 A[0.2]-160 A[0.2]-140 A[0.3]-180 A[0.2]-100 A[0.2]-80 A[0.3]-80
A[0.2]-200 A[0.3]-200 A[0.3]-140 A[0.3]-120 A[0.4]-160
A[0.3]-160 A[0.4]-200 A[0.4]-180
30 A[0.1]-140 A[0]-100 A[0.2]-140 A[0.1]-100 A[0.3]-160 A[0.3]-120 A[0.3]-100 A[0.4]-120
A[0.2]-180 A[0.3]-180 A[0.4]-160 A[0.4]-140
A[0.3]-200 A[0.4]-180
31 A[0]-120 A[0]-100 A[0.1]-120 A[0]-80 A[0.2]-120 A[0]-60 A[0.1]-60 A[0.4]-140 A[0.1]-40
A[0.1]-160 A[0.2]-160 A[0.1]-100 A[0.3]-160 A[0.1]-80 A[0.2]-80 A[0.3]-60
A[0.2]-200 A[0.3]-180 A[0.2]-100 A[0.4]-180 A[0.4]-100
A[0.3]-200 A[0.3]-140 A[0.4]-200 A[0.5]-200
32 A[0.1]-140 A[0.1]-120 A[0.2]-140 A[0.2]-120 A[0.1]-80 A[0.3]-120 A[0.3]-100 A[0]-40 A[0.4]-80
A[0.2]-180 A[0.2]-160 A[0.3]-200 A[0.3]-160 A[0.3]-140 A[0.4]-180 A[0.4]-140 A[0.2]-60 A[0.5]-140
A[0.4]-200 A[0.4]-160 A[0.3]-80 A[0.5]-160
A[0.4]-120 A[0.5]-180
33 A[0.2]-140 A[0]-80 A[0.2]-100 A[0.4]-160 A[0.4]-120 A[0.4]-100 A[0.2]-40
A[0.3]-200 A[0.1]-100 A[0.4]-200 A[0.5]-160 A[0.5]-120
A[0.3]-180 A[0.5]-180
A[0.5]-200
34 A[0]-100 A[0.1]-100 A[0.2]-120 A[0.1]-80 A[0]-60 A[0.2]-80 A[0.2]-60 A[0.1]-40 A[0.4]-60
A[0.1]-120 A[0.3]-180 A[0.3]-160 A[0.2]-100 A[0.3]-120 A[0.3]-100 A[0.3]-80 A[0.3]-60 A[0.5]-100
A[0.2]-160 A[0.3]-140 A[0.4]-180 A[0.4]-140 A[0.5]-180 A[0.5]-140
A[0.4]-200 A[0.5]-200
35 A[0.3]-200 A[0]-80 A[0.3]-140 A[0.3]-120 A[0.4]-160 A[0.1]-60 A[0]-40 A[0.4]-80 A[0.5]-80
A[0.2]-120 A[0.4]-200 A[0.4]-180 A[0.5]-200 A[0.4]-100 A[0.5]-120 A[0.6]-160
A[0.3]-160 A[0.5]-160 A[0.6]-180
A[0.6]-200
36 A[0.2]-140 A[0.4]-200 A[0.1]-80 A[0]-60 A[0.2]-80 A[0.4]-120 A[0.5]-140 A[0.5]-100 A[0.3]-40
A[0.3]-180 A[0.2]-100 A[0.4]-160 A[0.3]-100 A[0.5]-180 A[0.6]-180 A[0.6]-120
A[0.4]-180 A[0.4]-140 A[0.6]-200 A[0.6]-140
A[0.5]-200
37 A[0.3]-140 A[0.3]-120 A[0.4]-140 A[0.1]-60 A[0.3]-80 A[0.3]-60 A[0.2]-40 A[0.5]-60
A[0.4]-180 A[0.4]-120 A[0.5]-160 A[0.4]-80 A[0.4]-60 A[0.6]-100
A[0.5]-180 A[0.5]-120 A[0.6]-160
A[0.6]-200
38 A[0]-80 A[0.1]-80 A[0]-60 A[0.2]-80 A[0.5]-160 A[0.2]-60 A[0.1]-40 A[0.5]-80 A[0.4]-40
A[0.1]-100 A[0.2]-100 A[0.4]-160 A[0.3]-100 A[0.4]-100 A[0.5]-100 A[0.6]-120 A[0.6]-80
A[0.2]-120 A[0.5]-180 A[0.5]-140 A[0.6]-160 A[0.6]-140 A[0.7]-200
A[0.3]-160 A[0.5]-200 A[0.6]-180
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39 A[0.4]-200 A[0.3]-120 A[0.4]-140 A[0.1]-60 A[0.3]-80 A[0]-40 A[0.6]-140 A[0.7]-140
A[0.4]-160 A[0.5]-200 A[0.4]-120 A[0.5]-120 A[0.7]-160
A[0.6]-200 A[0.7]-180
40 A[0.3]-140 A[0.5]-200 A[0.2]-80 A[0.5]-160 A[0.2]-60 A[0.6]-180 A[0.6]-120 A[0.3]-40 A[0]-20
A[0.4]-180 A[0.3]-100 A[0.4]-100 A[0.6]-100 A[0.6]-60
A[0.5]-180 A[0.5]-140 A[0.7]-180 A[0.7]-100
A[0.6]-200 A[0.7]-200 A[0.7]-120
41 A[0]-60 A[0.4]-120 A[0.3]-80 A[0.5]-120 A[0.3]-60 A[0.2]-40 A[0.5]-60 A[0.5]-40
A[0.4]-140 A[0.5]-140 A[0.6]-180 A[0.4]-80 A[0.4]-60 A[0.6]-80 A[0.7]-80
A[0.5]-180 A[0.5]-100 A[0.5]-80 A[0.7]-140
A[0.6]-160 A[0.7]-200 A[0.7]-160
42 A[0.1]-80 A[0.2]-80 A[0.1]-60 A[0.4]-100 A[0]-40 A[0.1]-40 A[0.6]-100 A[0.7]-120 A[0.8]-180
A[0.2]-100 A[0.3]-100 A[0.5]-160 A[0.6]-200 A[0.6]-160 A[0.6]-140 A[0.7]-160 A[0.8]-200
A[0.3]-120 A[0.7]-180
A[0.4]-160
43 A[0.5]-200 A[0.4]-120 A[0.5]-140 A[0.2]-60 A[0.4]-80 A[0.6]-120 A[0.7]-140 A[0.4]-40 A[0.1]-20
A[0.5]-160 A[0.6]-200 A[0.5]-120 A[0.7]-200 A[0.7]-100 A[0.7]-60
A[0.6]-180 A[0.8]-120
A[0.8]-140
A[0.8]-160
44 A[0.4]-140 A[0.3]-80 A[0.6]-160 A[0.3]-60 A[0.5]-80 A[0.6]-80 A[0.6]-60 A[0.6]-40
A[0.5]-180 A[0.4]-100 A[0.5]-100 A[0.7]-180 A[0.8]-180 A[0.8]-100
A[0.6]-180 A[0.6]-140 A[0.8]-200
45 A[0]-60 A[0.1]-60 A[0]-40 A[0.6]-120 A[0.4]-60 A[0.3]-40 A[0.7]-80 A[0.2]-20
A[0.5]-140 A[0.6]-140 A[0.7]-200 A[0.7]-160 A[0.5]-60 A[0.8]-140 A[0.8]-80
A[0.6]-200 A[0.7]-120 A[0.8]-160
46 A[0.3]-100 A[0.4]-100 A[0.5]-120 A[0.4]-80 A[0.1]-40 A[0.2]-40 A[0.7]-100 A[0]-20 A[0.7]-40
A[0.5]-160 A[0.6]-180 A[0.6]-160 A[0.5]-100 A[0.7]-180 A[0.6]-100 A[0.8]-180 A[0.8]-120 A[0.8]-60
A[0.7]-200 A[0.7]-140 A[0.8]-200
47 A[0.2]-80 A[0.3]-80 A[0.2]-60 A[0.3]-60 A[0.5]-80 A[0.8]-160 A[0.5]-40 A[0.9]-140
A[0.4]-120 A[0.7]-180 A[0.7]-160 A[0.8]-100 A[0.9]-160
A[0.9]-180
A[0.9]-200
48 A[0.6]-200 A[0.5]-120 A[0.6]-140 A[0.6]-120 A[0.6]-100 A[0.7]-120 A[0.4]-40 A[0.7]-60 A[0.3]-20
A[0.6]-160 A[0.7]-200 A[0.7]-160 A[0.7]-140 A[0.8]-200 A[0.6]-60 A[0.9]-200 A[0.9]-100
A[0.8]-140 A[0.9]-120
49 A[0.5]-140 A[0.2]-60 A[0]-40 A[0.1]-40 A[0.4]-60 A[0.6]-80 A[0.7]-80 A[0.8]-80 A[0.8]-40
A[0.6]-180 A[0.7]-200 A[0.4]-80 A[0.8]-200 A[0.8]-180 A[0.8]-120 A[0.9]-160 A[0.9]-80
A[0.5]-100 A[0.9]-180
A[0.7]-180
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50 A[0.1]-60 A[0.6]-140 A[0.6]-120 A[0.5]-80 A[0.2]-40 A[0.3]-40 A[0.9]-200 A[0.1]-20 A[0.4]-20
A[0.7]-140 A[0.7]-120 A[0.5]-60 A[0.6]-40 A[0.9]-60
A[0.8]-180 A[0.7]-100 A[0.9]-140
A[0.8]-160
51 A[0.4]-100 A[0.4]-80 A[0.3]-60 A[0.6]-100 A[0.8]-140 A[0.8]-100 A[0.9]-120 A[1]-180
A[0.6]-160 A[0.5]-100 A[0.7]-160 A[0.8]-200 A[0.9]-180 A[1]-200
A[0.7]-180
52 A[0.3]-80 A[0]-40 A[0.4]-60 A[0.6]-80 A[0.5]-40 A[0.8]-60 A[0.9]-40
A[0.5]-120 A[0.8]-180 A[0.8]-160 A[0.9]-140 A[0.9]-100 A[1]-100
A[0.9]-160 A[1]-120
A[1]-140
A[1]-160
53 A[0.7]-200 A[0.6]-120 A[0.7]-140 A[0.7]-120 A[0.5]-60 A[0.7]-80 A[0]-20 A[0.2]-20 A[0.5]-20
A[0.7]-160 A[0.8]-200 A[0.7]-100 A[0.8]-120 A[0.7]-60 A[0.9]-80 A[1]-60
A[0.8]-140 A[0.9]-200 A[0.8]-80 A[1]-200 A[1]-80
54 A[0.6]-140 A[0.3]-60 A[0.1]-40 A[0.2]-40 A[0.6]-60 A[0.9]-120 A[0.7]-40
A[0.5]-80 A[0.8]-160 A[0.9]-180 A[1]-160
A[0.6]-100 A[1]-180
55 A[0.7]-180 A[0.7]-140 A[0.8]-180 A[0.6]-80 A[0.3]-40 A[0.4]-40 A[0.9]-100 A[1]-120 A[0.6]-20
A[0.8]-200 A[0.8]-140 A[0.8]-120 A[0.8]-100 A[1]-140 A[1]-40
A[0.9]-200 A[0.9]-160
56 A[0.2]-60 A[0.8]-180 A[0.7]-120 A[0.7]-100 A[0.9]-180 A[0.9]-140 A[0.6]-40 A[0.9]-60
A[0.8]-160 A[0.9]-200 A[1]-180 A[1]-100
A[1]-200
57 A[0.4]-80 A[0.5]-80 A[0.4]-60 A[0.5]-60 A[0.7]-80 A[0.1]-20 A[0.3]-20 A[0.7]-20
A[0.5]-100 A[0.6]-100 A[0.9]-160 A[0.8]-60 A[0.8]-40
A[0.7]-160 A[1]-160
58 A[0.6]-120 A[0.1]-40 A[0.8]-120 A[0.6]-60 A[0.8]-80 A[0.9]-80 A[1]-80 A[0.8]-20
A[0.7]-120 A[0.9]-180 A[0.8]-100 A[0.9]-120 A[1]-140
A[0.8]-160 A[1]-200
59 A[0.8]-200 A[0.6]-80 A[0.3]-40 A[0.9]-140 A[0.7]-60 A[1]-120 A[0.9]-20
A[0.8]-140 A[0.9]-160 A[1]-180 A[1]-20
A[0.9]-200
60 A[0]-40 A[0.4]-60 A[0.2]-40 A[0.4]-40 A[0.5]-40 A[0.4]-20
A[0.7]-140 A[0.7]-100 A[1]-200 A[0.9]-100 A[1]-60
A[0.9]-180 A[1]-160
61 A[0.3]-60 A[0.8]-140 A[0.7]-80 A[0.9]-120 A[0]-20 A[0.2]-20 A[0.9]-40
A[0.8]-180 A[0.9]-200 A[0.8]-100 A[1]-180 A[0.7]-40
A[0.9]-140 A[1]-100
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62 A[0.9]-180 A[0.5]-60 A[1]-200 A[1]-140 A[0.9]-60
A[0.8]-120
A[0.9]-160
63 A[0.5]-80 A[0.6]-80 A[0.6]-60 A[0.8]-80 A[1]-120 A[1]-80
A[0.6]-100 A[0.7]-100 A[1]-160
A[0.8]-160
64 A[0.7]-120 A[0.2]-40 A[0.9]-120 A[0.7]-60 A[0.8]-60 A[0.5]-20
A[0.8]-120 A[1]-180 A[0.9]-100 A[0.9]-80
65 A[0.9]-200 A[0.9]-160 A[0.3]-40 A[0.4]-40 A[1]-140 A[0.6]-40 A[1]-40
A[0.7]-80 A[1]-160
A[0.9]-140
A[1]-200
66 A[0.1]-40 A[0.5]-60 A[0.8]-100 A[0.5]-40 A[0.1]-20 A[0.3]-20
A[0.8]-140 A[1]-100 A[0.8]-40
67 A[0.9]-180 A[0.9]-140 A[1]-180 A[0.8]-80 A[0]-20 A[1]-60
A[1]-200 A[1]-120
68 A[0.4]-60 A[0.6]-60 A[0.9]-100 A[0.6]-20
A[0.9]-120 A[1]-140
69 A[0.7]-100 A[0.7]-80 A[1]-160 A[0.7]-60 A[0.9]-80
A[0.8]-100
A[1]-180
70 A[0.6]-80 A[0.3]-40 A[1]-120 A[0.8]-60 A[0.9]-60 A[0.4]-20
A[0.9]-160 A[1]-100 A[1]-80
71 A[0.8]-120 A[0.9]-120 A[1]-140 A[0.5]-40 A[0.6]-40 A[0.7]-40 A[0.9]-40 A[0.7]-20
A[1]-160
72 A[1]-200 A[0.4]-40 A[0.2]-20
A[0.8]-80
73 A[0.2]-40 A[0.6]-60 A[0.9]-100 A[0]-20 A[0.1]-20
A[0.9]-140 A[0.9]-80
74 A[1]-140 A[1]-100 A[0.8]-20
75 A[0.5]-60 A[0.7]-60 A[0.8]-60 A[1]-80 A[0.5]-20
A[1]-180 A[1]-120
76 A[0.8]-80 A[0.9]-60 A[0.8]-40 A[1]-40
A[0.9]-100 A[1]-60
77 A[0.8]-100 A[0.4]-40 A[0.9]-20
78 A[0.7]-80 A[1]-120 A[0.6]-40 A[0.7]-40 A[0.3]-20
A[0.9]-120
A[1]-160
79 A[0.5]-40
A[0.9]-80
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80 A[0.3]-40 A[0.7]-60 A[1]-100 A[0.1]-20 A[0.2]-20 A[0.6]-20 A[1]-20
A[1]-80
81 A[1]-140
82 A[0]-20
83 A[0.6]-60 A[0.8]-60 A[0.9]-60 A[1]-60 A[0.9]-40
84 A[0.9]-80 A[0.4]-20
A[1]-100
85 A[0.9]-100 A[0.5]-40 A[0.7]-40 A[0.8]-40
86 A[0.8]-80 A[0.6]-40 A[0.7]-20
A[1]-120
87 A[1]-80 A[0.3]-20
88 A[0]-20 A[0.2]-20
A[0.8]-60
89 A[0.4]-40 A[1]-40
90 A[0.1]-20 A[1]-60
91 A[0.7]-60 A[0.9]-60 A[0.5]-20 A[0.8]-20
92 A[1]-80 A[0.9]-40
93 A[0.6]-40 A[0.8]-40
94 A[1]-100 A[0.4]-20
95 A[0.9]-80 A[0.7]-40
96 A[0.3]-20 A[0.9]-20
97 A[0.1]-20
A[0.9]-60
98 A[0.5]-40 A[0.2]-20 A[0.6]-20
99 A[1]-60
100 A[1]-40
101 A[0.8]-60 A[0.9]-40 A[1]-20
102 A[0.7]-40 A[0.5]-20
103 A[0]-20
104 A[1]-80 A[0.8]-40 A[0.4]-20
105 A[0.7]-20
106 A[0.2]-20
A[1]-60
107
108 A[0.6]-40 A[0.3]-20
109
110 A[1]-40 A[0.6]-20
111 A[0.9]-60
112 A[0.8]-40 A[0.8]-20
113 A[0.1]-20 A[0.9]-40 A[0.5]-20
114
115
116
117 A[0.3]-20
118 A[0.4]-20
119 A[0.7]-40 A[0.7]-20
120 A[0.9]-20
121
122 A[1]-60
123 A[0.9]-40 A[0.6]-20
124 A[1]-40
125 A[0.2]-20
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8.8 In Vivo Pharmacokinetic Parameters 
Table 16: Pharmacokinetic parameters for CP-Dox micelles of various chain lengths 
   Chain Length (Pentamers) 
Parameter Symbol 40 80 160 
initial concentration Co [µM] 229.1 (13.9) 224.8 (12.4) 293.1 (12.6) 
distribution half-life α t1/2 [58] 33.6 (9.0) 126.7 (67.2) 71.9 (22.2) 
elimination half-life β t1/2 [hr] 9.6 (0.4) 12.1 (1.0) 15.5 (0.9) 
area under the curve AUC [µM hr] 1202.9 (42.8) 2690.5 (119.6) 3734.6 (112.3) 
plasma clearance CL [µL hr-1 g-1] 0.15 (.01) 0.07 (0.00) 0.05 (0.00) 
initial volume of distribution Vo [µL g-1] 0.77 (0.05) 0.78 (0.04) 0.60 (0.03) 
tissue to plasma rate constant ktp [hr-1] 0.47 (0.12) 0.23 (0.13) 0.33 (0.11) 
plasma to tissue rate constant kpt [hr-1] 0.65 (0.21) 0.08 (0.05) 0.21 (0.07) 
elimination rate constant ke [hr-1] 0.19 (0.01) 0.08 (0.01) 0.08 (0.00) 
 
 
Table 17: Pharmacokinetic parameters for asymmetric amphiphiles with various 
assembly domains 
Parameter Symbol X = None 
A[1]-160-X 
X = (FGG)8 X = (YG)8 
initial concentration Co [µM] 50.4 (2.4) 44.6 (1.7) 44.7 (3.8) 
distribution half-life α t1/2 [58] 30.7 (7.9) 94.4 (35.9) 17.1 (6.6) 
elimination half-life β t1/2 [hr] 9.1 (0.5) 16.0 (2.6) 10.9 (1.0) 
area under the curve AUC [µM hr] 332.1 (9.9) 628.0 (40.1) 329.7 (19.1) 
plasma clearance CL [µL hr-1 g-1] 0.53 (.02) 0.28 (0.02) 0.53 (0.03) 
initial volume of distribution Vo [µL g-1] 3.5 (0.17) 3.94 (0.15) 3.94 (0.33) 
tissue to plasma rate constant ktp [hr-1] 0.68 (0.18) 0.27 (0.12) 1.14 (0.42) 
plasma to tissue rate constant kpt [hr-1] 0.59 (0.17) 0.14 (0.05) 1.22 (0.53) 
elimination rate constant ke [hr-1] 0.15 (0.01) 0.07 (0.01) 0.14 (0.01) 
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8.9 Detailed Procedures 
8.9.1 PRe-RDL 
8.9.1.1 Concatemerization  
This is the first step when inserting many oligos into a vector at once. This can also be 
modified to insert a single oligo into a vector, if you are designing complementary 
leader or trailer vectors, for instance. All references to DNA quantities are based on a 
normal miniprep eluted into 50 µL of ddH2O. 
 Vector Prep 
 15 µL DNA 
 2 µL BseRI 
 9 µL NEB 2, NEB 4, or CutSmart Buffer 
 64 µL H2O 
 Incubate at 37°C for 3 h (can leave overnight) 
 Add 1 µL CIP, incubate at 37°C for 15 min 
 
PCR Purification 
 Add 500 µL PBI solution to the entire vector prep 
 Follow the directions from the PCR Purification Kit (Qiagen) 
 Elute in 30 µL H2O 
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Concatemerization Ligation (1 h) 
 3 µL Vector Prep 
 1 µL Oligo (if only want 1 insert, use 0.1 µL) 
 2 µL 10x Ligase Buffer 
 1 µL Ligase 
 13 µL H2O 
 Incubate at Room Temp for 1 h 
*If none of the colonies have a high insert to vector ratio, simultaneously 
try a vector:insert ratio of 1:1, 1:3, and 1:5. Miniprep or colony PCR all 
colonies from the 1:3 and the 1:5 plates. 
  
Transformation and Plating (~1.5 hrs) 
 3 µL of Ligation mixture 
 25 µL of EB5α cells, unthawed on ice 
 Incubate mixture on ice for ~5 minutes 
 Place on 42°C hot plate for 45 sec 
 Incubate on ice for 2 min 
 Add 50 µL Luria Broth 
 Incubate at 37°C for 1 h (recovery period) 
 Plate on prewarmed agarose plates 
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 Incubate plates at 37°C overnight 
 
8.9.1.2 PRe-RDL Day 1: 
prRDL A Reaction (3 h) 
 40uL DNA 
 2uL AcuI 
 4uL BglI 
 9uL NEB4 
 35uL H2O 
 
prRDL B Reaction (3 h) 
 40uL DNA 
 2uL BseRI 
 4uL BglI 
 9uL NEB4 
 35uL H2O 
 
Incubate both preps for ~3 h at 37°C. 
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Gel Purification (1 h) 
Make a 1% low melting point gel (0.75 g agarose, 75 mL TAE buffer, 7.5 µL 
SybrSafe) 
 Let cool in 4°C fridge for ~1 hour before use 
 Use large 4 well comb 
Add 18 µL loading dye to each prep 
Load all 106 µL of prep into a single well on the gel 
Run gel at 130mV (takes ~30 min) 
 
When gel purifying, always cut out the top band (whole procedure ~30 min) 
Expect: 
 PRe-RDL A:  1586 bp, 1821 bp, 1891 + ELP 
 PRe-RDL B: 1891 bp, 3407 + ELP 
*If you have more than 3 bands for an ‘A’ cut or 2 bands for a ‘B’ cut, prepare 
new DNA and start over. The most common cause is incomplete DNA digestion 
due to poor mixing of the enzymes and DNA or suboptimal cutting conditions 
(time period is too short, temperature is not 37°C, etc). 
 
Mix the band of agarose that was cut from the gel with: 
400 µL Buffer QG 
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80 µL Isopropanol 
Follow the directions from the Gel Purification Kit (Qiagen) 
Elute in 30 µL H2O 
 
Ligation (~ 1 h) 
 3 µL PRe-RDL A 
 3 µL PRe-RDL B 
 2 µL 10x Ligase Buffer 
 1 µL Ligase 
 11 µL H2O 
 Incubate at room temperature for 1 h 
 
8.9.1.3 PRe-RDL Day 2: 
Colony PCR (3 h) 
Use cPCR to rapidly screen for fragments <2 Kb 
 12.5 µL Master Mix 
 1 µL Forward Primer 
 1 µL Reverse Primer 
 10.5 µL H2O 
 Pick colony with a pipette tip and pipette up and down until tip is clean 
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 Remember to number colonies on the plates 
 Place plates back in the incubator 
 Run PCR program A-29 (Jon) 
 Make sure to change extension time (1 min per kb) 
 
Make a 1% agarose gel (0.50 g agarose in 50 mL TAE)  
 Let solidify at room temperature for 15-30 minutes before use 
Run 9 µL of PCR solution on gel (no dye is needed)  
Remember to include a ladder – either BstEIII for large ELPs (>1500 bp) or 
100bp for smaller ELPs 
 Run at 130mV for ~30 minutes 
 Runtime depends on gene size.  Longer genes require longer runtimes. 
  
Observe gel, pick colonies to grow (15 min) 
 4 mL TBDry Media 
 4 µL kanamycin 
 Colony 
 Incubate overnight at 37°C. 
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8.9.1.4 PRe-RDL Day 3: 
Miniprep all samples 
 Use 750 µL to make a DMSO stock for each sample 
 Use 3 mL to miniprep 
Follow directions included with the Miniprep Kit (Qiagen) 
 Elute minipreps in 50 µL ddH2O 
 
Diagnostic Digest 
 10 µL DNA 
 0.5 µL BamHI 
 0.5 µL XbaI 
 2 µL CutSmart Buffer 
  7 µL H2O 
 Incubate 1 hr at 37°C. 
 
Make a 1% agarose gel right after starting incubation.   
Run Diagnostic Digest at 130mV for ~20-30 minutes.   
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Sequence 
 Check the DNA concentration (should be ~80-100 ng/µL) 
 If sequencing with Eton, submit 10-15 µL DNA in H2O 
On the following morning, check the sequences in SeqBuilder. If the 
forward and reverse sequencing are appropriate, start the process again 
at Day 1 using the selecting sequences. 
 
8.9.2 Drug Conjugations 
8.9.2.1 Synthesis of CP-Gemcitabine Conjugate 
Synthesis of 3′, 5′-O-Bis (tert-Butoxycarbonyl)gemcitabine (1):  
Selective protection of 3′-OH and 5′-OH of gemcitabine was performed as 
described previously [227]. Briefly, to a stirred solution of gemcitabine hydrochloride 
(240 mg, 0.8 mmol) in 16 mL of 1M aqueous KOH, di-tert-butyl dicarbonate (DBDC) 
(1.75 g, 8 mmol) in 16 mL of dioxane was added drop wise. The reaction mixture was 
then stirred at 25°C for an additional 40 min and extracted with ethyl acetate, washed 
with brine, dried over Na2SO4 and concentrated to dryness under reduced pressure.   
At 25°C, additional DBDC (1.74 g) in 16 mL of dioxane was added to a stirred 
clear solution of the above residue, followed by the addition of 40 mL of 1 M aqueous 
KOH. The reaction mixture was stirred at 25°C for another 40 min and subsequently 
extracted by a similar procedure as described before. The product was purified by 
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column chromatography, and synthesis was confirmed via TLC (chloroform-acetone-
EtOH 5:4:1) and LC/MS (Agilent Series 1100 LC/MSD Trap; Agilent Technologies). Rf: 0.6 
in CH2Cl2-acetone-EtOH 5:4:1. ESI/MS: 464 [M+H].  
Synthesis of 3′,5′-O-Bis(tert-butoxycarbonyl)-4-N-(ß-maleimidopropiocarbonyl) 
gemcitabine (2):   
To a stirred solution of BMPA (0.036 g, 0.2 mmol) and EDCI (0.041 g, 0.2 mmol) 
in anhydrous DCM at 0°C,  1 (0.05 g, 0.1 mmol)  was added, along with a catalytic 
amount of triethylamine. The reaction mixture was stirred for an additional 16 h at room 
temperature and subsequently extracted with ethyl acetate, washed with brine, dried 
over Na2SO4 and concentrated to dryness under reduced pressure. The product was 
purified by column chromatography, and synthesis of 2 was confirmed via TLC 
(chloroform-acetone-EtOH 5:4:1) and LC/MS. Rf: 0.8 in CH2Cl2-acetone-EtOH 5:4:1. 
ESI/MS: 615 [M+H].  
Synthesis of activated gemcitabine and conjugation of activated gemcitabine and CP:  
Prior to conjugation to CP, gemcitabine-BMPA was activated via removal of t-
BOC groups.  Trifluoroacetic acid (500 µL) was added to a stirred solution of 2 (0.05 g, 
0.1 mmol) in anhydrous DCM (500 µL) at 0°C, and the reaction mixture was stirred at 
0°C for 3 h. TFA was subsequently removed under reduced pressure and the mixture 
was triturated with ether to yield the desired product 3. Activated gemcitabine 3 was 
immediately used for the next step.  
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Prior to reaction, purified CP was suspended in reaction buffer (0.1 M NaPO4, 1 
mM EDTA, pH 7.0) and reduced with 1 mL of TCEP at neutral pH (100 mM, pH 7.0) at 
~5x excess to thiol. Excess TCEP was removed from the solution by initiating the phase 
transition with sodium chloride (2.5 M) and centrifugation at 4,000 rpm at 25°C for 10 
min. The CP pellet obtained by centrifugation was re-suspended in 5 mL of reaction 
buffer. Activated gemcitabine (0.03 g, 0.07 mmol) was re-suspended in 2 mL of methanol 
and slowly transferred to the stirring CP solution. After mixing, 1 mL of pH neutral 
TCEP (100 mM) was added and the reactants were stirred for 16 hours at 20°C in the 
dark. After reaction, the methanol was evaporated under a nitrogen stream, and 
unreacted gemcitabine precipitates were removed via centrifugation at 13,000 rpm at 
4°C for 10 minutes. The supernatant contained CP-gemcitabine conjugate, which was 
further purified by initiating the CP phase transition with sodium chloride (2.5 M) to 
aggregate the CP-Gem conjugate followed by centrifugation at 4,000 rpm at 25°C for 10 
min. The CP-gemcitabine conjugate pellet obtained by centrifugation was re-suspended 
in phosphate buffered saline (PBS) (pH 7.4) at a concentration of 10 mg / mL and 
purified using size exclusion PD-10 chromatography (GE Healthcare Life Sciences).  
Determination of gemcitabine conjugation ratio: 
The conjugation ratio of gemcitabine to CP was determined by matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) of the 
CP-gemcitabine conjugates and free CP using a Voyager DE-Pro Maldi-MS (Applied 
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Biosystems) instrument equipped with a nitrogen laser (337 nm). The MALDI-TOF-MS 
samples were prepared in an aqueous 50% acetonitrile solution containing 0.1% TFA, 
using a sinapinic acid matrix. The conjugation ratio was determined by examining the 
increase in mass of the conjugate relative to free CP.  
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Figure 48: Synthesis scheme for CP-Gemcitabine conjugate. 
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Figure 49: ESI-MS of 3′,5′-O-Bis(tert-butoxycarbonyl)-4-N-(ß-
maleimidopropiocarbonyl) gemcitabine (2) 
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Figure 50: MALDI-MS of CP-Gemcitabine conjugate 
 
8.9.2.2 Synthesis of CP-Oxycodon Conjugate 
Synthesis of Oxycodone-BMPH (I) conjugate:  
Oxycodone-BMPH was prepared as described previously [2].  Briefly, oxycodone 
(25 mg, 79.2 µmoles) and BMPH (28 mg, 95 µmoles) were co-dissolved in 1 mL 
anhydrous methanol with 2 µL of tri-fluoroacetic acid. The reactants were stirred for 16 
h at 20°C in the dark.  The white precipitate was isolated by centrifugation and washed 
with MeOH. Drying under vacuum produced the white purified product (I).  Activated 
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BMPH was immediately used in a second reaction with the ELP. ESI-MS: 481 [M+H], 503 
[M+Na]. 
Conjugation of oxycodone with CP:  
Prior to conjugation with activated oxycodone, purified CP was suspended in 
reaction buffer (0.1 M NaPO4, 1 mM EDTA, pH 7.0) and reduced with 1 mL of TCEP at 
neutral pH (100 mM, pH 7.0) at ~5x excess to thiol. Excess TCEP was removed from the 
solution by initiating the phase transition with sodium chloride (2.5 M) and 
centrifugation at 4,000 rpm at 25 °C for 10 minutes. The CP pellet obtained by 
centrifugation was re-suspended in ~1 mL of reaction buffer. Compound I was re-
suspended in ~1 mL of methanol-H2O (1:1) and slowly transferred to the stirring CP 
solution. 1 mL of pH neutral TCEP (100 mM) was added and the reactants were stirred 
for 16 hr at 20°C in the dark. After reaction, the methanol was evaporated under a 
nitrogen stream to a volume ~1 mL. Unreacted oxycodone precipitates were removed 
via centrifugation at 13,000 rpm at 10°C for 10 min. The supernatant was further purified 
by initiating the CP phase transition with sodium chloride (2.5 M) to aggregate the CP-
oxycodone conjugate followed by centrifugation at 4,000 rpm at 25°C for 10 min. The 
CP-oxycodone pellet obtained by centrifugation was re-suspended in phosphate 
buffered saline (PBS) (pH 7.4) at a concentration of ~10 mg mL-1 and dialyzed using 
Spectra/Por 2 membrane (Spectrum labs, MWCO 12-14 kD) in 20 % acetonitrile-water, 
followed by 100% DI water.  
 234 
Determination of the oxycodon conjugation ratio: 
The conjugation ratio of oxycodon to CP was determined by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) of the CP-
oxycodone conjugates and free CP using a Voyager DE-Pro Maldi-MS (Applied 
Biosystems) instrument equipped with a nitrogen laser (337 nm). The MALDI-TOF-MS 
samples were prepared in an aqueous 50% acetonitrile solution containing 0.1% TFA, 
using a sinapinic acid matrix. The conjugation ratio was determined by examining the 
increase in mass of the conjugate relative to free CP.  
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Figure 51: Synthesis scheme for CP-Oxycodon conjugate 
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Figure 52: ESI-MS of Oxycodone-BMPH (I). 
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Figure 53: MALDI-MS of CP-Oxycodone conjugate 
 
8.9.2.3 Synthesis of CP-Paclitaxel Conjugate 
Synthesis of paclitaxel-levulinic acid (I) conjugate:  
Paclitaxel-levulinic acid was prepared as described previously [228].  Briefly, 
levulinic acid (0.08 g, 0.7 mmol) and DCC (0.145 g, 0.7 mmol) were codissolved in dry 
DMF and stirred for 30 min at -20°C.  Paclitaxel (0.5 g, 0.58 mmol) and DMAP (0.5 g, 0.58 
 238 
mmol) were dissolved in dry DMF and were added to the above mixture.  The reaction 
mixture left stirred for 24 h at 4°C.  The reaction mixture was filtered and the DMF was 
evaporated to dryness.  Compound I was purified with column chromatography with 
silica gel and 1.5% MeOH in chloroform as eluent.  Rf: 0.48 in EtOAc/Hexane=2:1. 
Synthesis of activated paclitaxel (II) and conjugation of paclitaxel with CP:  
Compound I (0.05 g, 0.05 mmol)  and BMPH (0.018 g, 0.06 mmol) were dissolved 
in dry MeOH and stirred in the dark for 48 h at 45°C.  After the MeOH was evaporated 
to dryness, compound II was purified with column chromatography with silica gel and 
2-2.5 % MeOH in chloroform as eluent. Compound II was immediately used in the next 
step. Rf: 0.6 in 10 % MeOH in CHCl3. ESI-MS: 1117 [M+H], 1139 [M+Na]. 
Prior to conjugation with activated paclitaxel, purified CP was suspended in 
reaction buffer (0.1 M NaPO4, 1 mM EDTA, pH 7.0) and reduced with 1 mL of TCEP at 
neutral pH (100 mM, pH 7.0) at ~5x excess to thiol. Excess TCEP was removed from the 
solution by initiating the phase transition with sodium chloride (2.5 M) and 
centrifugation at 4,000 rpm at 25°C for 10 min. The CP pellet obtained by centrifugation 
was resuspended in ~2 mL of reaction buffer. Compound IV was resuspended in ~2 mL 
of methanol and slowly transferred to the stirring CP solution. 1 mL of pH neutral TCEP 
(100 mM) was added and the reactants were stirred for 16 h at 20°C in the dark. After 
reaction, the methanol was evaporated under a nitrogen stream to a volume ~20 mL. 
Unreacted paclitaxel (PTX) precipitates were removed via centrifugation at 13,000 rpm 
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at 10°C for 10 min. The supernatant was further purified by initiating the CP phase 
transition with sodium chloride (2.5 M) to aggregate the CP-PTX conjugate followed by 
centrifugation at 4,000 rpm at 25°C for 10 min. The CP-PTX pellet obtained by 
centrifugation was resuspended in phosphate buffered saline (PBS) (pH 7.4) at a 
concentration of ~10 mg mL-1 and dialyzed using Spectra/Por 2 membrane (Spectrum 
labs, MWCO 12-14 kD) in 20 % acetonitrile-water, followed by 100% DI water.  
Determination of the paclitaxel conjugation ratio: 
The conjugation ratio of paclitaxel to CP was determined by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) of the CP-
Paclitaxel conjugate and free CP using a Voyager DE-Pro Maldi-MS (Applied 
Biosystems) instrument equipped with a nitrogen laser (337 nm). The MALDI-TOF-MS 
samples were prepared in an aqueous 50% acetonitrile solution containing 0.1% TFA, 
using a sinapinic acid matrix. The conjugation ratio was determined by examining the 
increase in mass of the conjugate relative to free CP.  
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Figure 54: Synthesis scheme for CP-Paclitaxel conjugate 
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Figure 55: ESI-MS of activated Paclitaxel (II) 
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Figure 56: MALDI-MS of CP-Paclitaxel conjugate 
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